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Abstract 
The prevalence of the metabolic disorders, type 2 diabetes (T2D) and non-alcoholic 
steatohepatitis (NASH) are rapidly increasing worldwide in parallel with increasing 
obesity rates. These obesity-related conditions are also associated with adipose tissue 
inflammation and dysfunction. In response to overfeeding, some individuals develop 
healthy obesity and are resistant to obesity-associated metabolic diseases; whereas 
others readily develop one or more of these disorders. The reasons for such disparity in 
responses to overfeeding are unclear.  
Fat aussie (foz/foz) mice have a spontaneous mutation in the Alms 1 gene, causing 
defective appetite regulation, overfeeding and obesity. Interestingly, after 24 weeks of 
age on high fat (HF) diet, female Balb/c foz/foz mice develop healthy obesity; whereas 
NOD.B10 foz/foz mice on HF diet develop obesity and both T2D and NASH. HF-fed 
NOD.B10 foz/foz mice also exhibit a relative defect in adipose tissue expansion (termed 
adipose restriction) compared to Balb/c foz/foz mice. 
We hypothesized that a primary defect in the adipose tissue response to overfeeding in 
the NOD.B10 foz/foz mice underlies its propensity to develop T2D and NASH, and that 
this defect would not be observed in diabetes and NASH-resistant Balb/c mice. The 
major aim of this study therefore, was to determine the role of adipose tissue in the 
development of T2D and NASH using NOD.B10 and Balb/c foz/foz mice. 
Female NOD.B10 and Balb/c wild-type and foz/foz mice were fed on chow or HF diet 
over an 8 week period, and mice length, weight, body composition, adipose tissue 
depots and liver weights, fed-state blood glucose and plasma insulin, intraperitoneal 
glucose tolerance, hepatic triacylglyceride (TG) content, plasma alanine transaminase, 
plasma adiponectin and monocyte chemoattractant protein-1 (MCP-1) levels, as well as 
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the expression of genes associated with differentiation, function, inflammation and 
adipokine/chemokine production were measured at various time-points from 4 to 12 
weeks of age.  
Obesity developed in HF-fed foz/foz mice of both strains. However, only HF-fed 
NOD.B10 foz/foz mice developed hyperglycaemia (from 6 weeks of age), profound 
hyperinsulinaemia (from 8 weeks), glucose intolerance (from 5 weeks), hepatomegaly 
with increased TG content (from 8 weeks) and NASH (at 12 weeks of age), whereas 
HF-fed Balb/c foz/foz mice only developed obesity and hepatic steatosis. Adipose tissue 
restriction was not clearly evident by 12 weeks of age, and although changes in the 
majority of measured adipose tissue genes at the mRNA level were similar in HF-fed 
foz/foz mice of both NOD.B10 and Balb/c strains, the diabetes prone HF-fed NOD.B10 
foz/foz mice had increased expression of inflammation genes (in particular MCP-1) at 
12 weeks of age. 
Taken together, glucose intolerance and hyperinsulinaemia precede the development of 
both adipose tissue inflammation and NASH in HF-fed NOD.B10 foz/foz mice. The 
results suggest, therefore, that adipose tissue most probably plays a secondary role in 
the pathogenesis of metabolic disorders associated with obesity. However, these 
findings do not preclude an important role of adipose inflammation and dysfunction in 
the progressive worsening of metabolic disorders in susceptible subjects. 
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1. Introduction 
1.1 Obesity: The Global Pandemic 
     1.1.1 Epidemiology of obesity 
Obesity is a complex condition that occurs when there is abnormal or excessive 
accumulation of fat in the body.[1] The increased rise in obesity rates have been 
associated with augmented caloric intake, changes in diet composition (rich in sugars 
and saturated fats), combined with reduced physical activity (due to modernization) and 
even changes in gut microbiota.[2, 3] Overweight or obesity is classified by a simple 
anthropometric index of weight (kg) for height (m2) called body mass index (BMI). An 
individual with BMI > 25 kg/m2 is classified in the overweight class, BMI > 30 kg/m2 
for obesity class I, BMI > 35 kg/m2 for obesity class II and BMI > 40 kg/m2 for obesity 
class III.[4] Due to inter-racial differences in BMI ranges, other measurements such as 
waist circumference and waist-to-hip ratio are also used for classification of obesity.[4] 
Metabolically healthy obesity (MHO) is determined by the absence of insulin 
resistance, major cardiovascular risk factors or metabolic syndrome (MetS).[2] However, 
almost 50% of metabolically healthy obese individuals were found to become 
metabolically unhealthy obese within 10 years.[5] Metabolically unhealthy obesity is that 
which is associated with features of the MetS and higher rates of metabolic conditions 
such as type 2 diabetes (T2D) and non-alcoholic steatohepatitis (NASH), as well as 
cardiovascular diseases.  
Obesity was previously viewed as a first world problem. However, it has now 
developed into a global pandemic, affecting low and middle income developing nations, 
especially in urban cities, with 62% of the world’s obese population now living in 
developing countries.[6] According to a recent Lancet study of the global prevalence of 
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overweight and obesity from 1980-2013, the worldwide overweight and obese 
population has increased from 857 million in 1980 to 2.1 billion in 2013, affecting 
36.9% of the male and 38% of the female adult population.[6] Obesity is also becoming 
increasingly prevalent in children and adolescents, with 42 million children under 5 
years of age found to be overweight or obese worldwide.[6]  
The World Health Organization (WHO) estimates over 50% of European adult men and 
women are overweight or obese, while around 20% men and 23% women are obese.[7] 
In North America, USA still has the highest prevalence of obesity (one-third men and 
women are obese) and account for 13% of the worldwide obese population.[6, 8] The 
national medical care costs of obesity linked diseases in adults in USA have increased 
to $209.7 billion, taking up 20.6% of the US National health expenditure.[9] Obesity 
rates in Asian countries like China and India are relatively low. However, due to their 
high population, China and India jointly make up 15% of the world obese population in 
numbers.[6] Obesity rates in China have increased from 1993 to 2009, from 3% to 11% 
in men and from 5% to 10% in women.[10] In India, around 15% of women were found 
to be obese or overweight.[11]  
Africa has the double burden of under-nutrition along with rising over-nutrition rates, 
due to migration to cities and a sedentary lifestyle. Over 42% of South African women 
have been found to be obese.[6] Countries in the Middle East have also witnessed a rapid 
increase in obesity rates with 66% men and 71% women classified as overweight or 
obese in Saudi Arabia, and 74% men and 77% women overweight or obese in 
Kuwait.[12]  Obesity rates have also increased in Central and South Latin America with 
over 30% adults obese, and 70% adults overweight or obese in Mexico.[13]  
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The prevalence of obesity in Australia has nearly doubled over the past two decades, 
making Australia one of the fattest nations in the developed world. 60% of the 
Australian population are classified as overweight or obese, of which 25% are obese.[14] 
Aboriginal and Torres Strait Islander Australians were found to be 1.9 times more likely 
to be obese than non-indigenous Australians, with the fourth highest diabetes rates in 
the world.[15] Furthermore, 25% of Australian children (aged between 2-16 years) are 
overweight or obese, of which 6% are obese.[16] The economic burden of obesity and 
obesity-related diseases in Australia has been found to be $21 billion in direct health 
care and other related costs, with an additional $35.6 billion in government subsidies 
costs, with a total direct annual health cost of over $56 billion.[17] 
 
     1.1.2 Environmental factors leading to human obesity 
A sedentary lifestyle with reduced physical activity and/or increased caloric intake with 
diets rich in sugar or saturated fats have been implicated to contribute to the 
development of obesity.[18-20] Saturated fatty acids and n-6 polyunsaturated fatty acids 
(PUFA) have been linked to the induction of inflammation and insulin resistance, and, 
therefore, may confer the pathogenesis of metabolic disorders associated with 
obesity.[20, 21] 
Migration studies in Pima Indians have shown that a change in physical activity and diet 
due to urbanization led to Pima Indians in USA being 25 kg heavier than Pima Indians 
in Mexico, despite the same genetic predisposition.[22]  
An abnormal intra-uterine environment of malnutrition or excessive nutrient supply 
may also play a major role in the development of metabolic conditions later in life. Fetal 
under-nutrition leading to intra-uterine growth restriction (IUGR) can increase 
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predisposition to later onset of obesity and T2D, postulated to be due to epigenetic 
programming for adaptation of the fetus for expected postnatal under-nutrition. Growth 
restricted infants were found to be seven times more likely to develop T2D by 64 years 
of age.[23, 24] Gestational Diabetes Mellitus (GDM) occurs during the later stages of 
pregnancy when women develop insulin resistance that cannot be compensated by 
increased insulin secretion. Consequential hyperglycemia poses risks for the developing 
child, with the development of fetal macrosomia due to intra-uterine over-nutrition. This 
places the baby at risk of neonatal hypoglycemia, shoulder injury and breathing 
problems, and also increases the chances of later development of obesity and T2D.[25, 26] 
Although gestational diabetes in the mother disappears after the pregnancy, it makes her 
susceptible to the development of T2D later in life.[25] GDM affects at least 4.6% of 
pregnant women in Australia and 2-10% of pregnancies in the USA.[25] 
 
     1.1.3 Genetic components of human obesity 
Family studies have shown that obesity has 55-85% heritability for BMI.[27] 
Monozygotic twin studies have shown that there was 6 times less degree of variance of 
weight gain and fat distribution within twin pairs, compared to between twin pairs.[28]  
Monogenic obesity arises from single gene disorders such as mutation in the leptin gene 
shown in ob/ob mice or mutation in the leptin receptor in db/db mice.[29, 30] Since leptin 
plays a major role in the energy balance of the body by regulating food intake via the 
hypothalamus, leptin or leptin receptor mutations in mice causes excess adiposity, 
reduced physical activity, obesity and diabetes. In humans, rare mutations in leptin and 
the leptin receptor cause pituitary dysfunction and early onset of severe obesity.[31, 32] 
Another single gene disorder leading to obesity is caused by mutation in the 
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melanocortin-4 receptor (MC4R), which regulates the effect of leptin, and mutations in 
the MC4R gene in mice and humans lead to morbid obesity.[33, 34] Alström syndrome, 
caused by a point mutation in the Alms1 gene also generates the obesity phenotype 
among other metabolic conditions.[35] 
However, most obesity is polygenic and occurs due to the interaction of many 
susceptible genes with environmental factors. Genome-wide association studies 
(GWAS) have opened the doors to uncover novel loci contributing to the development 
of obesity, which was impossible to be detected in candidate genes studies or family 
studies. GWAS are based on associations between the obesity phenotype and all 
common variations across the entire human genome.[36] Multiple loci associated with 
BMI and obesity have been discovered through this unbiased methodology, most 
notable being the fat mass and obesity (FTO) gene. The FTO gene is still considered the 
most robust common obesity susceptibility locus due to its high prevalence in the 
population, especially among Caucasians.[37, 38] This gene has been found to be 
expressed largely in the brain and regulates energy balance by monitoring food 
intake.[39] Overexpression of the FTO gene in mice leads to increased food intake and 
obesity, while inactivation of the FTO gene in mice causes post-natal growth restriction 
and reduced adiposity.[40, 41] In humans, a homozygous R316Q point mutation in the 
dioxygenase-encoding FTO gene causes inactivation of FTO enzymatic activity and 
results in severe growth retardation and multiple malformations.[42] 
Meta-analyses of GWAS data sets has uncovered even more loci including 
transmembrane protein 18 (TMEM18), glucosamine-6-phosphate deaminase 2 
(GNPDA2), potassium channel tetramerization domain containing 15 (KCTD15), SH2B 
adaptor protein 1 (SH2B1), mitochondrial carrier 2 (MTCH2) and neuronal growth 
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regulator 1 (NEGR1), which have been found to be associated with the development of 
obesity.[43] 
     1.1.4 Health burden of human obesity 
Despite widespread global calls, the rate of obesity is still increasing worldwide, which 
makes obesity a major public health challenge, principally in the middle income 
countries. Obesity has been found to cost from 0.7% to 2.8% of a country’s total health 
care expenditure, with obese individuals having over 30% higher medical costs 
compared to non-obese counterparts.[44] According to the latest estimates by WHO, 
around 3.4 million adults die worldwide each year from obesity related illnesses.[6] 
Individuals with high BMI are at major risk for multiple chronic diseases, including 
cardiovascular disease (coronary heart disease and stroke), certain type of cancers, T2D, 
osteoarthritis, NASH and chronic kidney disease.[45-48] The health consequences 
associated with obesity includes premature death to serious chronic diseases that could 
reduce or impact the overall quality of life.  
 
 
     1.1.5 Epidemiology of Type 2 Diabetes (T2D) 
T2D is a complex metabolic disorder characterized by the inability of the body to 
maintain adequate insulin production (β-cell dysfunction) and reduced action of insulin 
in target tissues (insulin resistance), resulting in elevated blood glucose levels (or 
hyperglycemia). [49, 50] T2D accounts for 90-95% of all diabetic cases and can occur at 
any age, mostly in overweight and obese individuals.[25] The diagnostic criteria set for 
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T2D includes individuals with a fasting plasma glucose level of > 7.0 mmol/L (or 126 
mg/dL) or a random plasma glucose measurement of > 11.1 mmol/L (or 200 mg/dL).[51]  
T2D has become a global epidemic with 4.6% of the world population diagnosed with 
the disorder, increasing from 153 million people affected in 1980 to 382 million in 
2013, with numbers predicted to rise to 592 million by 2035.[25, 52] Diabetes caused 5.1 
million deaths in 2013 in people aged between 20 to 79 years, costing $548 billion in 
medical expenses worldwide. One in 10 adults in the Middle East and North Africa 
were found to develop diabetes.[25] Among Asian countries, Pakistan, India, China and 
Japan were most affected by diabetes with an estimated 7, 31, 20 and 6 million people 
affected in 2000 respectively, with predictions of a dramatic increase by 2030.[53]  
In the USA, 11.8% males and 10.8% females over 20 years of age have been diagnosed 
with diabetes, making it the 7th leading cause of death, due to its association with 
metabolic complications.[25] Diabetes in children and adolescents has also increased 
over the years due to increased childhood obesity rates affecting around 215,000 people 
in USA.[54] A recent epidemiological study found that Native Americans  and African 
Americans had the highest prevalence of diabetes with 14.2% and 12.6% incidence rates 
respectively, followed by Hispanics (11.8%) and Asians (8.4%).  T2D prevalence was 
found to be the lowest among the Caucasian population, with only 7.1% of Caucasians 
diagnosed with the disease.[54] 
In Australia, approximately 2 million people were found to have prediabetes and were at 
a high risk of developing diabetes.[55] 1.7 million people are affected by diabetes and it 
has been predicted that around 3.3 million people will develop the disease by 2031, 
costing around $10.3 billion in medical costs.[55] Indigenous Australians are three times 
more likely to develop T2D than non-Indigenous Australians.[55] 
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     1.1.6 Environmental and Genetic components of T2D 
T2D is a complex polygenic disorder influenced by genetic and environmental factors. 
However, due to the multiplicity of genes contributing to T2D development in diabetes 
patients and related family, no predominant genetic susceptibility locus that increases 
predisposition to T2D development has been discovered yet.[56] 
A population-based twin study of 606 twins in the Danish Twin Register showed that 
genetics play an important role in T2D development, with strong links to family 
history.[56] T2D has high heritability, where the life time risk of developing the disease 
is 40% in individuals with one diabetic parent, and increases to 70% if both parents are 
diabetic.[57] Interestingly, having a diabetic mother has been found to increase T2D 
development risk more than a diabetic father.[57] Among ethnic groups, Pima Indians 
and African-Americans in USA had a higher risk of developing T2D than Caucasians, 
with the same observation made in Indigenous and Torres Strait islanders in 
Australia.[54, 58]  
T2D is a multi-factorial polymorphic disorder with variants of multiple genes associated 
with pathogenesis. The advent of GWAS studies has identified more than 65 genetic 
variants that increase the risk of T2D development. Of these, at least 10 loci found are 
associated with β-cell dysfunction and fewer with insulin resistance or obesity. FTO 
gene which is associated with obesity was also discovered during the GWAS of 
diabetes, suggesting a close association between obesity and T2D.[37] Among the several 
loci found through GWAS, TCF7L2 (encoding transcription factor-7-like-2) was 
identified as the highest T2D susceptibility risk locus, with the T allele of the 
Rs7903146c/T polymorphism linked with β-cell demise. TCF7L2 has been proposed to 
regulate proglucagon gene expression, and synthesis of glucagon like peptide -1 (GLP-
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1) by the intestinal endocrine L-cells, which is associated with reduction of β-cell mass 
and function.[59] TCF7L2 polymorphisms in non-diabetic patients was found to cause 
predisposition to NAFLD, whereas in individuals with NASH, it was associated with 
increased hepatocyte apoptosis, altered adipokine profiles and  reduced β-cell 
function.[60] 
Individuals with mutation in candidate genes involved in glucose metabolism and 
insulin secretion, such as Calpain 10, PPAR-γ and GLUT2 have also been found to be at 
the most risk of developing T2D.[61]  
 
 
     1.1.7 Epidemiology of non-alcoholic fatty liver disease (NAFLD) 
NAFLD has become one of the most common chronic end-stage liver disorders 
worldwide due to its progression from simple steatosis to cirrhosis and liver failure. 
According to the 2014 Global Guidelines published by the World Gastroenterology 
Organization, the prevalence of NAFLD ranges from 20 to 40% of the general 
population in Western countries, and from 40-90% in the worldwide overweight/obese 
population of 2.1 billion people.[6, 62-64] NAFLD has been strongly associated with 
MetS, T2D and obesity, where 78% of NAFLD patients in an American 
epidemiological study were diagnosed with either T2D or impaired glucose tolerance 
(IGT).[6, 64, 65]  
Even East Asian countries like Japan, China and Korea have recently displayed an 
increase of 29% in the prevalence of NAFLD.[66, 67] In South Asia, up to 18% of the 
general population in Pakistan and over 19% of the urban population in India is affected 
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by NAFLD.[68, 69] The mechanisms by which Asians develop NAFLD are different from 
the people in western countries. Differences in genetic susceptibility, body fat 
distribution, diet and lifestyle, can cause ethnical variations in NAFLD prevalence. 
Epidemiological studies have also indicated that aging is another risk factor for 
increased susceptibility to NAFLD, although pediatric NAFLD is becoming 
increasingly common due to the increase in childhood obesity rates.[6, 63, 70]  
Older patients are found to be more vulnerable to NAFLD development, possibly due to 
the presence of more NAFLD risk factors, such as hypertension, T2D and 
hyperlipidemia. They are also more likely to progress to NASH compared to younger 
patients.[63, 71] Men over 20 years of age were twice more likely to be affected by 
NAFLD than women up to the age of 60, after which no significant gender difference 
was observed.[63, 71] In USA, NAFLD was observed to be most prevalent among the 
Hispanic population (45%), followed by Caucasians (33%) and African Americans 
(24%).[72] This could be correlated to differences in genetic predisposition to unhealthy 
body fat distribution, obesity, insulin resistance or T2D.  
In Australia, NAFLD has become the most prevalent liver disease with 40% of adults 
over 60 years of age developing NAFLD.[73] In 2012, 5.5 million Australians were 
affected by NAFLD, with a prediction of 7.2 million NAFLD affected persons by 2030. 
Fifteen % of Australian school children develop NAFLD.[74, 75] NAFLD increases the 
risk of liver cancer, with NSW witnessing an annual increase of liver cancer by 5.3% in 
men and 8.8% in women from 1997 to 2006.[76] In general, around 2000 Australians die 
due to NAFLD and related diseases each year. Chronic liver diseases like NAFLD and 
hepatitis have been found to have a total burden of $50.7 billion in the Australia health 
system.[75]  
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     1.1.8 Environmental and Genetic components of NAFLD 
GWAS have identified the rs738409, I148M allele of the patatin-like phospholipase 
domain-containing 3 gene (PNPLA3) as an important genetic contributor to NAFLD.[77] 
The PNPLA3 gene encodes for adiponutrin, an enzyme expressed in the liver and 
adipose tissue, responsible for the regulation of the hydrolysis of TG.[78] Homozygous 
carriers of this allele had double the hepatic fat content compared to non-carriers, and 
this allele was most prevalent in Hispanics and less in African-Americans.[79] Another 
variant of the PNPLA3 gene, PNPLA3-S453I, was found to be associated with low 
hepatic fat content and was most common in African-Americans and rare in 
Hispanics.[77] This suggests that the difference in NAFLD prevalence between different 
ethnicities could be due to variations in the genetic sequence of this gene. 
Homozygosity in the polymorphisms of the PNPLA3 gene has also been found to 
influence liver fibrosis in NAFLD patients and could determine NAFLD severity.[80]  
Other loci identified through meta-analysis of GWAS data were genes encoding 
neurocan (NCAN; rs2228603), protein phosphatase 1 regulatory subunit 3B (PPP1R3B; 
rs 4240624), glucokinase regulatory protein (GCKR; rs780094) and lysophospholipase-
like protein 1 (LYPLAL1; rs12137855), which have been associated with hepatic 
steatosis, lobular inflammation, altered serum lipid levels and fibrosis.[81] 
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1.1.9 Association between Obesity, T2D and NASH 
A strong association between diabetes and obesity has been extensively described. 
Recently, the term “diabesity” was coined to describe this close relationship. 
Observational studies of young men with no family history of diabetes on excessive 
calorie intake for 6 months showed that they displayed an increase in BMI, with 
reversible increases in fasting glucose, insulin and triacylglyceride levels.[82]  
Around 90% of people who develop T2D are obese or overweight suggesting that 
weight gain increases the risk of diabetes. High BMI and visceral adiposity are strongly 
associated with NAFLD and NASH.[48, 83] T2D and NASH often co-exist during 
obesity, where 69% of T2D patients develop NAFLD and the prevalence of NAFLD 
was found to be 64% in South Asian subjects with T2D, while it was only 20% in South 
Asians with normal glucose tolerance.[64, 84] In addition, NAFLD disease progression to 
NASH is more common in diabetic NAFLD patients when compared to non-diabetic 
NAFLD patients.[64] Obesity, insulin resistance and hyperinsulinemia are common 
entities for both T2D and NASH.[85, 86] 
Although there is good evidence for associations between obesity, T2D and NASH, the 
triggering mechanisms leading to NASH progression are still unknown. Exercise and 
diet weight loss intervention programs leading to reduction in obesity have shown 
improved blood glucose levels in diabetic patients and reduction in serum ALT levels in 
NAFLD patients.[87] Donnelly et al also observed that most of the lipids in the liver 
during NAFLD originated mostly from fatty acids from peripheral adipose tissue, 
suggesting that adipose tissue dysfunction may be causing hepatic steatosis during 
NAFLD.[88]  
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However, in the study conducted by Speliotes et al, it was suggested that fatty liver 
occurs due to dyslipidemia and abnormal glycemic levels, independent of visceral 
fat.[89] Excessive fuel intake has also  been associated with the development of insulin 
resistance and β-cell failure in susceptible cells (due to genetic or intra-uterine 
environmental factors), consequently leading to dyslipidemia and hyperglycemia.[90] A 
disturbance in circulating glucose and lipid homeostasis due to islet β-cell failure could 
affect peripheral tissues, like adipose tissue, as well as liver, causing pathological 
changes such as steatosis and inflammation, which are observed during NASH and 
adipose tissue dysfunction (Figure 1).[91]  
Failure of subcutaneous adipose tissue expansion to accommodate the excess nutrients 
and abnormal expansion of visceral adipose tissue, which causes hypoadiponectinemia 
and systemic inflammation, could be implicated in the pathogenesis of NASH.[85, 92] 
Adipose tissue dysfunction modulates the risk of liver injury and signals progression 
from hepatic steatosis to NASH, while pro-inflammatory adipose tissue hormones like 
tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) can cause inflammation and 
macrophage infiltration in the liver causing NASH.[93, 94] Taken together, this suggests 
that the adipose tissue could also play a primary role in the pathogenesis of NASH. 
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Figure 1: Potential interplay between pathogenic factors causing T2D and NAFLD/NASH. 
(Nolan et al, 2010)[91]. 
 
 
 
 
 
 
 
 
                                                                                                     Introduction 
 
 Page 15 
 
1.2 Obesity-related diseases 
     1.2.1 Obesity-related Type 2 diabetes (T2D) 
          1.2.1.1 Pancreatic islet architecture 
The pancreas is a glandular organ with both exocrine and endocrine functions. 
Endocrine cells only populate 2% of the entire pancreatic cell mass and are arranged in 
small clusters of cells called islets or islets of Langerhans.[95] Islets are comprised of 
five main cell types: glucagon producing alpha cells (α-cells), insulin producing beta 
cells (β-cells), somatostatin producing delta cells (δ-cells), pancreatic polypeptide 
producing gamma cells (PP-cells) and ghrelin producing cells (ε-cells).[96, 97] Human β-
cells are aligned along blood vessels and make up 55% of the islet, while rodent β-cells 
appear in clusters, making up 77% of the islet cells.[98, 99] β-cells maintain glucose 
homeostasis by producing and releasing insulin into the circulation.  
Insulin comprises of two amino acid side chains linked together by two disulphide 
bonds. Insulin mRNA translates into a single chain inactive precursor called 
preproinsulin, which is proteolytically excised in the endoplasmic reticulum (ER) and 
undergoes post-translational processing to generate proinsulin. Proinsulin consists of a 
B chain with an amino terminal, an A chain with a carboxy terminal and a connecting 
C-peptide in the middle. Several specific endopeptidases in the ER cleave C-peptide to 
generate mature and active insulin. This insulin and C-peptide are then packaged in 
golgi bodies and stored in secretory granules within the cytoplasm. Stimulation of β-
cells to secrete insulin leads to the release of insulin from the granules through 
exocytosis into circulation via the portal system.[100, 101] 
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          1.2.1.2 Glucose-stimulated insulin secretion (GSIS) 
In normal pancreatic β-cells, insulin secretion can be stimulated by several factors, 
including fuels such as glucose, amino acids and fatty acids, as well as non-fuel stimuli 
like neurotransmitters (acetylcholine), hormones and enteric factors (glucagon-like 
peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP)). The latter stimuli are 
known to potentiate nutrient-stimulated insulin secretion. Glucose stimulated insulin 
secretion (GSIS) is mediated by two pathways: the triggering or KATP dependent 
pathway (also known as classical pathway) and the amplifying or KATP independent 
pathway.[102, 103] 
Elevation in blood glucose concentrations results in facilitated diffusion of glucose 
across the β-cell plasma membrane via the glucose transporter (GLUT2 in rodents, 
GLUT1 in humans).[104, 105] Glucose undergoes glycolysis and generates pyruvate, 
which enters the Krebs cycle and generates ATP. An increase in ATP:ADP ratio causes 
closure of KATP dependent channels in the plasma membrane, preventing K+ ions flux 
across the membrane. Increase in intracellular K+ ion concentration creates a positive 
charge, leading to plasma membrane depolarization. This causes the opening of the 
voltage-gated calcium (Ca2+) channels, and consequent influx of extracellular Ca2+ ions. 
Increase in intracellular Ca2+ concentration triggers insulin granules exocytosis into 
circulation.[102, 106-108]  
Signals generated by the KATP dependent pathway are not enough to sustain insulin 
secretion. Thus, other metabolic coupling factors generated through glucose metabolism 
have been proposed as possible amplification pathways, such as the anaplerosis 
pathways, citrate cataplerosis and malonyl-CoA/LC-CoA pathway. In the anaplerosis 
pathways, glucose is catalyzed by pyruvate carboxylase to generate increased levels of 
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Krebs cycle intermediates such as NADPH and Malonyl-CoA from the malate-pyruvate 
shuttle. NADPH generated from the malate-pyruvate shuttle has been known to inhibit 
voltage-gated K+ channels and modulate GSIS. Malonyl-CoA blocks fatty acid 
oxidation and induces fatty acid esterification by inhibiting the action of carnitine 
palmitoyltransferase-1 (CPT-1), leading to accumulation of LC-CoA, TG, DAG and 
phospholipids in the cytosol. This causes accumulation of fatty acids and LC-CoA in 
the cytosol, leading to enhanced insulin secretion, since free fatty acids have been 
known to augment GSIS via KATP independent pathways.[106-111]  
 
          1.2.1.3 Effect of insulin on peripheral tissues 
Insulin is a pleiotropic hormone responsible for maintaining fuel homeostasis by 
regulating metabolic processes in tissues such as liver, skeletal muscle and adipose 
tissue.  
                (i) Effect of insulin on liver 
Insulin activates the intrinsic tyrosine kinase activity of the β-subunits of the insulin 
receptor which in turn phosphorylates proximal substrate proteins like insulin receptor 
substrate-1 (IRS-1).[112, 113] Tyrosine kinase activation of IRS-1 initiates a signaling 
cascade which branches into the phosphatidylinositol-3-kinase (PI3K)-AKT pathway 
and the Ras-mitogen activated kinase (MAPK) pathway.[113, 114] In the hepatocytes, the 
AKT pathway increases glycogen synthesis by inactivating glycogenolysis. Insulin 
promotes glycogenesis and inhibits gluconeogenesis and glycogenolysis by regulating 
the activity of enzymes involved in these processes. Glycolysis stops when circulating 
insulin levels are low, and glucagon stimulates glycogen breakdown instead.[115, 116]  
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Insulin promotes the synthesis and storage of lipids in hepatocytes and inhibits fatty 
acid oxidation. It enhances the activity of ATP- citrate lyase, which catalyzes cytosolic 
citrate into acetyl CoA and oxaloacetate (OAA) during lipogenesis.[117] Insulin also 
stimulates the expression of lipogenic genes such as acetyl CoA carboxylase and fatty 
acid synthase that are involved in the conversion of acetyl CoA into acyl CoA, which 
can be converted into triacylglycerides (TG) and stored in lipid droplets.[118, 119] In 
rodents, liver-specific insulin receptor knockout has been found to lead to severe insulin 
resistance, glucose intolerance and failure of insulin to inhibit hepatic glucose 
production and progressive hepatic dysfunction.[120] 
 
               (ii) Effect of insulin on skeletal muscles 
High blood glucose levels activate insulin secretion, which in turn promotes glucose 
uptake in skeletal muscles through glucose transporter GLUT4. GLUT4 is present in 
cytoplasmic vesicles as preformed transporters that translocate to the plasma membrane 
upon insulin receptor activation. When the insulin receptor is inactive, GLUT4 returns 
to the cytoplasmic vesicles.[121]  
Similar to hepatocytes, in skeletal muscles, the insulin-activated signaling cascade 
stimulates glycogen synthesis and storage. It also promotes glycolysis. Insulin increases 
the storage of circulating fatty acids as TG in myocytes, which is used during exercise 
and for heat production.[116, 122, 123] Similar to insulin, exercise causes GLUT4 
recruitment and increased glucose oxidation in skeletal muscles, causing up-regulation 
of glucose uptake.[124, 125] Skeletal muscle specific disruption of the insulin receptor gene 
in mice leads to elevated serum TG and free fatty acid levels and increases fat mass, but 
normal blood glucose and insulin levels are maintained, suggesting that insulin 
                                                                                                     Introduction 
 
 Page 19 
 
resistance in muscle plays a secondary role in disruption of glucose homeostasis 
compared to other tissues such as liver and adipose tissue.[126] 
 
               (iii) Effect of insulin on adipose tissue 
Similar to skeletal muscle, glucose uptake into adipocytes is facilitated by the insulin 
regulated GLUT4 transporter. GLUT4 expression in adipose tissue is reduced during 
obesity and T2D. Mice with adipose specific GLUT4 reduction have normal growth and 
adipose tissue mass, but develop glucose intolerance and hyperinsulinemia. [127] 
Unlike in liver and skeletal muscles, insulin promotes the storage of glucose in the 
adipocytes in the form of TG, instead of glycogen, by stimulating the action of pyruvate 
dehydrogenase (PDH) and acetyl CoA carboxylase (ACC).[128, 129] Insulin also 
stimulates the translocation of lipoprotein lipase (LPL) to the endothelial cells, where it 
hydrolyzes circulating chylomicron and VLDL TG to generate glycerol and fatty acids, 
which then enters the adipocytes to form TG.[130] Insulin prevents the lipolysis of the 
TG stored in the lipid droplets by inhibiting the action of hormone sensitive lipase 
(HSL), which is one of the main enzymes responsible for the lipolysis of TG into 
diacylglycerols and monoacylglycerols.[131] 
Adipocyte specific disruption of the insulin receptor gene in mice leads to low fat mass 
and protection against hypothalamic lesion-induced obesity and obesity-related glucose 
intolerance, due to failure of insulin to induce fat accumulation. However, the 
adipocytes of these mice exhibited a decrease in expression of adipogenic genes such as 
fatty acid synthase (FAS), CCAAT/enhancer binding protein-α (C/EBP-α) and sterol 
response element-binding protein-1c (SREBP-1c).[132]  
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          1.2.1.4 β-cell compensation 
Islet β-cells compensate with enhanced insulin secretion in response to obesity-related 
insulin resistance, in order to maintain euglycemia, through two mechanisms: β-cell 
mass expansion and β-cell function enhancement.[133, 134]  
Compensatory increase in β-cell mass occurs predominantly by increase in β-cell 
number by replication and possibly reduced apoptosis. Some of the factors responsible 
for stimulating β-cell mass expansion are short-term increase in circulating glucose and 
fatty acid levels, enhanced activation of IRS2 by insulin and insulin like growth factors 
(IGF) and increase in incretin hormones like GLP-1 which stimulate Pdx1 expression, 
promote β-cell proliferation and reduce apoptosis.[90, 135-137] In response to insulin 
resistance, islets enhance β-cell function and insulin secretion by increasing glucose 
metabolism via up-regulated GLUT2 activity and up-regulation of both the KATP 
dependent and independent pathways.[138, 139] In addition, increased expression of GLP-1 
can potentiate GSIS along with promoting cell growth.[140] Both glucose and GLP-1 can 
also promote the transcription of the insulin gene to increase insulin biosynthesis.[141] 
Individuals unable to adequately compensate for insulin resistance by either mechanism 
are predisposed to develop diabetes.[134, 135, 138, 141, 142]  
 
 
 
 
 
 
                                                                                                     Introduction 
 
 Page 21 
 
          1.2.1.5 Pathophysiology of T2D 
Over-nutrition and obesity have been strongly associated with insulin resistance, where 
a chronic excess supply of glucose and fatty acids in the blood can lead to a continuous 
increased demand for insulin secretion.[143, 144] Insulin resistance develops when target 
tissues generate a subnormal biological response to a normal concentration of 
insulin.[143, 145] Loss of insulin action could also stem from defects in the insulin 
signaling cascade or the increased activity of pro-inflammatory cytokines like TNF-α in 
the adipose tissue, which has been known to decrease insulin sensitivity. Expression of 
insulin receptor substrate (IRS) and insulin receptors were found to be reduced in 
rodents and humans with T2D.[145, 146] However, insulin resistance alone does not cause 
or aggravate diabetes, unless the β-cells are susceptible to dysfunction as well. 
T2D develops when the islet β-cell is unable to adequately sustain the compensatory 
mechanisms of increased β-cell mass and/or enhanced β-cell function to increase insulin 
secretion, in response to insulin resistance.[100, 143] Increase in β-cell apoptosis and/or 
reduction in cell regeneration decreases β-cell mass and causes β-cell failure, leading to 
T2D development.[142, 147] Decrease in β-cell compensation due to loss of β-cell mass 
could lead to T2D since a 38% reduction in β-cell mass was observed during autopsy of 
T2D patients of European origin, compared to matched controls.[148] Loss of β-cell mass 
and consequential abnormal insulin secretion in T2D has been observed to occur when 
high levels of circulating glucose and fatty acid levels co-exist (known as 
glucolipotoxicity). Reduction in β-cell mass has been described during islet 
inflammation augmented by reactive oxygen species (ROS) or endoplasmic reticulum 
(ER) stress.[149, 150]  
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     1.2.2 Obesity-related non-alcoholic steatohepatitis (NASH) 
Liver is a pleiotropic organ with critical roles in carbohydrate and lipid metabolism, 
synthesis of plasma proteins and drug detoxification. The liver plays an important role 
in maintenance of glucose homeostasis in a non-diabetic state through uptake of excess 
glucose levels during post-prandial states or by production of glucose during fasting 
state.[151] In the last few decades, the Westernized lifestyle (increased food intake and 
reduced physical activity) leading to increased prevalence of obesity and MetS have 
promoted pathophysiological changes in the liver. Although adipose tissue stores 
circulating free fatty acids in lipid droplets within adipocytes, chronic excess nutrient 
supply can lead to ectopic deposition of excess fatty acids into the liver in the form of 
triacylglyceride (TG) leading to steatosis and lipotoxicity, possibly progressing to 
cirrhosis and hepatocellular cancer.[152]  
 
          1.2.2.1 Liver architecture 
The liver is divided by fissures into four distinct lobes: the left, right, caudate and 
quadrate lobes. Each lobe is formed by thousands of hexagonal lobules, which contains 
a central vein surrounded by six hepatic portal veins and six hepatic arteries; all 
connected by a fenestrated net of capillaries called sinusoids.[153] The hepatic lobules are 
made up of three main cell types: cholangiocytes, kupffer cells and hepatocytes. 
Cholangiocytes form bile ducts to transport bile and maintain the pH and secretion of 
bile.[154] Kupffer cells are macrophage cells responsible for innate immune responses 
and host defense in the liver, detoxification of blood from bacteria, viruses, parasites, 
endotoxins, alcohol and drugs, as well as the breakdown of old erythrocytes into 
bilirubin, a component of bile.[155] In addition, Kupffer cells have also been found to 
                                                                                                     Introduction 
 
 Page 23 
 
trigger early phase NASH development in a diet-induced obese mouse model, by 
increasing the production of tumor necrosis factor-α (TNF-α) and leading to recruitment 
of monocyte chemoattractant protein-1 (MCP-1).[156] Hepatocytes make up 80% of the 
liver parenchyme and perform the most crucial metabolic functions of the liver, 
including hepatic glucose utilization and hepatic glucose production.[153] 
 
          1.2.2.2 Normal hepatocyte biology 
               (i) Glucose metabolism in hepatocytes 
Circulating glucose rapidly enters hepatocytes through GLUT2, a bidirectional 
transmembrane glucose transporter which functions independent of insulin regulation. 
Hepatocytes rapidly take up excess circulating post-prandial glucose. Glucokinase 
phosphorylates the absorbed glucose to glucose-6-phosphate (G6P), trapping it within 
the hepatocytes, since G6P cannot be transported out through GLUT2. Glycogen 
synthase then synthesizes glycogen from G6P (glycogenesis) and also produces 
pyruvate (glycolysis) to generate mitochondrial ATP via the Krebs cycle.[157] Low blood 
glucose levels during short term fasting state activate glycogen phosphorylase to 
depolymerize glycogen back to glucose (glycogenolysis), which is released into 
circulation. However, if hepatic glycogen reserves deplete, hepatocytes synthesize 
glucose from amino acids, glycerol and non-hexose carbohydrates like lactate and 
pyruvate (gluconeogenesis).[158]  
Amino acids undergo deamination into α-ketoacids, which are converted to precursors 
of the Krebs cycle.[158] Lactate and pyruvate enter the Krebs cycle to produce 
oxaloacetate (OAA), which is released from the mitochondria in the form of malate, and 
reverts back to OAA once in the cytoplasm. Phosphoenolpyruvate carboxylase 
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(PEPCK) catalyzes the conversion of OAA into phosphoenolpyruvate (PEP), which 
undergoes various phosphorylation cycles to produce fructose-6-phosphate (F6P). F6P 
is finally converted to G6P and dephosphorylated to generate hepatic glucose in the 
endoplasmic reticulum. Murine studies have shown that PEPCK null livers cause 
decrease in whole body gluconeogenesis from PEP, but maintain euglycemia during the 
fasting state by gluconeogenesis from glycerol.[159] Inhibition of the Krebs cycle leads to 
accumulation of Krebs cycle intermediates which increases hepatic steatosis.[160] 
Gluconeogenesis is regulated by pancreatic hormones insulin (inhibits) and glucagon 
(stimulates), growth hormone (GH) which stimulates PEPCK expression through 
JAK2/STAT5 pathway and gastrointestinal molecules like FGF19 and glucagon-like 
peptide 1 (GLP-1).[161-163] 
 
               (ii) Lipid metabolism in hepatocytes 
TG present in circulating chylomicrons and adipose tissue, upon contact with lipase 
enzymes, is hydrolyzed into free fatty acids (FFA) and glycerol.  FFAs are transported 
into the hepatocytes via membrane-bound transport protein fatty acid translocase 
(FAT)/CD36 and fatty acid transport proteins (FATP). FFAs that enter hepatocytes 
either undergo oxidation to generate energy and ketone bodies, or are converted to TG 
to be stored in lipid droplets inside the hepatocytes or exported as very low density 
lipoproteins (VLDL) into circulation.  
During low blood glucose levels (fasting state), β-oxidation of short, medium and long 
chain fatty acids (LCFA) occurs in the mitochondria, while very long chain fatty acids 
are metabolized in the peroxisomes. Mitochondrial β-oxidation produces acetyl-CoA 
and generates 14 ATP of energy per oxidation cycle via the electron transport chain.[164] 
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Peroxisome proliferator-activated receptor-α (PPAR-α) has been identified as the main 
regulator of fatty acid β-oxidation. PPAR-α agonists stimulate mitochondrial β-
oxidation in liver and skeletal muscles while PPAR-α nullizygous mice displayed 
reduced constitutive mitochondrial fatty acid β-oxidation.[165, 166] Peroxisomal α-
oxidation and microsomal ω-oxidation produce H2O2 instead of NAD+, and less ATP 
since peroxisomes do not have an electron transport chain like mitochondria.[167] 
Peroxisomal and microsomal oxidation function with the mitochondria to maintain lipid 
homeostasis, although increased peroxisomal oxidation produces more reactive 
oxidation species causing hepatic oxidative stress.[168]  
Hepatocytes are capable of de novo lipogenesis by metabolizing pyruvate into citrate via 
the Krebs cycle. Citrate is then exported into the cytoplasm and ATP-citrate lyase 
(ACP) cleaves it into acetyl-CoA and OAA. Acetyl-CoA carboxylase (ACC) and fatty 
acid synthase (FAS) convert acetyl-CoA first into malonyl-CoA and then into palmitic 
acid, respectively. Palmitic acid forms mono- and poly-unsaturated LCFA by the action 
of fatty acyl-CoA elongase 6 (EVOVL6) and stearoyl-CoA desaturase-1 (SCD-1).[169] 
De novo lipogenesis only makes a minor contribution to the total hepatic lipid pool. The 
expression of lipogenic genes like FAS, ACC and SCD-1 are promoted by insulin-
stimulated SREBP1c, and glucose-activated carbohydrate response element binding 
protein (ChREBP).[170, 171]  
 
               (iii) Protein metabolism in hepatocytes 
Hepatocytes are also the site for deamination and transamination of amino acids, by 
enzymes such as aspartate aminotransferase (AST) and alanine transaminase (ALT) 
which are used as clinical markers for liver damage.[172, 173] Hepatocytes also synthesize 
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most of the circulating plasma proteins, most importantly albumin, prothrombin and 
fibrinogen. Albumin is necessary for the maintenance of plasma osmotic pressure and 
transport of drugs, hormones and metabolites, whereas prothrombin and fibrinogen are 
important components of the coagulation system.[174]  
 
          1.2.2.3 Pathophysiology of NAFLD 
NAFLD encompasses a wide pathological spectrum ranging from simple steatosis, to 
fibrosis and cirrhosis, in the absence of significant alcohol intake (<20 g ethanol/day in 
women, <30 g ethanol/day in men) (Figure 2).[62] Simple steatosis is characterized by 
excessive fat accumulation in the liver in the form of TG, without inflammation or 
hepatocellular injury. This occurs due to altered hepatic lipid metabolism derived from 
an imbalance between lipid intake and production (fatty acid uptake, de novo 
lipogenesis) and lipid output (mitochondrial fatty acid β-oxidation and lipoprotein 
synthesis and export) in the hepatocytes.[92] Simple steatosis is a benign condition and 
does not cause major hepatocellular injury, unless it progresses to NASH, which is the 
more severe form of NAFLD. Several studies have shown that around one-third of 
NAFLD patients progress to develop NASH, with reduction in survival rate due to 
cardiovascular disorders and other liver-related complications.[175, 176]  
NASH is characterized by steatosis in more than 5% of hepatocytes, accompanied by 
lobular and portal inflammation (macrophage and lymphocyte inflammation), 
hepatocyte injury (ballooning degeneration of parenchymal hepatocytes and the 
presence of Mallory bodies), and even hepatic fibrosis.[92] NASH may remain 
asymptomatic for years in most cases, but up to one-third of NASH patients develop 
cirrhosis, ultimately leading to liver failure and/or liver cancer (hepatocellular 
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carcinoma) due to the destruction of hepatocytes by inflammatory cells (hepatocellular 
necrosis).[177]  
Despite various efforts, the exact mechanism involved in NAFLD progression to NASH 
is still unclear. Day and James proposed the “two-hit” theory to explain the 
pathogenesis of NASH. According to this theory, the “first hit” is the development of 
hepatic lipid accumulation (simple steatosis), which is not enough to cause NASH 
development. But it renders the liver more vulnerable to other cellular stresses (2nd hit), 
causing further pathogenic processes characteristic of NASH, which include 
inflammation, fibrosis and hepatocellular apoptosis. Of note, several factors have been 
suggested to play a role as the 2nd hit in NASH pathogenesis, including pro-oxidant 
agents initiating hepatic lipid peroxisomal α-oxidation and microsomal ω-oxidation with 
the production of reactive oxygen species (ROS), circulating pro-inflammatory 
cytokines which may originate in inflamed adipose tissue, and excess exposure of liver 
to gut-derived bacterial endotoxins.[168, 178, 179]  
However, this theory has now been modified to a more globally recognized “multi-hit” 
hypothesis; where the “first hit” has been identified to be insulin resistance with its 
associated factors of hyperglycemia, hyperlipidemia and hyperinsulinemia, which cause 
hepatic steatosis. This leaves the liver susceptible to “multiple hits” of oxidative stress 
from increased production of ROS, altered adipokines such as reduced adiponectin and 
increased TNF-α, endoplasmic reticulum stress, apoptosis and/or overexpression of Toll 
like receptors (TLR).[180] These “multiple hits” are different in each individual, making 
it difficult to identify a common established cause of NASH pathogenesis among the 
general population. 
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Figure 2: Representation of the pathological spectrum of NAFLD ranging from simple steatosis 
to non-alcoholic steatohepatitis (NASH) and finally ending with cirrhosis and hepatocellular 
carcinoma. 
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1.2.3 Obesity-related adipose tissue dysfunction and inflammation 
     1.2.3.1 Adipose tissue architecture 
Adipose tissue is a loose connective tissue consisting of a heterogeneous cell population 
constituted by mature adipocytes (fat cells), supported by a framework of stromal cells 
which includes preadipocytes, fibroblasts, mesenchymal stem cells, endothelial cells 
and immune cells (in particular, adipose tissue macrophages). White adipose tissue 
(WAT) forms the majority of the adipose tissue mass and is located in large 
subcutaneous and visceral depots throughout the body, whereas brown adipose tissue 
(BAT) has limited distribution, particularly in adult individuals.[181] 
 
          (i) White adipose tissue (WAT) 
WAT is located throughout the body in the connective tissues underlying the skin 
(subcutaneous), between muscles and relates to many internal organs in the body 
(visceral). Each depot has its distinct morphology, developmental time and function.  
In rodents, subcutaneous WAT develops before the visceral (peri-ovarian, mesenteric) 
WAT. White adipocytes generally have a unilocular appearance with a single large lipid 
droplet occupying most of the cell, pushing the cytoplasm and nuclei to the 
periphery.[182] Subcutaneous adipocytes are heterogeneous with mature unilocular 
adipocytes interposed with small multilocular adipocytes, whereas visceral adipocytes 
are more homogenous with mostly unilocular adipocytes.[152]  
Subcutaneous adipocytes have a higher adipocyte turnover rate to allow enhanced 
storage of large amounts of TG through increased adipocyte differentiation and cell size 
expansion.[183] This reduces lipid accumulation in visceral adipocytes and ectopic 
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deposition in liver and muscles. Subcutaneous adipocytes also respond more to 
estrogen, while visceral adipocytes are stimulated by glucocorticoids.[184] This explains 
why pre-menopausal women are more predisposed to increased subcutaneous adipose 
tissue expansion. Subcutaneous adipocytes also express higher levels of leptin, 
adiponectin and glycogen synthase, while visceral adipocytes express increased levels 
of pro-inflammatory adipokines such as IL-6.[152] Therefore subcutaneous adipocytes 
may play a protective role against inflammation. Abnormal lipid distribution into 
visceral adipose tissue leading to visceral or central obesity has been positively 
associated with insulin resistance and increased lipolysis and inflammatory cell 
infiltration.[185]  
 
          (ii) Brown adipose tissue (BAT) 
Brown adipose tissue is distinct from white adipose tissue in morphology, biological 
function and developmental time. During human gestation, BAT development is earlier 
than WAT and makes up 5% of the body weight in infants, which then regresses with 
age and is replaced by WAT instead.[152] Interestingly, recent studies using 
integrated 18F-flurodeoxyglucose positron emission tomography and computed 
tomography (PET-CT) scans have found major depots of metabolically active fat in the 
cervical-supravicular region of adult humans. BAT was found to be prevalent 
predominantly in females. This observation suggests that BAT may potentially play a 
greater role in human metabolism than previously described.[186-190]  BAT is prominent 
in small mammals living in cold environments and in hibernating animals. In adult 
mice, it is present as two large lobulated brown depots on the dorsal region of the 
thorax, between the scapulae.[191]  
                                                                                                     Introduction 
 
 Page 31 
 
Brown adipocytes are smaller and fewer in number and are characterized by multi-
locular lipid droplets of varying sizes with considerable cytoplasm volume and single 
central round nuclei.[152] They also have high mitochondrial content, giving it its 
characteristic brown color, and unlike white adipocytes, they express mitochondrial 
uncoupling protein-1 (UCP-1), which allows the mitochondria to uncouple oxidative 
phosphorylation in the electron transport chain to generate heat instead of ATP.[192] 
BAT converts nutrients into heat to provide non-shivering thermogenesis to aid 
newborns in adapting to a lower external temperature.[193] BAT mass has been found to 
be inversely correlated to BMI, especially in ageing humans and has also been shown to 
protect mice from diet-induced obesity. [186, 188, 194-197] Therefore, beside cold-induced 
thermogenesis, BAT may possibly play a therapeutic role in protection from diet-
induced obesity and diabetes.  
Increasing interest has been on beige or brite adipocytes, brown-like adipocytes present 
within WAT, inducible by cold or catecholamine stimuli. In mice, beige adipocytes 
develop after brown adipocytes, but regress into WAT. Unlike brown adipocytes, beige 
adipocytes originate from non-Myf5 stem cells. Unlike white adipocytes, they express 
low levels of UCP-1 which is activated with cAMP stimulation. The genetic expression 
pattern of beige adipocytes is different from both white and brown adipocytes.[198, 199]  
 
     1.2.3.2 Adipocytes: Origin and differentiation 
Adipose tissue is responsible for the storage and accumulation of fat in the body. 
Excessive nutrient supply in healthy individuals is stored in adipocytes as TG and very 
little accumulates in other tissues such as liver, skeletal muscles and pancreas. However, 
in obese unhealthy individuals (metabolically unhealthy obesity), adipocytes are unable 
to accommodate all the excess fats, consequently leading to spillover of TG into other 
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tissues which can cause tissue dysfunction. Obesity leads to adipose tissue expansion, 
which can occur via an increase in number of adipocytes (hyperplasia) and increase in 
size (hypertrophy) as well.[200]  
The process where fibroblast-like preadipocytes differentiate into mature lipid-laden 
adipocytes, able to store fat, is known as adipogenesis. Adipogenesis is a complex 
multi-step dynamic process regulated by various transcription factors and cell cycle 
proteins, comprising of 3 distinct phases: preadipocyte determination, growth of 
preadipocytes and terminal differentiation (Figure 3). Adipogenesis can produce two 
different cell types: white adipose tissue (WAT) and brown adipose tissue (BAT), as 
previously discussed.  
          1.2.3.2.1 Preadipocyte determination phase 
In the determination phase, mesenchymal stem cells (MSC) are converted to 
morphologically similar committed preadipocytes, which then can differentiate into 
adipocytes only.[201] This phase has been mostly studied in pluripotent fibroblast cell 
lines like C3H10T1/2 (10T1/2) cells and from adipose derived stem cells (ADSC). 
ADSC have been purified from the stromal vascular fraction (SVF) of the adipose tissue 
and can differentiate in vitro into mature adipocytes, allowing an insight into in vivo 
preadipocyte commitment.[202] Despite numerous studies conducted in C3H10T1/2 cell 
lines, no adipocyte specific commitment factor has been identified until now.  
          1.2.3.2.2 Preadipocyte growth arrest phase 
In humans, adipocyte differentiation begins before birth, but most occurs shortly after 
birth; whereas in rodents, preadipocytes only begin differentiation after birth.[201, 
203] Clonal cell lines are mostly used to study the pathways leading to the differentiation 
of committed preadipocytes. Primary preadipocyte cell cultures are not commonly used 
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to study differentiation since these cells are morphologically similar to fibroblasts and 
are at different stages of differentiation. Besides, these cells also have a limited life span 
in culture and only constitute a small percentage of the total adipose tissue.[201] 
Therefore, preadipocyte cell lines such as 3T3-L1 cells, already committed to the 
adipocyte cell lineage, are used instead. These cell lines have a homogenous cell 
population at the same differentiation stage, allowing uniform response to 
treatments.[204]  
3T3-L1 is a unipotent preadipocyte cell line which has undergone the determination 
phase and can either remain as a committed preadipocyte population, or undergo 
differentiation with hormonal induction.[204] Differentiated 3T3-L1 cells can form fat 
tissue that is very similar to adipose tissue in vitro, as well as in vivo when implanted in 
athymic mice.[205] Maximal differentiation is achieved by early hormonal induction of 
3T3-L1 cells, by a defined adipogenic cocktail made of insulin, dexamethasone (DXM) 
and methylisobutylxanthine (MIX), and fetal bovine serum (FBS), collectively termed 
as MDI (MIX, DXM and Insulin).[200, 201]  
Within an hour of MDI induction in vitro, 3T3-L1 preadipocytes start expressing the 
transcriptional factors CCAAT/enhancer binding protein (C/EBP) β and δ.[206] After 24 
hours, preadipocytes undergo a post-confluent mitosis called mitotic clonal expansion 
(MCE) and by day 2, enter into an unusual growth arrest called GD.[207] This growth 
arrest phase is necessary to unwind DNA, allowing transcription factors to induce or 
silence genes related to adipogenesis and adipocyte phenotype.[201, 206] After day 2, 
growth arrested cells begin to express differentiation markers, such as PPAR-γ and 
C/EBP-α. This triggers changes in cell morphology from a fibroblast like shape to a 
spherical shape, followed by the ability to accumulate lipid droplets by terminal 
differentiation by day 5-7 of MDI induction.[200]  
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Figure 3: Schematic representation of adipocyte differentiation. Abbreviations used: BMP: 
Bone morphogenetic protein, C/EBP: CCAAT/enhancer binding protein, FGF: Fibroblast 
growth factor, PPAR: Peroxisome proliferator-activated receptor, TGF: Transforming growth 
factor. 
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          1.2.3.2.3 Terminal differentiation phase  
Terminal differentiation is driven by the action of a number of transcription factors 
leading to activation of adipogenic genes. 
 
                (i) CCAAT/enhancer binding protein (C/EBP) 
C/EBP transcription factors are characterized by their ability to bind to the CCAAT 
motif in several gene promoters, and have 5 isoforms- α, β, δ, ε and ξ (CHOP-10). 
C/EBPβ and δ are early regulators of differentiation while C/EBP-α is a late adipogenic 
regulator with PPAR-γ.[208] CHOP-10 acts as a dominant negative C/EBP function and 
C/EBP-ε has no known adipogenic function.[209]  
 
               C/EBP-β and δ 
C/EBP-β and δ are the first transcription factors to be expressed after adipogenic 
induction. Overexpression of either C/EBP-β or δ in 3T3-L1 preadipocytes accelerates 
adipocyte differentiation.[200] On the other hand, mice lacking either C/EBP-β or 
C/EBP-δ display reduced lipid accumulation and UCP-1 expression in their BAT, 
whereas WAT seems to develop normally. Deletion of both C/EBP-β and C/EBP-δ 
causes severe impairment in adipocyte development with 15% survival rate only. Alive 
mice have severe reduction in BAT mainly due to reduced lipid accumulation, and 
moderate impairment in WAT tissue mass, due to reduced cell number, without 
alterations in the cell size or morphology.[210] During mitotic clonal expansion of 
preadipocytes, C/EBP-β is phosphorylated and activated by glycogen synthase kinase-3 
(GSK-3) and mitogen activated protein kinase (MAPK), thus acquiring its DNA binding 
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potential.[200] C/EBP-β and δ directly induce expression of C/EBP-α and PPAR-γ, which 
are key transcriptional regulators of adipogenesis.[211] 
 
               C/EBP-α 
C/EBP-α is a pleiotropic transcriptional activator of genes specific to adipocytes. Its 
expression is induced by C/EBP-β and δ within 2 days of MDI expression along with 
PPAR-γ expression.[200] Although initial activation of C/EBP-α is by C/EBP-β and δ, 
C/EBP-α is also induced by PPAR-γ, and once expressed, it can auto-activate itself to 
maintain its own expression. It can also bind to its site on the PPAR-γ promoter and 
mutually induce each other, forming a stable regulatory loop.[200] C/EBP-α acts 
synergistically with PPAR-γ to activate transcription of adipogenic genes like FABP4, 
leptin, SCD-1 and GLUT4.[200] However, C/EBP-α alone cannot induce adipogenesis, as 
observed when ectopic C/EBP-α expression in mouse embryonic fibroblasts lacking 
PPAR-γ, failed to induce adipogenesis, whereas PPAR-γ alone could initiate 
adipogenesis in C/EBP-α deficient cells.[212] Insulin has also been found to reduce 
C/EBP-α mRNA and protein levels since two of the three phosphorylation sites of 
C/EBP-α (Thr 222 and Thr 226) are insulin sensitive sites phosphorylated by GSK3.[213]  
C/EBP-α overexpression in 3T3-L1 cells can stimulate adipogenesis even without MDI 
induction, whereas blocking C/EBP-α expression with an antisense C/EBP-α RNA 
inhibits adipocyte differentiation.[214, 215] C/EBP-α null mice had defective lipid 
accumulation and died from hypoglycemia within 8 hours, proving its importance in 
adipogenesis.[216] 
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               (ii) Peroxisome proliferator activated receptor-γ (PPAR-γ) 
PPAR-γ belongs to the nuclear hormone receptor super family of ligand activated 
transcription factors, and has two isoforms: the constitutively expressed γ1 and the 
adipose tissue restricted γ2.[217] PPAR-γ is the master regulator of preadipocyte 
differentiation and plays a central role in the maintenance of mature adipocyte function 
and insulin sensitivity.[218] Generation of PPAR-γ (-/-) mice leads to complete absence 
of adipose tissue, whereas PPAR-γ (+/-) mice are resistant to diet-induced obesity.[219, 
220] Adenoviral expression of a dominant negative PPAR-γ into mature differentiated 
3T3-L1 adipocytes caused dedifferentiation.[221] Selective deletion of PPAR-γ in mature 
adipocytes of mice led to reduced cell viability, causing apoptosis within a few days.[222] 
Humans with dominant-negative mutations in a single allele of PPAR-γ were found to 
develop partial lipodystrophy and insulin resistance.[223]  
PPAR-γ is responsible for activating adipogenic genes like adipose protein-2 (aP2), 
lipoprotein lipase (LPL), acyl CoA synthase and phosphoenolpyuravate carboxykinase 
(PEPCK), by binding to the peroxisome proliferator response element in the promoters 
of these target genes.[200] Activated PPAR-γ directly targets adiponectin, which 
promotes fatty acid oxidation and insulin sensitivity.[224, 225] PPAR-γ also controls genes 
involved in glucose homeostasis by increasing GLUT expression.[226] PPAR-γ can also 
be anti-inflammatory causing reduced TNF-α production.[227] Although the 
transcriptional activity of PPAR-γ can be controlled by exogenous natural ligands such 
as long chain polyunsaturated fatty acids and synthetic ligands such as 
thiazolidinediones (TZD), identification of an endogenous ligand responsible for the 
regulation of PPAR-γ activity during adipogenesis has not been determined yet.[228] 
SREBP-1c expression has been found to be up-regulated during early adipogenesis, 
suggesting a role in the production of the endogenous PPAR-γ ligand.[229] 
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               (iii) Sterol regulatory element binding protein-1c (SREBP-1c) 
SREBP-1c is a pro-adipogenic, basic helix-loop-helix leucine zipper transcription factor 
implicated in stimulating endogenous PPAR-γ ligand production and inducing PPAR-γ 
expression.[229] It is activated post-prandially by insulin and targets lipogenic genes that 
encode for enzymes like FAS, HMG-CoA synthase, LDL-receptor and acetyl CoA 
carboxylase (ACC).[230] Adipose determination and differentiation factor 1 (ADD1) in 
rat adipocytes are homologous to human SREBP-1c.[229]     
SREBP-1c remains membrane bound in the endoplasmic reticulum until activation by 
cholesterol, which causes translocation to Golgi bodies for proteolytic cleavage. 
SREBP-1c is then released into the cytosol and enters the nucleus to bind to target genes 
through the sterol response element for gene activation.[230] In vitro, insulin has been 
found to increase SREBP-1c mRNA levels in isolated rat hepatocytes, while glucagon 
has the reverse effect.[231] In vivo, fasting mice with low insulin and high glucagon 
levels have reduced SREBP-1c mRNA levels and less activity of SREBP-1c target 
genes.[232] During adipogenesis, SREBP-1c mRNA levels were found to be increased 
within the first day of MDI induction of 3T3-L1 preadipocytes.  
Overexpression of SREBP-1c in these cells increased PPAR-γ mRNA levels.[229] 
However, SREBP-1c null mice had normal adipose tissue, suggesting compensatory 
action by SREBP-2, another isoform of SREBP family capable of stimulating 
endogenous PPAR-γ ligand production.[233] 
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     1.2.3.3 Adipocyte turnover 
Adipocyte turnover is a dynamic process that occurs throughout one’s life span. 
Adipose tissue can respond to excess energy by expanding up to 60-70% of body 
weight by two mechanisms: hypertrophy and hyperplasia.[234] Hypertrophy entails an 
increase in individual adipocyte size due to enhanced storage of TG within lipid 
droplets. Excessive adipocyte hypertrophy can cause adipocyte dysfunction.  
Hyperplasia entails an increase in total adipocyte number. Stem cells present in the 
adipose tissue proliferate and differentiate into new adipocytes which provides an 
alternative to adipocyte hypertrophy for storage of excess lipids in circulation.[235] 
Rodents have a higher adipocyte proliferation rate than humans, where it is estimated 
that young adult mice generate approximately 15% new adipocytes per month.[235] In 
humans, only around 10% of adipocytes are renewed annually at all adult stages.[236] 
However, total adipocyte number is believed to be determined during childhood and 
adolescence and does not change with later weight gain or loss. Therefore, life-long 
obesity occurs primarily through adipose hyperplasia, while hypertrophy contributes to 
adult onset-obesity or obesity worsening.[237]   
 
     1.2.3.4 Adipose tissue physiology 
          1.2.3.4.1 Regulation of glucose and lipid homeostasis 
Adipose tissue serves a protective role as an insulating buffer and structural support for 
internal organs. However, its key metabolic functions in the body are the storage of 
excess circulating fatty acids during surplus and mobilization of TG during deficit, and 
secretion of adipocytokines.[152]  
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               1.2.3.4.1.1 Fatty acid transport into adipocytes 
Circulating dietary TG packaged in chylomicrons (from the gut) and VLDLs (from the 
liver) are too large to enter adipocytes and therefore need to be hydrolyzed by the action 
of LPL.[238] They are then transported into the adipocyte by the action of proteins like 
CD36, fatty acid transport protein (FATP) and aP2/FABP4.  
 
               (i) CD36 
CD36 (or fatty acid translocase in mice) is an integral membrane protein expressed on 
macrophages, adipocytes, hepatocytes and myocytes. It is primarily known as a 
scavenger receptor which has the ability to recognize foreign substances and as 
pathogens, thus playing a major role in immune defense, as well as many endogenous 
molecules and particles including oxidized LDLs.[239] However, in adipocytes it is 
considered an important facilitator of fatty acid uptake since CD36 null mice have 
defective fatty acid uptake and severely reduced fatty acid oxidation.[240]  
CD36 is also a marker for adipose differentiation since implantation of CD36 gene 
silenced preadipocytes in athymic mice reduced de novo fat pad formation.[241] Mice 
with CD36 deletion are lean and protected from high fat diet induced obesity.[242] 
Conversely, muscle-specific overexpression of CD36 in mice causes enhanced fatty 
acid oxidation, reduces plasma TG levels and increases plasma insulin levels, and in 
MKR mice (transgenic mice with murine creatine kinase muscle (Ckm) promoter 
directing expression of the human IGF-1R gene containing the K1003R mutation), it 
reverses insulin resistance and diabetes.[243, 244] C/EBP-α plays a key role in the 
regulation of CD36 and overexpression of C/EBP-α increases CD36 mRNA and protein 
levels.[245]  
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               (ii) Adipocyte protein 2 (aP2) 
Also known as fatty acid binding protein 4 (FABP4), aP2 is expressed in adipocytes and 
macrophages, is the most abundant protein found in mature adipocytes and has been 
extensively used as a marker for adipocyte differentiation. aP2 is a cytoplasmic protein 
that binds to long-chain fatty acids and facilitates its trafficking into the adipocyte.[246] 
Its secretion is strongly regulated by lipolysis-related fatty acids.[246] The exact 
biological function of FABP4 is not yet fully understood, but FABP4 null mice are 
protected from obesity-induced insulin resistance and diet-induced atherosclerosis.[247, 
248] Double knockout of both FABP4 and FABP5 in mice leads to defective uptake of 
fatty acids and compensatory up-regulation of glucose metabolism, resulting in 
hyperlipidemia during fasting states and hepatic steatosis.[249]  
aP2 has recently been identified as a lipid activated adipocytokine expressed in 
macrophages, suggesting a role in adipose inflammation.[250] Circulating aP2 plasma 
levels were found to be high during obesity and could independently predict 
inflammation and fibrosis in NAFLD patients.[251, 252]  
 
          (iii) Stearoyl-CoA desaturase -1 (SCD-1) 
SCD-1 is a δ-9 fatty acid desaturase, located on the endoplasmic reticulum membrane, 
and responsible for the synthesis of monounsaturated fatty acids (MUFA) from 
saturated fatty acids by introducing a double bond between carbon 8 and 10. SCD-1 
activity produces palmitoleic acid and oleic acid, which are key substrates in the 
synthesis of phospholipids and TGs.[253] SCD-1 expression is regulated by nutritional 
and hormonal signals. Insulin, glucose, cholesterol and fatty acids induce SCD-1 
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expression, while n-3 and n-6 polyunsaturated fatty acids inhibit SCD-1 expression. [254, 
255] Insulin and PPAR-γ have been found to induce SCD-1 expression.[254, 256]  
SCD-1 deficient mice had low MUFA levels, leading to decreased TG and fatty acid 
synthesis. Loss of SCD-1 function increased insulin sensitivity and reduced hepatic 
steatosis and adipocyte inflammation, protecting the mice from diet-induced obesity.[257, 
258] Overexpression of SCD-1 in myocytes induces abnormal lipid partitioning and 
progression to obesity in lean humans.[259]  
 
          (iv) Lipoprotein Lipase (LPL) 
LPL is synthesized in adipose, skeletal and cardiac parenchymal cells, but it functions 
by interacting with heparin sulphate proteoglycans (HSPG) at the endothelial luminal 
surface.[260] LPL is responsible for hydrolyzing TG in chylomicrons and VLDLs into 
fatty acids, which are then transported into adipocytes.[238] LPL is an important marker 
for adipogenesis. SREBP-1c and PPAR-γ initiate the transcription of LPL gene, 
whereas Angiopoietin-like-4 catalyzes LPL conversion into inactive monomers.[261, 262] 
TNF-α inhibits LPL transcription by blocking the interaction of the nuclear factor Y 
with the CCAAT box on the LPL gene promoter in the nucleus.[263] LPL is also 
nutritionally regulated, with high activity observed in postprandial conditions in 
association with high circulating insulin levels, and reduced activity during fasting state 
when insulin levels are low.[264, 265] 
 LPL null mice have high plasma TG and VLDL levels at birth, and die due to 
hypoglycemia stemmed from their inability to hydrolyze dietary lipids.[266] LPL 
sensitivity to insulin and feeding is reduced during obesity, despite an increase in LPL 
mRNA expression per adipocyte.[267, 268]  
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          (v) Angiopoietin-like 4 (Angptl4) 
Angptl4 is mostly expressed in adipose tissue in mice, but in humans it is ubiquitously 
expressed.[269] Angptl4 plays an important role in the clearance of circulating lipids by 
regulating the activity of LPL. Angptl4 inactivates LPL by binding and converting it 
from an active dimer to an inactive monomer, thus hindering LPL-HSPG interaction at 
the cell surface and increasing TG levels in the plasma.[262]  
Overexpression of Angptl4 in transgenic mice led to significant hypertriglyceridemia 
and reduced LPL activity, whereas knockdown of Angptl4 caused reduced plasma TG 
levels and enhanced LPL activity.[270] Angplt4 expression is stimulated by fasting or 
NEFA via the activation of PPAR-γ.[271] Although a direct effect of Angptl4 on 
inflammation pathways has yet to be identified, it has recently been associated with 
regulation of inflammation since it decreases the expression of pro-inflammatory 
adipokine IL-6 and serum amyloid A, as observed in Angptl4 knockout mice which 
displayed increased serum levels of these pro-inflammatory adipokines and hepatic 
macrophage infiltration.[269]  
 
     1.2.3.4.1.2 Triacylglycerol (TG) formation in adipocytes 
Fatty acids are stored in lipid droplets of adipocytes as TG, which is constituted by three 
fatty acid side chains esterified to a glycerol backbone. Since adipocytes lack glycerol 
kinase, TG formation in adipocytes requires glucose in order to produce glycerol-3-
phosphate and dihydroxyacetone phosphate (DHAP) produced during glycolysis.[272]  
Fatty acids trafficked into the adipocytes are activated into acyl-CoA by acyl-CoA 
synthetase and one acyl-CoA is esterified onto glycerol-3-phosphate by the action of 
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glycerol-3-phosphate acyltransferase (GPAT) in the mitochondria and endoplasmic 
reticulum to produce lysophosphatidic acid. The esterification of the second acyl-CoA 
is catalyzed by 1-acylglycerol-3-phosphate acyltransferase (AGPAT) in the 
endoplasmic reticulum to produce phosphatidic acid. Phosphatidic acid can then either 
be used to synthesize other phospholipids or to produce TG. Phosphatidic acid 
phosphatase (PAP) catalyzes the conversion of phosphatidic acid into intermediate 1, 2-
diacylglycerol form. The last acyl-CoA is esterified by the action of diacylglycerol 
acyltransferase (DGAT) to produce TG.[273] Overexpression of DGAT2, an isoform of 
DGAT in 3T3-L1 adipocytes led to an increase in MUFA accumulation, TG content and 
enhanced expression of genes related to fatty acid synthesis like SCD-1.[274]  
 
     1.2.3.4.1.3 Lipid droplet formation in adipocytes 
TG produced in the endoplasmic reticulum enters the cytoplasm by budding off as lipid 
droplets composed of a large TG core surrounded by an osmophilic phospholipid 
layer.[275] The main purpose of these lipid droplets is the regulation of lipid homeostasis 
by safely storing fatty acids when excessive, and releasing them into circulation when 
energy is required.[276]  
Perilipin (plin) proteins, whose expression is regulated by PPAR-γ, coat the lipid 
droplets and regulate lipid droplet turnover by either protecting them from lipolysis or 
recruiting HSL to the lipid droplet surface to induce lipolysis.[277, 278]  
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          (i) Adipose differentiation-related protein (ADRP) 
ADRP, also known as adipophillin, is a 50kDa lipid droplet associated protein found in 
most cells and tissues, but is expressed rapidly at high levels in adipose tissue during 
adipocyte differentiation. ADRP belongs to the PAT family (named after its founding 
members- perilipin, ADRP and TIP47), which are lipid-droplet coating proteins that 
associate primarily with lipid droplet surfaces.[279] ADRP is found to be up-regulated at 
sites of increased lipid accumulation such as fatty liver.[280]  
During adipogenesis, ADRP is highly expressed in 3T3-L1 preadipocytes from early 
stages of differentiation, due to up-regulation by PPAR-γ. However, towards the later 
stages of adipogenesis, despite no changes in ADRP gene expression, ADRP protein 
levels decrease and perilipin protein levels increase, suggesting that with increased TG 
accumulation in the adipocytes, perilipin takes over as the primary lipid droplet 
associated protein.[281]  
High-fat fed mice treated with antisense ADRP oligonucleotide displayed decrease in 
TG levels, but increased insulin action, thereby protecting the mice from diet-induced 
insulin resistance.[282] However, ADRP-deficient mice show no difference in fat pad 
mass and body weight. On the other hand, adenoviral overexpression of ADRP in 
murine fibroblasts induces lipid accumulation with no change in expression of 
adipogenic genes, suggesting ADRP does not affect adipogenesis.[283, 284]  
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     1.2.3.4.1.4 Lipolysis 
During periods of energy deficit like fasting or exercise, TG stored in the lipid droplets 
inside adipocytes are rapidly hydrolyzed via lipase action to produce free fatty acids, 
which are released into the circulation to meet the energy demands of vital organs. In 
adipocytes, TG hydrolysis occurs by the action of three lipase enzymes: adipocyte 
triacylglyceride lipase (ATGL), hormone sensitive lipase (HSL) and monoacylglycerol 
lipase (MGL).  
 
          (i) Adipose Triglyceride Lipase (ATGL) 
Adipose triglyceride lipase (ATGL), also known as desnutrin or patatin-like 
phospholipase domain-containing protein 2 (PNPLA2), is one of the key enzymes 
involved in TG hydrolysis and is highly expressed in adipose tissue, and moderately 
expressed in skeletal and cardiac muscles.[285] It is the first and rate-limiting enzyme that 
selectively catalyzes the sequential hydrolysis of TG in adipocytes, producing 
diacylglycerols (DAG) and free fatty acids, by cleaving the first ester bond.[286] 
ATGL expression is increased during adipose differentiation and its activity is tightly 
regulated by nutritional and hormonal signals since it is down-regulated by food intake, 
insulin and TNF-α, and is induced by fasting, glucocorticoids and PPAR-γ agonists.[287-
289] Activator protein CGI-58, also known as α/β hydrolase domain-containing protein 5 
(ABHD5), has been found to be the sole lipase activator for ATGL functioning via 
cAMP-dependent PKA pathway, whereas G0S2 has been found to inhibit ATGL 
activity in adipocytes.[285, 290]  
                                                                                                     Introduction 
 
 Page 47 
 
Overexpression of ATGL increases lipolysis with increase in glycerol and non-
esterified fatty acid (NEFA) release, while antibody mediated ATGL inactivation or 
ATGL knockout mice inhibit TG hydrolase activity, and reduces lipolysis with 
decreased glycerol release.[288] ATGL deficient mice have increased fat pad mass and 
body weight, since the adipose tissues are incapable of mobilizing sufficient amounts of 
fatty acids.[291] Lack of ATGL also prevents hepatic endoplasmic reticulum stress, thus 
protecting from NAFLD, while ATGL overexpression increases fatty acid oxidation and 
induces hepatic steatosis.[292, 293]  
 
          (ii) G0/G1 Switch gene 2 (G0S2) 
Initially named due to its association with re-entry of cells from G0 to G1 phase in the 
cell cycle of mononuclear cells, G0S2 mRNA levels were found to be highly expressed 
in adipose tissue, particularly during adipogenesis.[294, 295] It is a dose-dependent 
dominant inhibitor of ATGL in adipocytes.[290]  
Its expression is increased by insulin and down-regulated by chronic treatment with 
TNF-α.[296] G0S2 expression is reduced in obese individuals with poorly controlled 
T2D.[297] Knockdown of the G0S2 gene inhibited adipogenesis and accelerated 
gluconeogenesis. G0S2 knockout mice have normal appearance, but have less adipose 
mass, impaired adipogenesis and enhanced adipose lipolysis and are resistant to diet 
induced liver steatosis. Overexpression of G0S2 accelerated adipogenesis, inhibits fatty 
acid oxidation and causes liver steatosis.[298]  
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          (iii) Hormone Sensitive Lipase (HSL) 
Hormone sensitive lipase (HSL), an 84 kDa protein, is an intracellular neutral lipase 
with broad substrate specificity, capable of hydrolyzing TG, DAG and cholesteryl 
esters.[286] HSL hydrolyzes DAG ten times faster than TG, therefore HSL deficiency 
results in DAG accumulation in adipose tissue. HSL is found freely in the cytosol, but is 
expressed the highest in the adipose tissue, and to a lesser extent in adrenal, ovary and 
testes.[299]  
HSL activation is regulated by hormones like catecholamines and insulin. During 
fasting, catecholamine levels increase and activate G-coupled receptors, which activate 
adenylyl cyclase to generate cAMP. Increased cAMP-dependent PKA pathway 
phosphorylates HSL and translocates it to the lipid droplets.[300] Perilipin, a protein 
coating the lipid droplets responsible for the regulation of lipid droplet turnover, recruits 
HSL to the lipid droplet surface to trigger the lipolytic activity of HSL.[277] No 
differences in body weight are observed in HSL-null mice, despite decreased adiposity 
and increased DAG accumulation in the adipose tissue, muscles and testis.[301]  
 
     1.2.3.4.1.5 De novo lipogenesis in adipocytes 
De novo lipogenesis in adipocytes does not contribute much to the overall TG synthesis 
in the adipocytes. However, unlike de novo lipogenesis in liver, which causes 
steatohepatitis, in the adipose tissue it has been found to be beneficial by improving 
insulin sensitivity and glucose homeostasis. In mice with genetically silenced aP2, an 
increase in de novo lipogenesis was observed, making the mice resistant to diet-induced 
obesity, NAFLD, insulin resistance and T2D by stimulating muscle insulin action and 
suppressing hepatosteatosis.[302]  
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     1.2.3.4.2 Adipose tissue as an endocrine gland and source of cytokines and 
chemokines 
In addition to maintaining energy homeostasis in the body, white adipose tissue is also 
considered an active endocrine gland since it secretes a variety of hormones called 
adipokines, which have important effects on cellular metabolism. These include leptin, 
adiponectin, resistin, tumor necrosis factor-α (TNF-α), visfatin, interleukin-6 (IL-6), 
plasminogen activator inhibitor 1 (PAI1), monocyte chemoattractant protein-1 (MCP-
1), angiotensinogen, retinol-binding protein-4, serum amyloid A, vaspin and FGF21. 
Adiponectin and leptin are produced primarily by adipocytes and have structural 
similarity to cytokines such as TNF-α, IL-6 and MCP-1, and are therefore termed 
adipocytokines.[303] Most adipocytokines have pro-inflammatory functions, except 
adiponectin, which is anti-inflammatory. 
 
          (i) Adiponectin 
Adiponectin, also known as complement-related protein 30 (ACRP30), adipoQ, adipose 
most abundant gene transcript (apM1) and GBP-28, is one of the major adipocytokines. 
Adiponectin is highly expressed during adipocyte differentiation and is found in high 
levels in circulation in healthy individuals.[304] Its production and serum levels have 
been found to be inversely correlated to obesity, with decreased plasma levels observed 
with obesity, T2D and NAFLD.[305] 
Adiponectin has been shown to ameliorate whole body insulin sensitivity via 
enhancement in fatty acid oxidation and glucose uptake in myocytes and suppression of 
hepatic gluconeogenesis through activation of the AMPK signaling.[246, 306] Adiponectin 
also has anti-inflammatory functions, where it suppresses the production of TNF-α in 
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obese mice by inhibiting the activation of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) and stimulating the production of anti-inflammatory IL-10 
instead.[246, 307]  
Exogenous administration of adiponectin has been found to partially reverse insulin 
resistance in obese mice, while overexpression in transgenic mice leads to insulin 
sensitivity and alleviation of NAFLD.[308, 309] Adiponectin deficient mice also develop 
hepatic insulin resistance and inflammation due to increased TNF-α levels as well as 
reduced sensitivity to PPAR-γ.[310] TNF-α and IL-6 suppress adiponectin expression in 
adipocytes, whereas PPAR-γ ligands stimulate adiponectin expression.[225, 311]  
 
          (ii) Leptin 
Leptin (16 kDa) is a potent adipocytokine encoded by the obese (ob) gene. It is mainly 
expressed by adipocytes, but it is also found in mammary glands, gastric wall, placenta, 
ovaries, skeletal muscles, liver and pituitary gland. Leptin has many functions including 
regulation of appetite and energy balance, insulin sensitivity, activation of inflammation 
and reproduction and growth control.[312, 313] The effects of leptin on food intake and 
energy expenditure are mediated by signaling in the hypothalamic region of the central 
nervous system.[314]  
Leptin also has pro-inflammatory functions due to its structural similarity to cytokines 
like IL-6.[315] Leptin stimulates the production of IL-6, TNF-α and MCP-1 from immune 
cells.[316] Conversely TNF-α can induce the expression of leptin and its 
receptors.[317] Up-regulation of leptin expression in WAT as well as elevated levels of 
leptin in circulation is commonly observed during obesity and inflammation. Despite 
increased leptin levels, excessive adiposity is not reduced, suggesting leptin 
                                                                                                     Introduction 
 
 Page 51 
 
resistance.[318, 319] Animal models for leptin deficiency have played a key role in the 
determination of the functions of leptin. Murine studies in the leptin deficient (ob/ob) 
mice and leptin receptor deficient (db/db) mice found that loss of leptin function caused 
hyperphagia, obesity and insulin resistance in these mice models.[29, 30] In normal rats 
with no leptin deficiency, exogenous leptin administration enhanced fatty acid oxidation 
in myocytes and hepatocytes and lowered hepatic lipogenesis, suggesting that increased 
leptin expression could cause lower hepatic steatosis.[320]  
Multiple spliced isoforms of the leptin receptor allows leptin to mediate its different 
functions by activation of the PI3K/AKT pathway to induce insulin sensitivity, and 
JAK/STAT3 pathway to mediate the pro-inflammatory responses of leptin.[321]  
 
          (iii) Tumor Necrosis Factor-α (TNF-α) 
Although primarily expressed in monocytes and macrophages, pro-inflammatory TNF-α 
is highly expressed in adipose tissue of obese mice and humans and is strongly 
associated with peripheral insulin resistance.[322] TNF-α expression in adipocytes is 
stimulated by fatty acids, inducing lipolysis and hepatic lipogenesis, by activation of 
extracellular signal kinase.[323] Exogenous TNF-α administration inhibits the insulin 
signaling pathway either by serine phosphorylation of insulin receptor substrate-1 (IRS-
1) via the JNK1 pathway, or degradation of IRS-1 via the suppressor of cytokine 
signaling-3(SOCS-3).[324, 325]   
Further studies using genetic mouse models of TNF-α deficiency confirmed the 
negative effects of TNF-α on insulin signaling, since TNF-α (-/-) mice were protected 
from obesity-induced insulin resistance.[326] In vitro studies also demonstrated that TNF-
α treatment of 3T3-L1 adipocytes down-regulated the expression of adipocyte specific 
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genes such as HSL, adiponectin, C/EBP-α, PPAR-γ and GLUT4, and up-regulated 
leptin expression via activation of nuclear factor NFκB.[226, 327]  
 
          (iv) Interleukin-6 (IL-6) 
IL-6 is a pro-inflammatory adipocytokine that is more expressed in visceral adipocytes 
compared to subcutaneous adipocytes.[328] IL-6 expression in adipose tissue and 
circulatory levels of IL-6 are found to be increased during obesity and T2D and have 
been associated with insulin resistance.[329] Polymorphism of the IL-6 gene in humans, 
leading to reduction in plasma IL-6 levels, was associated with greater insulin 
sensitivity after a glucose load.[330] In addition, it has been shown from rodent studies 
that exogenous administration of IL-6 in mice blocks hepatic insulin signaling through 
inhibition of IRS-1 phosphorylation via SOCS-3 up-regulation, leading to hepatic 
insulin resistance.[331]  
However, IL-6 deficient mice develop obesity, high leptin levels, hepatic inflammation 
and insulin resistance, suggesting that similarly to leptin, IL-6 can also influence energy 
expenditure and feeding through the central nervous system.[332] A C-174G promoter 
polymorphism in the IL-6 gene in healthy Finnish subjects was found to lower energy 
expenditure and insulin sensitivity.[333] In pregnant mice, IL-6 deficiency caused 
reduced expression of energy balance regulating anabolic and oxerigenic peptides, 
suggesting a role for IL-6 in modulating the hypothalamic expression of these 
neuropeptides.[334, 335]  
IL-6 expression is stimulated by leptin, and increased IL-6 expression in adipocytes can 
suppress the expression of adiponectin.[225, 316] IL-6 has a role in the recruitment and 
differentiation of T-cells, and IL-6 null mice have impaired immune and acute phase 
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responses.[336] Interestingly, immediately after exercise, IL-6 released from skeletal 
muscles is augmented. This fact has been associated with enhanced insulin action, via 
AMPK activation, promoting glucose uptake and fatty acid oxidation.[337] 
 
          (v) Monocyte chemoattractant protein-1 (MCP-1) 
Also known as chemokine (C-C motif) ligand 2 (CCL2), it is a monomeric chemokine 
peptide belonging to the C-C chemokine family, and belongs to a family of four MCP 
proteins (MCP-1, 2, 3 and 4). MCPs are produced by various cell types including 
endothelial, fibroblast, epithelial, smooth muscle, mesangial, astrocytic, monocytic and 
microglial cells, either constitutively or after selective induction by oxidative stress, 
cytokines or growth factors, but are mainly secreted by macrophages.[338] MCP-1 carries 
the CCL2 receptor CCR2 (CC chemokine receptor 2) on their surfaces and are therefore 
the main chemokine responsible for attracting monocytes into foci of active 
inflammation.[339]  
An increase of MCP-1 as well as macrophage infiltration was observed in both white 
adipose tissue and plasma of obese mice, suggesting that adipose tissue in obesity could 
be characterized by chronic low-grade inflammation.[340] MCP-1 secretion from 
adipocytes was found to directly trigger macrophage infiltration into adipose tissue, 
resulting in inflammation, systemic insulin resistance and increase hepatic 
triacylglycerol content.[341] 
Knockout of MCP-1 gene, inhibition of MCP-1 expression by a dominant-negative 
mutant or knocking out MCP-1 receptor CCR2, in diet-induced and genetically obese 
mice attenuated macrophage infiltration and inflammation in adipose tissue, and 
increased insulin sensitivity and hepatic steatosis.[341, 342]  Increased MCP-1 expression 
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in adipose tissue precedes the expression of other macrophage markers in obesity, and 
an increase in circulating MCP-1 is sufficient to induce insulin resistance.[343, 344] MCP-
1 expression is higher in visceral adipocytes, compared to subcutaneous 
adipocytes.[345] MCP-1 is an insulin responsive gene that decreases insulin stimulated 
glucose uptake, down-regulates LPL expression and increases the expression of 
adipogenic genes.[340, 344] MCP-1-induced protein (MCPIP) also promotes adipogenesis 
with an increase in endoplasmic reticulum stress, ROS production and inducible nitric 
oxide synthase (iNOS) expression.[346] 
 
     1.2.3.4 Pathophysiology of adipose tissue dysfunction and inflammation 
Pathological obesity is associated with adipose tissue expansion and dysfunction, 
accompanied by chronic low grade inflammation.[1] Physiologically, adipose tissue 
responds to short-term excess nutrients by hyperplasia and hypertrophy of subcutaneous 
adipocytes, which safely stores the excess fatty acids as TG in lipid droplets.[234] 
However, environmental and genetic factors can lead to chronic over-nutrition and 
reduced energy expenditure, causing persistent increase in nutrient supply.[1] This 
nutrient-rich environment first causes subcutaneous adipocyte expansion and then 
abnormal lipid partitioning to visceral adipocytes when subcutaneous adipocytes reach 
their limits (Figure 4).[347].  
Over-expansion of adipocytes has been associated with activation of nuclear factor-
kappa light chain enhancer of activated B-cells (NF-κB) and c-Jun n-terminal kinases 
(JNK) signaling pathways. Other factors such as ceramide, elevated fatty acids which 
bind and activate toll like receptor 4 (TLR4), receptor for advanced glycation end-
products (RAGE) and cellular stresses such as reactive oxygen species (ROS) and ER 
                                                                                                     Introduction 
 
 Page 55 
 
stress have also been found to activate JNK and NF-κB pathways. JNK activation 
promotes phosphorylation of IRS-1, which negatively regulates insulin receptors, while 
activation of NF-κB leads to its translocation to the nucleus, triggering expression of 
various mediators and markers of inflammation, resulting in insulin resistance. [348] 
Obesity-induced insulin resistance has also been attributed to various other factors 
including adipose tissue hypoxia, ectopic fat deposition in organs such as the liver and 
muscles, angiogenesis, mitochondrial dysfunction and increased inflammation.[349-356]   
In the adipocytes, increased production of pro-inflammatory adipokines leads to the 
suppression of adipogenic genes like adiponectin, ATGL, C/EBP-α, PPAR-γ and HSL, 
and recruitment of immune cells like macrophages to adipose tissue, creating a milieu of 
chronic low grade inflammation and insulin resistance.[235, 311, 323, 339]  
Visceral adipocytes also exacerbate inflammation since they are less responsive to 
insulin and secretes more MCP-1 and IL-6 than subcutaneous adipocytes.[328, 345] Free 
fatty acids and adipokines like TNF-α and IL-6 play a prominent role in the 
development of insulin resistance by blocking the insulin signaling pathway and 
attenuating adipose differentiation and lipid uptake.[325, 336] Increased visceral adipose 
tissue is associated with increased insulin resistance.[340] This is due to the close 
proximity of visceral adipocytes to the liver, since free fatty acids released by these 
adipocytes during lipolysis and dysfunction enter the liver, causing insulin resistance, 
increased TG accumulation and hyperinsulinemia.[347] 
Adipose dysfunction can also lead to ectopic lipid deposition into non-adipose tissues 
like liver, pancreas and heart, which might lead to steatosis and organ dysfunction and 
eventually insulin resistance, T2D, NAFLD and cardiovascular diseases.[347] 
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Figure 4: Pathogenesis of adipose tissue dysfunction during obesity. Abbreviations used: CD: 
Cluster of differentiation; FFA: free fatty acids; IL: Interleukin; MCP-1: monocyte 
chemoattractant protein-1; TNF-α: Tumor necrosis factor-alpha. 
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1.3 Animal model: Alms 1 mutant (foz/foz) mouse model 
The fat aussie (foz) mouse has been identified to have a spontaneous mutation (foz) of 
an 11 bp truncating deletion in exon 8 of the Alms 1 gene.[35] Mutations in the ALMS1 
gene in humans are responsible for the development of Alström syndrome, which is a 
rare autosomal recessive condition affecting multiple organs. Individuals carrying an 
ALMS 1 mutation develop progressive loss of vision and hearing, obesity-related T2D 
and hypertriglyceridemia. Some individuals also develop hypothyroidism, infertility, 
low growth hormone levels, kidney failure, dilated cardiomyopathy, congestive heart 
failure and fatty liver disease.[357, 358]  
The fat aussie (foz/foz) mice develop a similar phenotype to the human syndrome. The 
foz/foz mice are hyperphagic and underactive and develop obesity by 100-120 days of 
age on a standard chow diet.[35] Both genders of mice develop T2D, however, female 
mice have a later onset of the disease. Significant hyperinsulinemia precedes the 
development of hyperglycemia in these mice in response to insulin resistance. High fat 
(HF) feeding does not change serum TG levels; however, cholesterol levels rise up to 
200% in the foz/foz mice compared to wild-type mice.[35] The foz/foz mice also develop 
hepatomegaly with moderate to severe steatosis. Male foz/foz mice are infertile, while 
females develop infertility after onset of obesity. Therefore, heterozygous mice are 
normally used for breeding purposes.[35]  
Further characterization of these mice revealed that female foz/foz mice fed on a high-
fat diet until 180 days of age develop NASH. This is characterized by hepatomegaly, 
steatosis, increased ALT levels, hepatic inflammation, fibrosis and severe hepatocellular 
ballooning degeneration, whereas wild-type littermates only developed simple 
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steatosis.[359] Therefore, the foz/foz mice serves as a mouse model of fatty liver disease, 
in which high-fat feeding triggers NAFLD progression to NASH.  
The metabolic phenotype of the foz/foz mice varies depending on genetic background. 
Female NOD.B10 mouse with the foz/foz mutation fed on high-fat diet for 24 weeks 
exhibit attenuation in subcutaneous adipose tissue expansion, termed as adipose 
restriction. This is associated with WAT inflammation, hypoadiponectinemia, moderate 
hyperglycemia and NAFLD progression to NASH.[360] Conversely, female Balb/c mice 
with the foz/foz mutation fed on the same diet, develop identical excessive weight gain 
as the female NOD.B10 foz/foz mice, but their adipose depots expand proportional to 
body weight. They remain normoglycemic and display no decrease in adiponectin levels 
or development of NASH (unpublished data). These dramatic strain differences present 
a great opportunity to study the pathophysiological basis underlying the abnormal 
metabolic responses to over-nutrition in the development of T2D and NASH.   
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1.4 Rationale  
In response to chronic overfeeding, some individuals develop healthy obesity; whereas 
others develop obesity in association with metabolic syndrome and have an increased 
risk for the development of conditions such as T2D and NASH. Adipose tissue 
inflammation and dysfunction is often associated with both these conditions. Unknown 
is the role of adipose tissue in determining whether the result of overfeeding is healthy 
or unhealthy obesity. For example, it is not known if a primary defect in adipose tissue 
in response to overfeeding results in early dysfunction of this tissue (e.g. adipose 
restriction and inflammation) with the secondary consequences of insulin resistance, 
islet β-cell failure, T2D and/or NASH. 
Alternatively, the adipose tissue dysfunction could be secondary to, for example, 
primary failure of islet β-cells to chronic overfeeding, hyperglycemia and then 
hyperglycemia-induced toxicity of adipose tissue. The Alms 1 mutant mouse on the 
Balb/c and NOD.B10 backgrounds provide an excellent model for studying the role of 
adipose tissue in overfeeding induced obesity, metabolic syndrome and T2D and NASH 
development. While both strains of mice overfeed and develop obesity, in response to 
the additional insulin of HF feeding, only NOD.B10 mutant mice develop T2D and 
NASH. Balb/c mutant mice become obese but do not develop these conditions 
suggesting the obesity of Balb/c mice is healthy obesity.  
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     1.5 Hypothesis and Aims  
This thesis is part of a bigger project with the overall aim to characterize over time, the 
early adipose tissue responses (expansion and restriction), in parallel to the development 
of insulin resistance, islet β-cell responses to the insulin resistance (compensation and 
decompensation), hepatic steatosis and NASH, as it develops in high-fat fed NOD.B10 
foz/foz and Balb/c foz/foz female mice. The work is being performed in order to identify 
the relationship between β-cell decompensation, adipose tissue dysfunction and the 
onset of T2D and NASH.  
Within this broader aim, this longitudinal study focuses on the role of adipose tissue in 
the development of T2D and NASH. 
 
     1.5.1 Hypothesis: 
A primary defective response of adipose tissue to chronic overfeeding in NOD.B10 
mice underlies its propensity to develop T2D and NASH; whereas a healthy adipose 
tissue response to overfeeding in Balb/c mice underlies its resistance to develop these 
metabolic conditions. 
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     1.5.2 Aims: 
The overall aim is to determine the role of adipose tissue in the determination of a 
healthy obesity response or obesity associated with metabolic diseases in Balb/c mice 
compared to NOD.B10 mice. 
 
     Specific Aims: 
1. To determine the early response and time-course of adipose tissue expansion, 
gene expression and inflammation, together with a secreted adipokine profile, of 
NOD.B10 and Balb/c mice, to the overfeeding challenges of HF diet, the foz/foz 
genotype and the combination of both. 
2. To determine the temporal relationship between the adipose tissue responses to 
the overfeeding challenges in the two mice strains and the development of T2D 
and NASH. 
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2. Materials and Methods 
2.1 Breeding history 
The fat aussie (foz) mouse model was first identified in a transgenic mice strain 
expressing the Fas ligand (FasL) in pancreatic beta cells under control of the human 
insulin promoter (HIP) in the Non-obese diabetic (NOD) mice background, known as 
the HIP-FasL NOD transgenic mice. These mice displayed obesity and hyperglycaemia 
by age of 100-120 days, which was associated with a a spontaneous Alms1 mutation. 
Homozygous mutant mice developed sterility upon onset of obesity, hindering breeding. 
Therefore, for mapping purposes, the foz mutation was outcrossed to a C57Bl/10 mouse 
strain. Since this phenotype segregated as a Mendelian monogenic recessive trait, a two 
generation outcross-intercross breeding strategy was applied. The mutation was 
outcrossed from the NOD mice to a B10.Br background and F1 progenies were 
intercrossed to breed the mutation in F2 progeny. These NOD.B10 (mixed NOD X 
B10.Br backgrounds) mice revealed the 11bp deletion on exon 8 and were homozygous 
for the foz mutation. The fat aussie phenotype observed in the NOD.B10 mice were 
recapitulated into the Balb/c mice strain. NOD.B10 heterozygous foz/+ mice were bred 
with Balb/c +/+ wild type mice to obtain an F1 generation of 50% Balb/c heterozygous 
foz/+ mice. These mice were then back-crossed with the Balb/c wild type +/+ mice over 
9 generations to get >99.5% Balb/c heterozygous foz/+ mice. 
 
2.2 Housing, diet and ethics 
Mice were maintained under specific pathogen-free conditions in an artificial 12-hour 
light/dark cycle, and were accommodated at a density of 2-5 mice per cage in a 
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temperature controlled room of 21-24oC with 40-60% humidity. Mice were fed on a 
normal chow diet (59.8% carbohydrate, 20.0% protein and 5.4% fat by weight; energy 
content 12MJ/g; Gordon’s Specialty Stockfeed, NSW, Australia) with free access to 
autoclaved tap water.  
For this study, heterozygous male and female mice from NOD.B10 and Balb/c strains 
were time-mated during 3 consecutive nights at the Animal Facility of The Canberra 
Hospital and Animal Facility at the Hugh Ennor building at the Australian National 
University, to produce foz/+ (heterozygous), foz/foz (foz mice) and +/+ (wild type) mice. 
Pups were born after 21 days of gestational period. At 3 weeks of age, mice were 
weaned on a normal chow diet with free access to autoclaved tap water.  
All animal procedures were approved by the Animal Experimental Ethics Committee at 
the Australian National University (Project A2011/27) and all animals received care in 
compliance with the guidelines prescribed by this committee. The focus of this study 
was directed towards the female mice since they have a slower progression towards 
T2D and NASH than the male mice, allowing better characterization of the 
pathophysiology of the diseases. The pups were identified using ear notch perforations 
(see ear notch chart in Appendix section). The ear biopsies were obtained under aseptic 
conditions and used to genotype the mice for the foz mutation.  
 
2.3 Genotyping 
     2.3.1 DNA extraction 
DNA samples from ear notches were obtained at 3 weeks of age. Each ear tissue was 
individually lysed overnight or over 4 hours by incubation at 65oC on a dry bath 
incubator (MD-02-220, Major Science, Taiwan) in a solution containing 400 µL of 
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Lysis buffer (see Appendix for solution preparation) mixed with 4 µL of Proteinase K 
(Serine protease, Cat # 03115828001, Roche, Mannheim, Germany). Samples were then 
vortexed (Ratex Vortex mixer, VIC, Australia) to break any tissue clumps and 
centrifuged at 14,800 rpm for 10 min at 4oC (Rotor# SX4750, Allegra X-15R 
Centrifuge, Beckman Coulter, CA, USA). The supernatant was then transferred to a 
new set of microtubes containing 400 µL ice-cold isopropanol (Cat# 425, Univar, Ajax 
FineChem, NSW, Australia). DNA was precipitated after centrifugation at 14,800 rpm 
for 10 min at 4oC (Rotor# SX4750, Allegra X-15R Centrifuge, Beckman Coulter, CA, 
USA). The supernatant was then removed and the DNA pellet washed with 1 mL of 
cold 70% ethanol (see Appendix), followed by centrifugation at 14,800 rpm for 10 min 
at 4oC (Rotor# SX4750, Allegra X-15R Centrifuge, Beckman Coulter, CA, USA). 
Supernatant was discarded and the DNA pellet was left to dry inside a fume hood (Dyna 
Safe control system MK3, Dyna Flow, NSW, Australia) for 20 min to evaporate any 
remaining ethanol. The DNA pellet was resuspended in 300 µL of Tris-EDTA (TE) 
buffer (see Appendix) and incubated on a 65oC dry bath incubator (Cat# MD-02W-220, 
Major Science, Taiwan) for 10 min. The pellet was homogenized by vortexing (Ratex 
Vortex mixer, VIC, Australia) and stored for further analysis. 
 
     2.3.2 Polymerase Chain Reaction (PCR) analysis 
The resultant DNA extracted from ear notches were used in a PCR reaction for 
identification of the 11 bp deletion of exon 8 on the Alms1 gene as previously 
described.[378] Primers flanking the 11 bp deletion of exon 8 on the Alms1 gene were 
purchased from GeneWorks (GeneWorks Pty. Ltd, SA, Australia). The primer sequence 
used was forward primer: 5’ ACA ACT TTT CAT GGC TCC AGT 3’ and reverse 
primer: 5’ TTG GCT CAG AGA CAG TTG AAA 3’. 
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Briefly, 1 µL of DNA sample was mixed in 12.5 µL Biomix™ Red (using Taq DNA 
Polymerase, cat# BIO-25006, BioLine, NSW, Australia), 0.5 µL of forward primer, 0.5 
µL of reverse primer and 10.5 µL of Milli Q water. DNA was amplified using a PCR 
machine (iCycler, BioRad, CA, USA) under the following conditions: initial 
denaturation at 95oC for 5 min, followed by 35 cycles of 95oC for 1 min, 55oC for 1 min 
and 72oC for 1 min for denaturation, annealing and extension, respectively.  
The resulting PCR products were separated on a 4% agarose gel by electrophoresis. 4 g 
of agarose (Cat# 16103102, BioRad, CA, USA) was added to 100 mL of 1X TAE 
buffer (Tris-Acetic acid-ethylenediaminetetracetic acid buffer) (see Appendix) and 
dissolved in a microwave by heating for 2 min. The gel was cooled down to around 
60oC prior to addition of 10 µL ethidium bromide at 10 mg/mL (Cat# 161-0433, 
BioRad, CA, USA), and set onto the gel chamber with a set of combs. After 
solidification, the combs were removed and the gel was assembled into the 
electrophoresis tank (BioRad wide mini sub cell GT, BioRad, CA, USA). 1X TAE 
buffer was then added to the gel chamber. 5 µL of ethidium bromide (Cat# 161-0433, 
BioRad, CA, USA) was added to the bottom chamber of the tank to improve visibility 
of the DNA bands. 10µL of PCR product was added to each well and electrophoresis 
was performed at 180V for 20min using the Power Pac Universal power supply 
(500V/2.5A/500W, BioRad, CA, USA). DNA bands were visualized under UV light 
(Gel Doc XR System PC, BioRad, CA, USA) and analyzed by Vision Capture 14.2 
software. Visualization of DNA bands allowed classification of the mice into 
heterozygous (HET), homozygous wild type (WT) and homozygous foz/foz (foz) mice 
according to the size and number of the DNA fragments amplified by the PCR. 
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2.4 Experimental time line and diet composition 
At 4 weeks of age, female wild-type and foz/foz (Alms1 mutant) littermates from both 
NOD.B10 and Balb/c strains were randomly distributed into two diet groups- standard 
chow (5.4% fat), or high-fat diet (41% carbohydrate, 22.6% protein, 23.5% fat by wt; 
energy content 20MJ/kg; SF03-020, Specialty Feeds, Glen Forrest, Australia)(Figure 5).  
NOD.B10 mice groups were assigned to tissue harvesting at increasing ages of 6, 8, 10 
and 12 weeks, whereas Balb/c mice at 6 and 12 weeks of age only (Figure 6). Balb/c 
mice were considered as controls, resistant to T2D and/or NASH and therefore no major 
changes were expected to occur between the two time-points (Figure 7).  
 
2.5 Body weight and glucose monitoring 
Body weight and non-fasting blood glucose levels of conscious mice were monitored 
every fortnight from 4 to 12 weeks of age (9-10 AM). Body weight was recorded on a 
weighing scale (AE Adam, Able Scientific, WA, Australia) and glucose levels were 
measured using a glucometer (StatStrip Xpress™, Nova Biomedical, Flintshire, UK) 
previously calibrated with low (ranging 2.6-4.2 mmol/L.46-76 mg/dL), intermediate 
(ranging 5.0-7.2 mmol/L, 90-130 mg/dL) and high (ranging 14.4-18.3 mmol/L, 260-330 
mg/dL) glucose control solutions. 5 µl of blood was collected from a small incision 
made on the lateral vein of the tail of restrained mouse using a carbon steel surgical 
blade (Blade size# 15, Swann-Morton, Sheffield, UK) and glycemic readings were 
recorded from the first blood droplet. 
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Figure 5: Experimental grouping of NOD.B10 and Balb/c mice at 4 weeks of age according to 
their genotype and diet. 
 
            Figure 6: Experimental time line for NOD.B10 mice from 4 to 12 weeks of age. 
 
 
       Figure 7: Experimental time line for Balb/c mice from 4 to 12 weeks of age. 
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2.6 Intraperitoneal Glucose Tolerance Test (ipGTT) 
One week before harvesting, mice were subjected to intraperitoneal glucose tolerance 
tests (ipGTT). Mice were fasted for 4 hours from 8 AM until 12 PM, with only water 
available. Body weights were measured to calculate the glucose injection dose (2 g 
glucose/kg body weight). Mice were restrained and the tail was heated under a heat 
lamp during bleeding procedures to induce heat vasodilation. Approximately 60 µL of 
tail blood was collected from a small incision at the lateral vein of the tail, as previously 
described, into EDTA rinsed microtubes. 
At time 0 of the ipGTT, a bolus of glucose (2 g/kg body weight, 25% glucose solution, 
Baxter Toongabbie, NSW, Australia) was injected intraperitoneally (IP). Glycaemia 
levels were checked at times 5, 15, 30, 60, 90 and 120 min. Food was provided to the 
mice after the conclusion of the experiment. 60 µL of tail blood was collected into 
EDTA-rinsed microtubes at times 0, 15 and 90 min and later centrifuged at 3000 rpm 
for 15 min at 4oC (Rotor# SX4750, Allegra®X- 15R centrifuge, Beckman Coulter, CA, 
USA). Plasma collected was then stored in a -80oC freezer for future analysis. 
 
2.7 Analysis of body fat composition by Dual Energy X-ray 
Absorptiometry (DEXA)  
Assessments of body fat composition were performed on 6 and 12 week old mice of 
both strains, using dual energy X-ray absorptiometry technique (DEXA). Prior to 
measurements, the PIXImus machine (Lunar PIXImus II Densitometer machine, GE 
Medical Systems, Lunar, Madison, WI) was calibrated for quality control with a 
phantom mouse with known values (Bone mass density (BMD) % CV less than 1%, 
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BMD calibration factor between 0.8 to 1.2, % fat standard deviation result between -1.0 
to +1.0 and a % fat offset value between -5.000 and 5.000).  
After 4 hours of fasting to prevent calcified food in the image, each mouse was 
anesthetized by exposure to 2% isoflurane (cat#05260-05, 100% isoflurane, IsoFloTm, 
Abbott diagnostics, IL, USA) via inhalation in an induction chamber (0.1 L/min flow 
rate of 2.5% vaporized isoflurane and 0.2 L/min flow rate of oxygen as the delivery gas 
for the anesthetic vapour). Body scans were conducted in unconscious mouse placed on 
the scanner bed in a prone position, with limbs and tail stretched away from the body. 
Continuous supply of isoflurane-oxygen was provided during the entire duration of the 
DEXA scan of around 5 min.  Lacrimal gel (LacriLube®, Allergan, CA, USA) was 
applied to the eyes of the mice to prevent dryness due to the vaporized anesthesia. 
Quantitative analysis on the lean and fat mass content and total % body fat content was 
obtained and analyzed using PIXImus2 2.10 software.  
 
2.8 Blood chemistry, euthanasia and tissue harvesting  
     2.8.1 Blood sampling   
On the day of harvesting, around 60 µL of non-fasting tail blood was collected from 
conscious mice into EDTA-rinsed microtubes containing 10 µL of 0.5M EDTA solution 
(Ethylenediaminotetraacetic acid, Cat# E9884, Sigma Aldrich, CA, USA). Plasma from 
these blood samples were centrifuged at 6000 rpm for 10 min at 4oC (Rotor# SX4750, 
Allegra X-15R Centrifuge, Beckman Coulter, CA, USA) and stored in a -80oC freezer 
for further measurement of plasma insulin and total cholesterol.  
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    2.8.2 Anesthesia    
Following blood collection, mice were anesthetized with a mixed solution of ketamine 
(20 mg/mL, Troy laboratories, NSW, Australia), xylazine (100 mg/mL, Troy 
laboratories, NSW, Australia), prepared in saline solution (1:1:8, v:v). The dose of 
anesthesia given to each mouse was 10 µL per gram body weight and it was injected on 
the left dorsal lower abdominal region using a 25G needle (0.5 mm X 25 mm, Cat# 
301807, BD precision glide™ needle, NJ, USA) and 1 mL tuberculin syringe (Cat# 
302100, BD Biosciences, NJ, USA).  
This procedure was followed by collection of 1 mL of cardiac blood through cardiac 
puncture using a 25G needle (0.5 mm X 25 mm, Cat# 301807, BD precision glide™ 
needle, NJ, USA) and 1 mL tuberculin syringe (Cat# 302100, BD Biosciences, NJ, 
USA). The collected blood was immediately transferred into a 4 mL BD Vacutainer 
(Cat#366164, BD UK, Plymouth, UK), kept on ice until  later centrifugation at 3000 
rpm for 15 min at 4oC (Rotor# SX4750, Allegra®X- 15R centrifuge, Beckman Coulter, 
CA, USA). Plasma collected from these samples were then stored in a -80oC freezer for 
further quantification of plasma alanine transaminase (ALT), adiponectin and monocyte 
chemoattractant protein (MCP-1).  
 
     2.8.3 Tissue harvesting 
All groups of mice were euthanized by cervical dislocation. The abdominal cavity was 
opened widely and liver and adipose tissue (subcutaneous, peri-ovarian, mesenteric and 
brown adipose tissue) were dissected and weighed on a scale (FX-200i, Max= 220 g, d= 
0.001 g, A&D company Ltd). 
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          2.8.3.1 Liver dissection 
The right lobe of the liver was quickly dissected, weighed and cut into small segments. 
One part was stored in disposable vinyl specimen molds (Tissue-Tek® Cryomold® 
standard, 25 mm x 20 mm x 5 mm, Cat# 4557, ProSciTech, QLD, Australia) covered in 
embedding medium (OCT compound, Cat# IA018, ProSciTech, QLD, Australia), 
frozen on dry ice and later stored in a -80oC freezer. Another part was placed inside a 
plastic cassette (Embedding cassette, Cat# LID-05, Techno Plas, SA, Australia), fixed 
in 10% neutral buffered formalin solution blue (cat# ANBFB, Biostain, VIC, Australia), 
and embedded in paraffin for later immunohistochemistry analysis. Small portions of 
the liver were also snap-frozen in 7 mL screw cap tubes (Cat# 58.536, Sarstedt, 
Germany) and later stored in a -80oC freezer for measurement of total TG content using 
a commercial kit (refer to item 2.10).  
The other lobes of the liver were also dissected, weighed, cut into small parts, snap-
frozen and later stored in -80oC freezer.  
 
          2.8.3.2 Adipose tissue 
Fat pad measurements from 4 different anatomical regions were obtained. Mesenteric 
WAT was scraped from around the intestines, while peri-ovarian and subcutaneous 
adipose tissues were dissected from the right side of the mouse. BAT was dissected out 
of the dorsal adipose tissue, behind the neck of the mouse. All the adipose tissues were 
quickly weighed and cut into three small sections. The first section was embedded in 
cryomolds (Tissue-Tek® Cryomold® standard, Cat# 4557, ProSciTech, QLD, Australia) 
covered by embedding medium (OCT compound, Cat# IA018, ProSciTech, QLD, 
Australia). The second section was placed in plastic cassettes (Embedding cassette, Cat# 
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LID-05, Techno Plas, SA, Australia), followed by fixation in 10% formalin solution 
(cat# ANBFB, Biostain, VIC, Australia) for immunohistochemistry analysis and the 
third section of the adipose tissue was snap-frozen in 7 mL screw cap tubes (Cat# 
58.536, Sarstedt, Germany) and later stored in a -80oC freezer for future mRNA 
expression analysis.  
 
2.9 Blood sample analysis  
     2.9.1 Radioactive Insulin Assay (RIA) 
Quantification of plasma insulin levels were determined by radioimmunoassay. This 
protocol required incubation of a known fixed concentration of radio-labelled tracer 
antigen (Cat # MP9011 , 125I- labelled insulin, Abacus, Millipore, MA, USA), with a 
known amount of anti-insulin antibody (Cat # ML1013-K, Millipore-Linco cat, 
Billerica, USA), so that there was limited antigen binding sites on the antibody. When 
plasma sample was added, it generated a competition between labelled and unlabeled 
insulin for binding sites of the antibody. Therefore, an increased concentration of 
unlabeled antigen decreased the ratio of antibody-bound tracer to free tracer and vice 
versa.  
Briefly, a standard curve was generated using purified human insulin (Cat# I-9278, 
Sigma, USA) diluted in BSA- Phosphate buffer at concentrations of 0, 0.0625, 0.125, 
0.25, 0.5, 1, 2, 4, 8 and 16 ng/mL. 50 µL of standards and plasma samples previously 
diluted in BSA- Phosphate buffer, were distributed into 12 mm X 75 mm polypropylene 
tubes (Cat#T400A, Simport, QC, Canada) in duplicates. Addition of 50 µL of 125I 
insulin tracer (Cat# MP9011, Millipore, MA, USA) at <0.143 µCi/mL and 50 µL of 
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diluted guinea pig anti-rat insulin serum (Cat#ML1013K, Millipore, MA, USA) to these 
tubes was followed by overnight incubation at 4oC. Four duplicate tubes containing 50 
µL of tracer alone were prepared without the addition of guinea pig anti-rat insulin 
serum to determine the total count and non-specific binding required for data analysis.  
On the next day, 500 µL of secondary antibody mixture consisting of 335 µL of 
polyethylene glycol-sodium phosphate buffer (See Appendix for preparation), 85 µL 
BSA-sodium phosphate buffer (see Appendix for solution preparation), 40 µL of 1:5 
diluted goat anti-guinea pig immunoglobulin G (Equitech-Bio Inc., TX, USA) and 40 
µL of 0.057  mg/mL guinea pig serum (Cat# MP1013K, Abacus, Jackson 
ImmunoResearch Laboratories Inc, PA, USA) were added to all tubes (except total 
count tubes) and incubated for 2 hours at 4oC. All tubes, except total count tubes, were 
centrifuged at 2500 rpm (Rotor# SX4750, Allegra®X- 15R centrifuge, Beckman 
Coulter, CA, USA) for 15 min at 4oC. All the tubes, except total count tubes, were 
inverted to discard the supernatant and remove any unbound tracer, thus separating the 
antibody-bound tracer from the free tracer. The quantity of unlabeled antigen (plasma 
insulin) was determined indirectly by measuring the radioactivity of the retained pellets 
by counting it at 1 minute/tube using the γ-counter (2480 Automatic gamma counter, 
WIZARD2®, Perkin Elmer, MA, USA).   
 
     2.9.2 Alanine transaminase (ALT)  
The amount of alanine transaminase (ALT) present in cardiac plasma samples collected 
from NOD.B10 and Balb/c mice at various ages was measured using the Abbott 
Architect c16000 chemical analyzer (Abbott Diagnostics, IL, USA) at the Clinical 
Chemistry department of ACT Pathology.  
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     2.9.3 Adiponectin 
Adiponectin concentrations in cardiac plasma were determined using the Quantikine® 
ELISA Mouse Adiponectin/Acrp30 Immunoassay (Cat# MRP300, R&D Systems, 
Minneapolis, MN, USA) according to manufacturer’s instructions. This assay uses the 
quantitative sandwich enzyme immunoassay technique, where plasma samples 
containing adiponectin were incubated in a 96-well microplate pre-coated with a 
monoclonal antibody specific for NS0-expressed recombinant mouse adiponectin 
protein. Addition of enzyme-linked polyclonal antibody specific for mouse adiponectin 
to the microplate wells causes binding to any mouse adiponectin that had attached to the 
antibody pre-coated microplate during the incubation period. Hydrogen peroxide and 
tetramethylbenzidine addition produced a blue colour. This blue colour is suggested to 
be proportional to the amount of mouse adiponectin in the well. 
Prior to assay performance, plasma samples were diluted 2000-fold in Calibrator 
Diluent RD5-26 (1X) provided in the kit. Mouse adiponectin standard (lyophilized 
recombinant mouse adiponectin) was reconstituted in Calibrator Diluent RD5-26 (1X) 
to produce a stock solution of 10 ng/mL and a 2-fold dilution series in Calibrator 
Diluent RD5-26 (1X) of 5, 2.5, 1.25, 0.62, 0.31 and 0.16 ng/mL concentrations was 
prepared. A zero standard of 0 ng/mL adiponectin was created by adding only 
Calibrator Diluent RD5-26 (1X) without the standard stock solution. A positive control 
of lyophilized recombinant mouse adiponectin with known concentration range was 
also assayed. 
50 µL of plasma samples, standard dilution series and control was distributed to 
corresponding wells in the microplate provided by the kit. 50 µL of Assay Diluent 
RD1W (buffered protein base) was added to all the wells and the plate incubated at 
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room temperature for 2 hours. Wells were then washed five times with 200 µL of wash 
buffer (provided by the kit) and 100 µL of mouse adiponectin conjugate (enzyme-linked 
polyclonal antibody specific for mouse adiponectin) was added to all the wells. The 
plate was then incubated at room temperature for 1 hour. After this incubation period, 
the plate was flipped over and any unbound enzyme-antibody reagent was removed by 
washing five times with 200 µL of wash buffer.  
100 µL of substrate solution (containing equal parts of hydrogen peroxide and 
chromogen (tetramethylbenzidine)) was added to all the wells. The microplate was 
covered with aluminium foil to protect from light and then incubated at room 
temperature for 30 min producing a blue colour. 100 µL of stop solution containing 
diluted hydrochloric acid was added to each well to stop the reaction from producing 
yellow colour. The optical density of each well was determined within 30 min using a 
microplate reader (Multiskan Ascent, Thermo Lab systems, USA), reading at 450 nm 
and then at 540 nm. Optical imperfections in the plate were corrected by subtracting the 
readings at 540 nm from readings at 450 nm.  
 
     2.9.4 Monocyte chemoattractant protein-1 (MCP-1) 
MCP-1 concentrations in cardiac plasma was determined by ELISA using Quantikine® 
ELISA Mouse/Rat CCl2/JE/MCP-1 Immunoassay kit (Cat# MJE00, R&D systems, 
Minneapolis, MN, USA) according to manufacturer’s instructions. Similar to the 
adiponectin ELISA kit (Section 2.9.4), this assay uses the quantitative sandwich enzyme 
immunoassay technique, where plasma samples containing MCP-1 bind to immobilized 
antibody (raised against E.coli expressed recombinant mouse MCP-1 factor) present in 
pre-coated 96 well microplates. Addition of a second polyclonal antibody against mouse 
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MCP-1 conjugated to horseradish peroxidase leads to binding to the plasma MCP-1 
attached to the plate. Finally, presence of this immunocomplex is developed by addition 
of hydrogen peroxide and chromogen tetramethylbenzidine, producing a blue colour, 
which is suggestive of the proportion of the amount of MCP-1 in the plasma.  
Prior to assay development, plasma samples were diluted 2-fold in Calibrator Diluent 
RD5-3 (provided by the kit). Lyophilized recombinant mouse MCP-1 was reconstituted 
in Calibrator Diluent RD5-3 to produce a standard stock solution of 1000 pg/mL. A 2-
fold standard dilution series was produced from this stock solution by additional 
dilution using Calibrator Diluent RD5-3 to produce 500, 250, 125, 62.5, 31.2 and 15.6 
pg/mL of mouse MCP-1. A zero standard (0 pg/mL) containing only Calibrator Diluent 
RD5-3 was added. A positive control of lyophilized recombinant mouse MCP-1 with a 
known concentration range was also included in the assay. 
Briefly, 50 µL of standard dilutions, control and diluted plasma samples were 
distributed in the 96-well microplate provided by the kit, following addition of 50 µL of 
assay Diluent RD1W (buffered protein base), and incubation at room temperature for 2 
hours. The plate was then washed five times with washing buffer (provided by the kit) 
to remove any unbound substances in the wells. 100 µL of mouse conjugate (polyclonal 
antibody against mouse MCP-1 conjugated to horseradish peroxidase) was added to 
each well following the 2 hour incubation at room temperature. Any unbound conjugate 
was removed by washing each well 5 times with washing buffer. 
100 µL of equal parts of hydrogen peroxide and chromogen (tetramethylbenzidine) was 
added to each well. The microplate was covered in aluminium foil to protect from light. 
Following the 30 min incubation at room temperature, which yields a blue colour, 100 
µL of stop solution (diluted hydrochloric acid) was added to each well to stop that 
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reaction, turning the blue colour into yellow. The optical density of each well was 
determined using a microplate reader (Multiskan Ascent, Thermo Lab systems, USA) at 
450 nm and 540 nm. Readings at 540 nm were subtracted from readings at 450 nm to 
correct for optical imperfections in the plate.  
 
2.10 Total hepatic triacylglyceride (TG) content measurement 
Concentration of triacylglycerides (TG) in liver samples was measured by the 
enzymatic hydrolysis of TG into free fatty acids and glycerol. Briefly, 40-50 mg of liver 
tissue was homogenized for 10 seconds in the presence of 500 µL of 0.5 M KOH 
prepared in ethanol (see appendix for preparation) in a 2 mL microtube (Cat# 34127-
3317, Edwards Instruments Co, USA) using a tissue homogenizer (Tissue Tearor, 5000 
to 32,000 rpm speed, BioSpec products Inc., OK, USA). The tubes were then incubated 
in a 70oC water bath (Ratek shaking waterbath, VIC, Australia) for 20 min. Samples 
were allowed to cool down for 10 min at room temperature (20-25oC). 1 mL of 0.15 M 
MgSO4 solution (see Appendix for preparation) was added to each sample to solubilize 
the lipids. 
 A solution of 500 µL of 0.5 M KOH and 1 mL of 0.15 M MgSO4 was used as a blank 
sample. All samples were vortexed (Ratex Vortex mixer, VIC, Australia) and 
centrifuged at 4750 rpm (Rotor# SX4750, Allegra®X- 15R centrifuge, Beckman 
Coulter, CA, USA) for 5 min at 4oC. The supernatant was then transferred into a new 
set of 2 mL microtubes (Cat# 34127-3317, Edwards Instruments Co, USA) and the 
amount of TG was measured using a Triglyceride Determination kit (Cat# TR0100, 
Sigma, USA) according to manufacturer’s instructions. This TG colorimetric kit 
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measures the glycerol released from the enzymatic hydrolysis of TG into free fatty acids 
and glycerol by the action of lipoprotein lipase (Figure 8).  
A standard curve containing 0, 0.052, 0.104, 0.156, 0.208 and 0.26 g/L of glycerol was 
produced. 10 µL of samples, standards and blank were distributed in duplicates in a 96-
well microplate (IWAKI, Cat# 3860-96, Osaka, Japan). 160 µL of freshly prepared 
Reagent A (free glycerol reagent) was added to each well and the microplate was 
incubated at room temperature for 15 min. 40 µL of reagent B (TG reagent) was then 
added to each well, and the microplate was incubated at room temperature for another 
15 min, followed by measurement of absorbance at 540 nm using the FLUOstar optima 
spectrophotometer (BMG LABTECH microplate reader, VIC, Australia). 
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Figure 8: Scheme of reactions used in a chemical colorimetric assay for quantification of 
triacylglyceride (TG) in liver tissue. Abbreviations used: 4-AAP: 4-aminoantipyrine; ESPA: N-
ethyl-N-(3-sulfoprotyl)-M-anisidine (ESPA). 
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2.11 Molecular Biology 
2.11.1 Peri-ovarian adipose tissue RNA extraction 
RNA extraction was performed using Trizol® reagent (Cat # 15596-018, Ambion Life 
Technologies, CA, USA) according to manufacturer’s instructions. Briefly, 50 mg of 
peri-ovarian WAT was homogenized and emulsified in a 2 mL microtube (Cat# 34127-
3317, Edwards Instruments Co, USA) containing 1 mL of ice-cold Trizol® reagent for 
10 seconds using a tissue homogenizer (Tissue Tearor, 5000 to 32,000 rpm speed, 
BioSpec products Inc., OK, USA). The homogenate was incubated at room temperature 
for 5-10 min. This procedure was followed by centrifugation at 12,000 rpm (Rotor# 
SX4750, Allegra X-15R Centrifuge, Beckman Coulter, CA, USA) for 10 min at 4oC, to 
separate nucleic acids from cell debris.  
The resulting pellet contained extracellular matrix, polysaccharides and high molecular 
weight DNA, while the supernatant contained the RNA. In samples obtained from a HF-
fed mouse, a layer of fat found above the supernatant was removed. The RNA-
containing supernatant was transferred to a fresh set of  1.5 mL microtubes (Cat# 
72.690.550, Sarstedt, Germany), where 200 µL of 100% (v/v) chloroform (Cat # 27710, 
BDH Chemicals, QLD, Australia) was added. Microtubes were vortexed vigorously 
(Ratex Vortex mixer, VIC, Australia) and allowed to settle for 15 min at room 
temperature. Samples were centrifuged at 12,000 rpm for 15 min at 4oC (Rotor# 
SX4750, Allegra X-15R Centrifuge, Beckman Coulter, CA, USA).  
The chloroform separated the sample into a lower red phenol-chloroform phase, an 
interphase and a colorless upper aqueous phase. The upper aqueous phase was around 
50 % of the total volume and the RNA remained exclusively in this phase. This phase 
was transferred into a sterile 1.5 mL microtube (Cat# 72.690.550, Sarstedt, Germany) 
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without disturbing the interphase. The RNA was then precipitated by the addition of 
500 µL 100 % (v/v) isopropanol (Cat# 425, Univar, Ajax FineChem, VIC, Australia) 
and 20 µL of 5 M NaCl (see Appendix for preparation) to increase RNA yield.  The 
sample was mixed by gentle inversion and equilibration was allowed for either 10 min 
at room temperature, or 30 min at 4oC. The sample was then centrifuged at 12,000 rpm 
(Rotor# SX4750, Allegra X-15R Centrifuge, Beckman Coulter, CA, USA) for 15 min at 
4oC to pellet the RNA and the supernatant was discarded.  
The RNA pellet was washed twice by vortexing (Ratex Vortex mixer, VIC, Australia)  
in 1 mL of ice cold 75% ethanol (see Appendix for preparation), followed by 
centrifugation at 12,000 rpm (Rotor# SX4750, Allegra X-15R Centrifuge, Beckman 
Coulter, CA, USA) for 10 min at 4oC. The ethanol was discarded and the samples were 
placed inside a fume hood (Dyna Safe control system MK3, Dyna Flow, NSW, 
Australia) to remove excess of ethanol by evaporation.  This procedure was performed 
for no longer than 20 min, to prevent the pellet from drying out, which can cause pellet 
insolubility. The RNA pellet was resuspended in 20 µL DEPC-water (see Appendix for 
preparation) and incubated at 55oC in a dry bath incubator (Cat# MD-02W-220, Major 
Science, Taiwan) for 10 min to allow homogenization. Quantitative and qualitative 
analysis of the RNA obtained was conducted by spectrophotometry using the Nanodrop 
spectrophotometer (TM100, ThermoFisher Scientific, USA) and electrophoresis 
analysis. 
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2.11.2 Electrophoresis 
RNA integrity was analyzed in 1% agarose gel electrophoresis. Sharp and clear 28S and 
18S RNA bands indicated intact and high quality RNA, while smeared bands indicated 
partially degraded and low quality RNA. Briefly, 0.5 g of agarose (Cat# 16103102, 
BioRad, CA, USA) was dissolved in 50 mL of 1X TAE buffer (see Appendix for 
preparation), microwaved for 2 min and allowed to cool to approximately 60oC. 2 µL of 
ethidium bromide at 10 mg/mL (Cat# 161-0433, BioRad, CA, USA) was added to the 
gel, which was allowed to set for 1 hour in a gel chamber set up with combs. On 
solidification, the combs were removed and the gel was placed in the electrophoresis 
tank (BioRad wide mini sub cell GT, Voltage limit 150 VDC, BioRad, CA, USA) and 
covered over 2-3 mm with 1X TAE buffer (see Appendix for preparation).  
Volume corresponding to 1 µg of RNA was resuspended in DEPC-water (see Appendix 
for preparation) to make up 13 µL solution and 3 µL of loading buffer dye was added 
per sample. The loading buffer was made up of bromophenol blue and sucrose. Of note, 
bromophenol blue is negatively charged in neutral buffer and moves in the same 
direction as the RNA during electrophoresis. This allows visual monitoring of the 
progress of the gel. Sucrose provides density to the sample, making it easier to load into 
the wells on the gel. The final 15 µL of the sample solution was loaded into each well 
and the gel was run at 80 V for 20 min using the Power Pac Universal power supply 
(500 V/2.5 A/500 W, BioRad, CA, USA). RNA bands were visualized using the Gel 
Doc XR System PC (BioRad, CA, USA) and analyzed by Vision Capture 14.2 software.  
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2.11.3 cDNA synthesis 
cDNA was synthesized using M-MLV (Moloney Murine Leukemia Virus) reverse 
transcriptase system (Cat# 28025-01, Invitrogen, USA). Briefly, 1 µg of RNA was 
resuspended in DEPC-water (see Appendix for preparation) to a final volume of 40.5 
µL. 1 µL of random primers Pd (N)6 (3µg/µ , Cat# 48190-011, Invitrogen, USA) was 
added to each sample. Samples were incubated at 73oC in a dry bath incubator (Cat# 
MD-02W-220, Major Science, Taiwan) for 3 min and then placed on ice for 2 min. 
Samples were then quickly spun and 8.5 µL of reverse transcriptase (RT) master mix 
was added. The RT master mix was made up of 5 µL 10X RT buffer (refer to Appendix 
for preparation), 2 µL of dNTP  mix at 25 mM (Cat# 10297-018, Invitrogen, USA), 1 
µL of 0.5M Dithiothreitol (DTT, Cat# D9779, Sigma Aldrich, CA, USA) and 0.5 µL of 
200 U/µL reverse transcriptase M-MLV. Samples were spun and incubated for 1 hour in 
a 37oC water bath (Ratek shaking waterbath, VIC, Australia) and later stored in a -20oC 
freezer until use. 
 
2.11.4 Real Time- PCR 
Primers used in this study were designed using Gene Runner Software 7/8/8.1 and 
Primer-BLAST (http://www.ncbi.nlm.nig.gov/tools/primer-blast/) and ordered from 
GeneWorks (VIC, Australia). All primers were resuspended in DEPC-water (see 
Appendix for preparation) to a final concentration of 100 µM. A working concentration 
of 10 µM primers was made in DEPC-water. Quantitative Real-Time PCR was 
performed using the 2X Power SYBR Green Kit (Cat# 4368577, Applied Biosystems, 
CA, USA) in 5 µL reactions containing 3 µL of mastermix and 2 µL of 1:10 diluted 
cDNA. The mastermix consisted of 0.5 µL forward primers (0.3 µM), 0.5 µL reverse 
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primers (0.3 µM), 0.2 µL DEPC-water and 2.5 µL of 2X Power SYBR Green. A 
complete list of the primers (Geneworks, VIC, Australia) and their final concentrations 
are listed in Table 1. 
 cDNA samples from each experimental group and mastermix were loaded onto the 
wells of 384-well clear optical reaction plates (Cat# 128, ABI PRISM, Applied 
Biosystems, USA) in quadruplicates, using EpMotion 5070 (Eppendorf, Hamburg, 
Germany) and later sealed with optical film (Applied Biosystems, CA, USA). Gene 
expression was determined using the ABI PRISM 7900 HT system (Applied 
Biosystems, CA, USA) under the following conditions: 50oC for 2 min, 95oC for 10 min 
followed by 40 cycles of 95oC for 15 seconds and primer annealing temperature for 1 
min. To validate PCR products, all plates were subjected to dissociation runs at 
temperature of 95oC for 15 seconds, 60oC for 15 seconds, then slowly ramped 2oC per 
minute to 95oC for 20 minutes.  
The RT-PCR dissociation curves, amplification plot and Ct counts (cycle threshold) 
were analyzed using SDS 2.4.1 software (Applied Biosystems, CA, USA). Serially 
diluted pooled peri-ovarian adipose tissue cDNA was used to generate a standard curve 
for each gene of interest. An XY-scatter graph was plotted to generate a standard curve 
with Ct values on y-axis and concentration of diluted standards on x-axis. A trendline 
and linear trendline regression was generated and this equation was used to calculate the 
expression of each corresponding marker. Six housekeeping genes were tested for stable 
expression across the different diet and genotype groups in NOD.B10 and Balb/c mice 
strains, including GAPDH, Cyclophillin, 18S rRNA, HPRT-1, B2M and RPL13a. All 
results obtained were normalized by dividing their values by the geometric mean of 
housekeeping genes.  
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2.12 Statistical analyses 
All analyses were performed using Two-Way analysis of variance (ANOVA) with 
Bonferroni post hoc testing. A P value of <0.05 was considered significant. Two-Way 
ANOVA analyses were performed using the PRISM software version 4 (GraphPad 
Software, San Diego, CA, USA). Data are presented as means ± SEM. 
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3. Results 
3.1 Determination of phenotype- Obesity  
Previous long-term studies in HF-fed NOD.B10 foz/foz mice (up to 24 weeks on diet) 
have shown that the development of T2D and NASH is associated with adipose tissue 
restriction (attenuation of normal subcutaneous white adipose tissue expansion). [360] If 
susceptibility of adipose tissue dysfunction (including restriction) in response to nutrient 
excess, is a primary defect in NOD.B10 mice increasing its susceptibility to T2D and 
NASH compared to Balb/c mice, it would be expected that differences in the obesity 
phenotype (including fat distribution), would be apparent between the two strains early 
on following induction of nutrient overload.  
To assess this, body weight, body fat composition scans and mice length analyses over 
time were performed to evaluate the effects of genotype and diet on the obesity 
phenotype of these murine models. Therefore, these analyses were conducted in this 
present study in chow and HF-fed NOD.B10 and Balb/c WT and foz/foz mice. 
 
     3.1.1 Fortnightly body weight  
Body weight of all NOD.B10 and Balb/c mice were measured every fortnight from 4 
weeks of age until the end of the experimental period of 12 weeks of age. Body weight 
results are shown in Figure 9. Representative photograph of mice showing respective 
size, shape and intra-abdominal fat content are shown in Figure 10. 
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The results show that at 4 weeks of age, the body weights of all mice groups were 
similar within each strain. However, Balb/c mice are smaller than NOD.B10 mice 
(Figure 9A-B).  
HF-feeding did not cause obesity in both WT NOD.B10 and Balb/c mice.  
The foz/foz genotype was associated with moderate excessive weight gains in both mice 
strains. NOD.B10 foz/foz mice on chow diet began to gain more weight than their WT 
controls from 8 weeks of age, and displayed significant weight gain by 12 weeks of age 
(36.2 ± 1.0 vs 25.1 ± 0.4 g, foz-chow vs WT-chow, respectively, p<0.0001). Balb/c 
foz/foz mice fed on chow diet also displayed similar results at 12 weeks of age (30.9 ± 
1.7 vs 23.1 ± 0.5 g, foz-chow vs WT-chow, respectively, p<0.001). 
The combination of HF-feeding and the foz/foz genotype caused marked obesity in both 
mice strains. HF-fed NOD.B10 foz/foz mice developed almost 30% more weight gain 
compared to the chow-fed foz/foz mice at 12 weeks of age (47.9 ± 1.5 vs 36.2 ± 1.0 g, 
respectively, p<0.0001). Similar results were observed in the Balb/c foz/foz mice at 12 
weeks of age (46.7 ± 1.5 vs 30.9 ± 1.7 g, foz-HF vs foz-chow, respectively, p<0.0001). 
The initial rate of weight gain tended to be greater in the HF-fed NOD.B10 foz/foz mice 
compared to the HF-fed Balb/c foz/foz mice. At 6 weeks of age, after only 2 weeks on 
HF diet, NOD.B10 foz/foz mice displayed higher body weight compared to WT-HF 
mice (28.4 ± 1.3 vs 22.4 ± 0.6 g, respectively, p<0.001) and foz-chow mice (28.4 ± 1.3 
vs 22.7 ± 0.4 g, respectively, p<0.01). This difference in weight gain progressively 
increased with time, and by 12 weeks of age, HF-fed NOD.B10 foz/foz mice were 
almost two times heavier than WT-HF mice (47.9 ± 1.5 vs 27.1 ± 1.1 g, respectively, 
p<0.0001). HF-fed Balb/c foz/foz mice displayed a similar pattern but with progressive 
increase in body weight from 8 weeks of age, compared to WT-HF mice (30.3 ± 1.0 vs 
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22.5 ± 0.6 g, respectively, p<0.0001) and foz-chow mice (30.3 ± 1.0 vs 23.2 ± 1.2 g, 
respectively, p<0.0001). 
The rate of weight gain from 10-12 weeks of age slowed in HF-fed NOD.B10 foz/foz 
mice compared to Balb/c foz/foz mice, such that the earlier differences in weight gain of 
the two strains was not present at 12 weeks of age (Figure 9C). At 12 weeks of age, HF-
fed foz/foz mice from both strains developed similar body weights (47.9 ± 1.5 vs 46.7 ± 
1.5 g, NOD.B10 vs Balb/c, respectively).  
Taken together, in both NOD.B10 and Balb/c strains, the foz/foz genetic background 
contributed to the increase in body weight and this was exacerbated when the foz/foz 
genotype was coupled with HF diet. Both mice strains developed severe obesity by 12 
weeks of age, but HF-fed NOD.B10 foz/foz mice initially gained more weight faster 
than their Balb/c counterparts. 
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Figure 9: Fortnightly measurements of body weight in female mice. (A) NOD.B10, (B) Balb/c 
mice strains and (C) comparison between HF-fed foz/foz mice of both strains from 4 to 12 
weeks of age. HF-fed foz/foz mice from both strains showed progressive increase in body 
weight compared to the other groups. Data are means ± SEM of 16-23 mice per group. Two-
way ANOVA with Bonferroni post-hoc test; +p<0.05, +++p<0.001, ++++p<0.0001, WT-chow vs 
foz-chow; ♯♯♯p<0.001, ♯♯♯♯p<0.0001, WT-HF vs foz-HF; ¶¶p<0.001, ¶¶¶¶p<0.0001, foz-chow vs 
foz-HF; *p<0.05, ****p<0.0001, NOD.B10 vs Balb/c.  
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Figure 10: Representative photographs showing comparative body shape and size of female WT 
and foz/foz on chow and HF diet of NOD.B10 strain (brown mice) and Balb/c strain (white 
mice) at 12 weeks of age. The lower panel for each strain shows the relative amount of intra-
abdominal adipose tissue. 
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     3.1.2 Measurement of mice body length  
Measurement of mice length is a very simple technique employed to analyze differences 
in growth rate between mice strains. Herein, mice body length (nose to anus) was 
measured in unconscious NOD.B10 and Balb/c mice on the day of harvesting. 
NOD.B10 mice lengths were measured at 6, 8, 10 and 12 weeks of age, while Balb/c 
mice lengths were measured at 6 and 12 weeks of age only. Results are shown in Figure 
11. 
No significant nose to anus length difference was observed between all groups of mice 
on the NOD.B10 or Balb/c strains (Figure 11A-B). Mice lengths of all mice groups 
were also similar when comparing the two mice strains at 6 (data not shown) and 12 
weeks of age (Figure 11C).  
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Figure 11: Body length measurements determined from the tip of the nose to the anus. (A) 
NOD.B10, (B) Balb/c, and (C) comparisons between strains at 12 weeks of age. No significant 
difference in mice lengths were observed in any of the mice groups in both strains. Data are 
means ± SEM of 5-15 mice per group. Two-way ANOVA with Bonferroni post-hoc test. No 
significant differences found.  
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     3.1.3 Body fat composition (DEXA) 
Increases in body weight due to excessive nutrient supply can cause changes in body 
composition. Thus, using DEXA, we examined fat mass distribution at 6 and 12 weeks 
of age in all mice groups of NOD.B10 and Balb/c strains fed on chow or HF diet 
(Figure 12 and 13).  
At 6 weeks of age, total lean mass was similar between all mice groups, with the 
exception of NOD.B10 foz/foz mice on chow diet, that had more total lean mass than its 
Balb/c counterparts (16.9 ± 0.7 vs 13.6 ± 0.3 g, respectively, p<0.001) (Figure 13A). At 
this same age, only NOD.B10 foz/foz mice on HF diet higher total fat mass compared to 
its Balb/c counterparts (5.9 ± 0.6 vs 4.4 ± 0.3 g, respectively, p<0.05) (Figure 13C). A 
mild increase in % of body fat mass was observed at 6 weeks of age with HF-feeding in 
WT and foz/foz mice of both strains (Figure 13E). 
At 12 weeks of age, total lean mass was still very similar between mice groups of both 
strains, with the exception of HF-fed NOD.B10 foz/foz mice, which displayed slightly 
higher total lean mass than its Balb/c counterparts (21.8 ± 0.9 vs 18.1 ± 0.6 g, 
respectively, p<0.05) (Figure 13B). At this same age, foz/foz mice fed on chow diet of 
both strains, exhibited increased fat mass (shown as absolute terms and as a % of body 
weight) when compared to their respective WT controls (Figure 13D, F). A further 
similar increase in fat mass was  observed in foz/foz mice of both strains when fed on a 
HF diet (14.9 ± 0.4 vs 23.9 ± 2.5 g, NOD.B10 foz-chow vs foz-HF, respectively, 
p<0.0001) and (10.4 ± 1.9 vs 25.7 ± 1.5 g, Balb/c foz-chow vs foz-HF, respectively, 
p<0.0001).  
In agreement with results obtained from body weight measurements, DEXA body fat 
composition scans showed that foz/foz mice of both strains exhibited similar increase in 
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fat mass content at both ages compared to their WT controls, with even higher fat mass 
observed when fed on HF diet. Of note, however, at 6 weeks of age, NOD.B10 foz/foz 
mice had greater fat mass compared to its Balb/c counterparts (Fig 13C), but this was 
not the case at 12 weeks of age (Fig 13D). 
 
Summary of results related to development of obesity 
The results show that in response to HF-feeding, NOD.B10 foz/foz mice compared to 
Balb/c foz/foz mice tend to have a greater initial weight gain and adipose tissue growth. 
However, this is not sustained out to 12 weeks of age. The results would be consistent 
with the development of relative adipose restriction in NOD.B10 foz/foz mice at 12 
weeks of age. However, these results alone do not prove this, as other explanations such 
as a relative change in food intake towards 12 weeks of age in HF-fed NOD.B10 foz/foz 
mice could also cause these results. 
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Figure 12: Representative body composition scans determined by dual-energy X-ray 
absorptiometry (DEXA). NOD.B10: (A) WT-chow, (B) WT-HF, (C) foz-chow and (D) foz-HF 
mice groups and Balb/c: (E) WT-chow, (F) WT-HF, (G) foz-chow and (H) foz-HF mice groups 
at 12 weeks of age.  
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Figure 13: Total lean mass (A-B), total fat mass (C-D) and % body fat  (E-F) measurements by 
DEXA of NOD.B10 and Balb/c mice strains at 6 and 12 weeks of age. HF-feeding and foz/foz 
genotype was observed to cause a progressive increase in fat mass. Data are means ± SEM of 10 
mice per group. Two-way ANOVA with Bonferroni post-hoc test. §p<0.05, §§p<0.01, 
§§§§p<0.0001, WT-chow vs WT-HF; ++++p<0.0001, WT-chow vs foz-chow; ♯♯♯♯p<0.0001, WT-
HF vs foz-HF; ¶¶¶¶p<0.0001, foz-chow vs foz-HF; *p<0.05, ***p<0.001, NOD.B10 vs Balb/c. 
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3.2 Determination of phenotype- Type 2 Diabetes  
Previous studies have shown that NOD.B10 foz/foz mice develop T2D by 24 weeks on 
HF diet.[360] However, the temporal relationship between the development of 
hyperglycaemia and adipose tissue changes in these mice is unknown. Therefore, serial 
non-fasting blood glucose levels and plasma insulin levels were measured, as well as 
intraperitoneal glucose tolerance tests performed to determine the temporal onset of 
hyperglycaemia and T2D compared to adipose tissue changes in HF-fed NOD.B10 
foz/foz mice. The other NOD.B10 and Balb/c mice groups were also assessed for full 
comparison of phenotypes.  
 
     3.2.1 Non-fasting blood glucose levels  
Non-fasting blood glucose levels (from tail vein blood) were measured between 9-10 
am every fortnight from 4 to 12 weeks of age for all female NOD.B10 and Balb/c mice. 
HF-feeding did not cause an increase in blood glucose levels of WT mice of both 
NOD.B10 and Balb/s strains. These mice remained normoglycaemic throughout the 
entire study period (Figure 14A).  
NOD.B10 foz/foz mice fed on chow diet also maintained normoglycaemia until 12 
weeks of age, when a mild elevation in glucose levels were observed compared to WT-
chow mice (8.4 ± 0.3 vs 6.8 ± 0.2 mmol/L, respectively, p<0.05).  
HF-feeding and the foz/foz genotype in NOD.B10 foz/foz mice caused a progressive 
increase in glucose levels, initially observed at 8 weeks of age, when compared to foz-
chow mice (9.5 ± 0.7 vs 7.9 ± 0.2 mmol/L, respectively, p<0.0001). These values 
continued to increase over the time course, and by 12 weeks of age, all mice were 
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hyperglycaemic with 50% of them considered to be diabetic (11.7 ± 0.8 vs 8.4 ± 0.3 
mmol/L, foz-HF vs foz-chow, respectively, p<0.0001).  
Of note, Balb/c foz/foz mice, fed on either chow or HF diet, remained normoglycaemic 
throughout the time course (Figure 14B). 
Thus, at 12 weeks of age, there was a marked difference in blood glucose levels 
between HF-fed NOD.B10 foz/foz mice and HF-fed Balb/c foz/foz mice (11.7 ± 0.9 vs 
6.9 ± 0.2 mmol/L, respectively, p<0.0001) (Figure 14C).  
HF-fed NOD.B10 foz/foz mice developed progressive elevations in non-fasting blood 
glucose levels, which were evident at a very early age, aggravating with time and 
leading to the development of diabetes, while HF-fed Balb/c foz/foz mice displayed 
excellent ability to maintain normoglycaemia. At the age at which blood glucose levels 
began to increase in HF-fed NOD.B10 foz/foz mice, there was no evidence of adipose 
tissue restriction. 
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Figure 14: Time course measurement of non-fasting tail blood glucose levels. (A) NOD.B10 
mice, (B) Balb/c mice and (C) comparison between HF-fed foz/foz mice of both strains from 4 
to 12 weeks of age. HF-fed NOD.B10 foz/foz mice developed hyperglycemia while Balb/c mice 
remained normoglycaemic. Data are means ± SEM of 16-23 mice per group. Two-way 
ANOVA with Bonferroni post-hoc test. +p<0.05, WT-chow vs foz-chow; ♯♯♯p<0.001, 
♯♯♯♯p<0.0001, WT-HF vs foz-HF; ¶¶¶¶p<0.0001, foz-chow vs foz-HF; **p<0.01, ****p<0.0001, 
NOD.B10 vs Balb/c.   
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     3.2.2 Non-fasting plasma insulin levels 
Overfeeding results in obesity, causing insulin resistance. In order to maintain 
normoglycaemia, the pancreatic islet β-cells need to compensate for the insulin 
resistance with insulin hyper-secretion. Failure to sustain this β-cell compensatory 
response is believed to contribute to hyperglycaemia and the development of T2D.  
Therefore, at the harvesting day, non-fasting tail blood was collected from anaesthetized 
mice for determination of plasma insulin levels from 6 to 12 weeks of age. 
HF-feeding did not cause an increase in plasma insulin levels in the WT mice of both 
strains throughout the study (Figure 15A-B).  
The foz/foz genotype caused progressive elevations in plasma insulin levels in the 
NOD.B10 foz/foz mice fed on chow diet, when compared to WT-chow mice, and by 12 
weeks of age, these mice were hyperinsulinaemic (5.1 ± 1.3 vs 0.4 ± 0.1 ng/mL, foz-
chow vs WT-chow, respectively, p<0.01). However, the foz/foz genotype did not cause 
any significant increase in plasma insulin levels in the Balb/c mice strain (Figure 15B). 
The combination of HF-feeding and the foz/foz genotype in the NOD.B10 foz/foz mice 
led to higher plasma insulin levels even at 6 weeks of age, when compared to the foz-
chow mice (2.2 ± 0.4 vs 0.8 ± 0.1 ng/mL, respectively, p<0.01). These values 
augmented progressively until the end of the time course at 12 weeks of age (55.7 ± 9.2 
vs 5.1 ± 1.3 ng/mL, foz-HF vs foz-chow, respectively, p<0.0001).  
HF-fed Balb/c foz/foz mice developed hyperinsulinaemia at 12 weeks of age, when 
compared to foz-chow mice (5.3 ± 1.4 vs 1.4 ± 0.3 ng/mL, p<0.0001) and WT-HF mice 
(5.3 ± 1.4 vs 0.6 ± 0.1 ng/mL, p<0.0001). However, the plasma insulin levels in these 
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mice were significantly lower than its NOD.B10 counterparts (5.3 ± 1.4 vs 55.7 ± 9.4 
ng/mL, respectively, p<0.0001) (Figure 15C).  
In the NOD.B10 mice, the foz/foz genotype alone caused hyperinsulinaemia only at 12 
weeks of age. However, HF-feeding in these mice caused massive augmentation from 8 
weeks of age, leading to profound severe hyperinsulinaemia, with 10 times higher 
plasma insulin levels than their Balb/c counterparts by the end of the experimental 
period. Significant hyperinsulinaemia was therefore an early failure in the NOD.B10 
mice strain in response to marked overfeeding, as a consequence of the combination of 
the foz/foz genotype and HF-feeding. 
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Figure 15: Time course measurement of non-fasting plasma insulin levels. (A) NOD.B10 mice, 
(B) Balb/c mice and (C)  comparison between NOD.B10 and Balb/c HF-fed foz/foz mice from 4 
to 12 weeks of age. Data are means ± SEM of 16-23 mice per group. Two-way ANOVA with 
Bonferroni post-hoc test. ♯♯♯♯p<0.0001, WT-HF vs foz-HF; ¶¶¶¶p<0.0001, foz-chow vs foz-HF; 
****p<0.0001, NOD.B10 vs Balb/c. 
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     3.2.3 Intraperitoneal Glucose Tolerance Test (ipGTT) 
To further determine the effects of HF-feeding and the foz/foz genotype on blood 
glucose regulation and insulin secretion on the two mice strains, ipGTT was performed 
in all mice groups at 5 and 11 weeks of age, one week prior to harvesting. 
At 5 weeks of age, fasting blood glucose levels (time 0 min) were similar between all 
NOD.B10 (Figure 16A) and Balb/c (Figure 16B) mice groups. As seen in Figure 17A, 
HF-fed NOD.B10 foz/foz mice developed glucose intolerance when compared to foz-
chow mice, particularly at time 30 min (22.8 ± 2.8 vs 15.7 ± 1.8 mM, respectively, 
p<0.05). These mice also displayed increased fasting plasma insulin levels when 
compared to its foz-chow controls at baseline (time 0 min) (0.9 ± 0.1 vs 0.5 ± 0.1 mM) 
and time 90 min (1.3 ± 0.2 vs 0.8 ± 0.1 mM, respectively, p<0.01) (Figure 16C).  
All Balb/c mice groups displayed excellent glucose control in response to 
intraperitoneal glucose load (Figure 16B). This effect was associated with elevations in 
plasma insulin levels with higher responses in mice fed on HF diet (Figure 16D). 
 
At 11 weeks of age, HF-feeding caused mild glucose intolerance in the NOD.B10 WT 
mice (Figure 17A). The foz/foz genotype also generated similar results in the NOD.B10 
foz/foz mice, with the development of mild hyperinsulinaemia. However, the Balb/c 
mice did not display these results and remained normoglycaemic (Figure 17B). 
Both HF-feeding and the foz/foz genotype led to higher glucose levels even during 
fasting (at time 0 min) in NOD.B10 foz/foz mice, when compared to foz-chow mice 
(11.9 ± 0.6 vs 7.9 ± 0.2 mM, respectively, p<0.05), and development of severe glucose 
intolerance after receiving the intraperitoneal glucose bolus (31.9 ± 1.3 vs 22.4 ± 2.0 
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mM, respectively, at time 30 min, p<0.001) (Figure 17A). Interestingly, the 
hyperglycaemia in these mice was associated with severe hyperinsulinaemia (Figure 
17C).  
HF-fed Balb/c foz/foz mice displayed a slight increase in glucose levels towards the end 
of the experiment at time 90 min (15.2 ± 1.9 vs 8.7 ± 0.7 mM, foz-HF vs foz-chow 
mice, respectively, p<0.05) (Figure 17B). This same group of mice displayed mild 
hyperinsulinaemia during fasting (time 0 min) (2.2 ± 0.3 vs 0.8 ± 0.2 mM, foz-HF vs 
foz-chow, respectively) (Figure 17D). Insulin secretion was augmented in response to 
glucose injection (time 15 min) but it returned close to initial values at time 90 min (2.2 
± 0.3 vs 3.3 ± 0.3 mM, Balb/c foz-HF, time 0 min vs time 90 min, respectively).  
 
After only 1 week on HF diet, at 5 weeks of age, NOD.B10 foz/foz mice were already 
displaying signs of impaired glucose tolerance, and by 11 weeks of age, they developed 
severe glucose intolerance during ipGTT, despite increased plasma insulin levels. 
Whereas, at 5 weeks of age HF-fed Balb/c foz/foz mice exhibited normal glucose 
tolerance maintained by mild elevation in plasma insulin levels, whereas by 11 weeks of 
age, higher levels of insulin were necessary to maintain a normal glucose response 
during the test.  
 
Summary of results relating to development of diabetes 
HF-fed NOD.B10 foz/foz mice displayed early signs of hyperglycaemia, 
hyperinsulinaemia and glucose intolerance, followed by development of severe 
impaired glucose tolerance, despite profound hyperinsulinaemia. On the other hand, 
HF-fed Balb/c foz/foz mice maintained normal glucose tolerance and normoglycaemia, 
accompanied by moderate hyperinsulinaemia. Of note, HF-fed NOD.B10 foz/foz mice 
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already had mild hyperglycaemia after only 1 week on the diet at which time insulin 
levels were not different from the Balb/c counterparts. These results suggest that HF-fed 
NOD.B10 foz/foz mice are able to sustain very high insulin levels in vivo, but the 
hyperinsulinaemia is inadequate to control blood glucose levels, whereas HF-fed Balb/c 
foz/foz mice are diabetes resistant. 
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Figure 16: Intraperitoneal Glucose Tolerance Test (ipGTT) performed on NOD.B10 (left panel) 
and Balb/c (right panel) mice at 5 weeks of age. Graphics (A, B) and (C, D) depict glucose and 
insulin excursions during the test, respectively.  HF-fed NOD.B10 foz/foz mice developed 
glucose intolerance during the experiment despite the high plasma insulin levels. HF-fed Balb/c 
foz/foz mice had higher plasma insulin levels and did not develop hyperglycaemia. Data are 
means ± SEM of 5-10 mice per group. Two-way ANOVA with Bonferroni post-hoc test. 
♯p<0.05, WT-HF vs foz-HF; ¶p<0.05, ¶¶p<0.01, foz-chow vs foz-HF.   
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Figure 17: Intraperitoneal Glucose Tolerance Test (ipGTT) performed on NOD.B10 (left panel) 
and Balb/c (right panel) mice at 11 weeks of age. Graphics (A, B) and (C, D) depict glucose and 
insulin excursions during the test, respectively.  HF-fed NOD.B10 foz/foz mice developed 
glucose intolerance despite the high plasma insulin levels. HF-fed foz/foz Balb/c mice had 
higher plasma insulin levels and only developed hyperglycemia towards the end of the 
experiment. Data are means ± SEM of 5-10 mice per group. Two-way ANOVA with Bonferroni 
post-hoc test. +++p<0.001, ++++p<0.0001, WT-chow vs foz-chow; ♯p<0.05, ♯♯p<0.01, ♯♯♯p<0.001, 
WT-HF vs foz-HF; ¶p<0.05, ¶¶p<0.01, foz-chow vs foz-HF. 
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3.3 Determination of phenotype- Liver disease 
Female NOD.B10 foz/foz mice have been found to develop hepatomegaly as well as 
increased intrahepatic TG content and elevated plasma ALT levels associated with 
NASH within 24 weeks on HF diet.[360] The increase in plasma ALT levels is a marker 
for hepatic injury and transition of NAFLD to NASH. Therefore, liver weight, hepatic 
TG content and plasma ALT levels were analyzed in foz/foz mice of both NOD.B10 and 
Balb/c strains from 6 to 12 weeks of age in order to determine the time of transition of 
NAFLD to NASH. This could then be related to the timing of changes in glucose 
regulation and adipose tissue parameters.  
 
     3.3.1 Liver weight  
Total liver tissue weights expressed as absolute weight and as % of body weight were 
measured at different ages in both mice strains (Figure 18, left and right panels, 
respectively).  
In the NOD.B10 mice, all mice groups had similar liver weights at 6 weeks of age 
(Figure 18A-B).  HF-feeding did not cause any further increase in liver weight in the 
WT mice throughout the time course. The foz/foz genotype initially caused slightly 
elevated liver weights in chow-fed NOD.B10 foz/foz mice when compared to the WT 
controls. However, no further changes were observed after the initial increase in liver 
weight.  
Interestingly, HF-feeding and the foz/foz genotype both caused a marked increase in 
liver weight in the NOD.B10 foz/foz mice from 10 weeks of age, when compared to foz-
chow mice, and when normalized to a % of body weight it still showed marked 
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hepatomegaly (6.7 ± 0.3 vs 4.8 ± 0.1, as % body weight, p<0.0001) (Figure 18B). This 
difference in liver weight was progressive with time and by 12 weeks of age, these mice 
developed progressive hepatomegaly when compared to their foz-chow littermates (8.0 
± 0.3 vs 4.4 ± 0.1, as % of body weight, p<0.0001) (Figure 18B).  
In the Balb/c mice, all mice groups displayed similar liver weights at 6 weeks of age, 
similar to the NOD.B10 mice (Figure 18C-D). HF-feeding did not cause any changes in 
liver weight in the WT mice. The foz/foz genotype also led to similar results in the 
chow-fed foz/foz mice. In fact, a slight reduction in % of liver weight was observed in 
these mice, when compared to WT-chow controls (4.3 ± 0.1 vs 5.5 ± 0.1, as % of body 
weight, respectively, p<0.01) (Figure 18D). 
The combination of HF-feeding and the foz/foz genotype in the Balb/c mice strain led to 
a significant increase in total absolute liver weight at 12 weeks of age, when compared 
to foz-chow mice (2.5 ± 0.1 vs 1.2 ± 0.1 g, respectively p<0.001) and WT-HF mice (2.5 
± 0.1 vs 1.4 ± 0.1 g, respectively, p<0.01) (Figure 18C). However, when normalized to 
a % of body weight, no differences in liver weight were observed (Figure 18D).  
Comparison of all mice groups at 12 weeks of age of both strains showed that only HF-
fed foz/foz mice on the NOD.B10 background had heavier livers compared to Balb/c 
mice (7.9 ± 0.3 vs 5.3 ± 0.2, as % of body weight, p<0.001) (Figure 18E-F).  
In summary, only HF-fed NOD.B10 foz/foz mice developed significant hepatomegaly 
by 12 weeks of age, while HF-fed Balb/c foz/foz mice only displayed increase in 
absolute liver weight which was proportional to body weight gain. Of note, the 
development of hepatomegaly in the HF-fed NOD.B10 foz/foz mice, as % of body 
weight, was evident as early as 8 weeks of age. 
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Figure 18: Liver weight measurements. Total liver weight (left panel) and liver weight 
normalized to body weight (right panel) of (A-B) NOD.B10 and (C-D) Balb/c mice strains and 
(E-F) comparison between the 2 strains at 12 weeks of age. Data are means ± SEM of 10-23 
mice per group. Two-way ANOVA with Bonferroni post-hoc test. ++p<0.01, WT-chow vs foz-
chow; ♯p<0.05, ♯♯♯♯p<0.0001, WT-HF vs foz-HF; ¶¶¶p<0.001, ¶¶¶¶p<0.0001, foz-chow vs foz-
HF; ****p<0.0001, NOD.B10 vs Balb/c. 
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     3.3.2 Total hepatic triacylglyceride (TG) deposition  
Previous studies in female NOD.B10 foz/foz mice fed with 24 weeks of HF diet had 
shown that excessive nutrient stress causes abnormalities in body lipid partitioning 
leading to ectopic fat deposition, particularly in the liver.[360] Development of steatosis 
followed by hepatocyte ballooning were observed in these mice. Herein, we studied the 
temporal development of hepatic steatosis in the NOD.B10 and Balb/c mice groups. 
Hepatic TG expressed as absolute values per gram of tissue (left panels) or as total TG 
content per liver (right panels) were obtained for all mice groups (Figure 19).  
In the NOD.B10 mice, HF-feeding had already caused an increase in hepatic TG 
deposition at 6 weeks of age (Figure 19A-B). HF-fed NOD.B10 WT mice displayed 
higher TG content at 6 weeks of age compared to its WT-chow controls (306.1 ± 39.8 
vs 68.9 ± 6.2 mg TG/g w:w, respectively, p<0.0001) and maintained this difference 
even at 12 weeks of age (Figure 19B). The foz/foz genotype also caused a slight 
elevation in hepatic TG content in the NOD.B10 foz/foz mice when compared to its 
WT-chow controls at 12 weeks of age (226.9 ± 32.4 vs 68.9 ± 6.2 mg TG/g w:w, 
respectively, p<0.0001) (Figure 19B).  
The combination of both HF-diet and the foz/foz genotype in the NOD.B10 foz/foz mice 
was associated with an increase in hepatic TG deposition when compared to the foz-
chow mice, observed from 8 weeks of age (971.7 ± 55.8 vs 178.3 ± 32.1 mg TG/g w:w, 
p<0.0001), which progressively increased with time (Figure 19B).  
In the Balb/c mice, HF-feeding was observed to cause similar increase in hepatic TG 
content in the WT mice, similar to the NOD.B10 WT mice (Figure 19C-D). The foz/foz 
genotype did not cause any changes in TG deposition in the Balb/c foz/foz mice. 
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However, HF-feeding with the foz/foz genotype in the Balb/c foz/foz mice led to a two-
fold increase in TG deposition at 12 weeks of age. 
Comparisons of hepatic TG levels between the two mice strains at 12 weeks of age 
showed that HF-feeding alone caused significant increased TG levels in both WT and 
foz/foz mice (Figure 19E-F). However, the foz/foz genotype and HF diet both caused 
more severe accumulation of hepatic TG in both strains. Interestingly, when these 
results were expressed as  total TG content in the entire liver, a significant difference in 
TG levels was observed between HF-fed NOD.B10 and Balb/c foz/foz mice (1229.2 ± 
102.4 vs 867.0 ± 38.1 mg TG/g w:w, respectively, p<0.0001) (Figure 19F).  
In summary, HF diet seems to drive the ectopic deposition of TG in the liver. since in 
both mice strains, WT and foz/foz mice showed higher hepatic TG deposition. However, 
the foz/foz genotype aggravates this by causing three times more TG deposition than its 
control. Although total hepatic TG per gram of liver tissue was similar in the HF-fed 
foz/foz mice of both strains, total TG content in the entire liver was higher in HF-fed 
NOD.B10 foz/foz mice.  
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Figure 19: Hepatic triacylglyceride (TG) accumulation in NOD.B10 and Balb/c mice fed on 
chow or HF diet. (A-B) NOD.B10, (C-D) Balb/c and (E-F) comparison between the two strains 
at 12 weeks of age. Increased hepatic TG deposition was observed with HF-feeding and foz/foz 
genotype in both strains. Data are means ± SEM of 10 mice per group. Two-way ANOVA with 
Bonferroni post-hoc test. §p<0.05, §§p<0.01, §§§p<0.001, §§§§p<0.0001, WT-chow vs WT-HF; 
+p<0.05, +++p<0.001, WT-chow vs foz-chow; ♯♯♯♯p<0.0001, WT-HF vs foz-HF; ¶¶¶¶p<0.0001, 
foz-chow vs foz-HF; *p<0.05, ****p<0.0001, NOD.B10 vs Balb/c. 
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     3.3.3 Plasma alanine transaminase (ALT) levels    
Increased levels of blood ALT has been extensively used as a marker of hepatocellular 
liver injury. ALT is a cytoplasmic enzyme that catalyzes the deamination and 
transamination of amino acids, facilitating crucial metabolic liver functions. 
Hepatocellular demise causes release of this enzyme into the circulation where it can be 
measured. Elevated plasma ALT levels can also be used to diagnose the development of 
NASH. Plasma obtained from cardiac blood during harvesting was used to measure 
ALT levels in NOD.B10 and Balb/c mice (Figure 20).  
In the NOD.B10 mice, at 6 weeks of age, no significant differences in plasma ALT 
levels were found between the mice groups (Figure 20A). However, by 12 weeks of 
age, plasma ALT levels in HF-fed NOD.B10 foz/foz mice increased five-fold, compared 
to the foz-chow mice (267.5 ± 23.1 vs 45.3 ± 4.3 μg/mL, respectively, p<0.0001).  
In the Balb/c mice, all mice groups exhibited similar plasma ALT levels at 6 weeks of 
age (Figure 20B). However, at 12 weeks of age, HF-fed Balb/c foz/foz mice displayed a 
moderate increase in plasma ALT levels compared to the foz-chow mice (122.1 ± 15.1 
vs 55.5 ± 10.6 μg/mL, respectively, p<0.05).  
Comparisons between both mice strains at 12 weeks of age showed that HF-fed 
NOD.B10 foz/foz mice had double the plasma ALT levels than their Balb/c counterparts 
(267.5 ± 23.1 vs 122.1 ± 15.1 μg/mL, respectively, p<0.0001) (Figure 20C). 
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Summary of results relating to development of liver disease 
The finding that HF-fed NOD.B10 foz/foz mice are the only mouse group that develops 
disproportionate hepatomegaly and that it develops this early, in association with 
increased hepatic TG content, would be consistent with early repartitioning of body fat 
to liver from adipose tissue stores in this strain. The Balb/c foz/foz mice, however, do 
accommodate more hepatic TG with HF-feeding, but not to the same degree as in the 
NOD.B10 strain. The ALT results suggest that the increased TG accumulation in the 
HF-fed NOD.B10 foz/foz mice is associated with elevated ALT levels consistent with 
the induction of NASH. ALT levels do rise in the HF-fed Balb/c foz/foz mice, but to a 
much lesser extent. 
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Figure 20: Alanine transaminase (ALT) levels determined from plasma of non-fasting 
NOD.B10 and Balb/c strains. (A) NOD.B10, (B) Balb/c and (C) comparisons between mice 
groups of both strains at 12 weeks of age. At 12 weeks of age, NOD.B10 foz/foz mice fed on 
HF-diet exhibit higher levels of plasma ALT, indicating the presence of hepatocellular injury. 
Data are means ± SEM of 10 mice per group. Two-way ANOVA with Bonferroni post-hoc test. 
♯p<0.05, ♯♯♯♯p<0.0001, WT-HF vs foz-HF; ¶¶¶¶p<0.0001, foz-chow vs foz-HF; ****p<0.0001, 
NOD.B10 vs Balb/c.   
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3.4 Determination of phenotype: Adipose tissue restriction  
Failure of safe partitioning of excess nutrients to subcutaneous adipose tissue depots has 
been implicated in the pathogenesis of NASH. This results in abnormal expansion of 
visceral adipose tissue, associated with reduced insulin sensitivity and WAT 
inflammation, and ectopic hepatic fat deposition causing the steatosis of NAFLD. 
Previous studies on NOD.B10 foz/foz mice have shown an attenuation in normal 
adipose tissue expansion (adipose restriction) after 6 weeks on HF diet, whereby further 
adipose tissue expansion did not occur despite increased nutrient intake.[360] In this 
study, by 12 weeks of age, HF-fed NOD.B10 foz/foz mice developed hepatomegaly, 
increased hepatic TG deposition and NASH, suggesting adipose restriction. The body 
weight and body composition data presented in Section 3.1 of the results are also 
consistent with some development of adipose restriction by about 10 weeks of age in 
these mice. 
Therefore, fad pad measurement of subcutaneous and visceral (mesenteric and peri-
ovarian) adipose tissues in both mice strains from 6 to 12 weeks of age, were analyzed 
to further confirm and characterize the development of adipose restriction. 
 
     3.4.1 Subcutaneous WAT expansion  
Subcutaneous adipose tissue (SAT) from the right abdominal side of the mice were 
extracted, weighed, and presented as absolute tissue weights (left panel) and normalized 
to % of body weight (right panel) (Figure 21). Both analyses displayed similar patterns. 
In the NOD.B10 mice, absolute SAT weights were similar for all mice groups at 6 
weeks of age (Figure 21A). HF-feeding was observed to cause a slightly higher SAT 
                                                                                                             Results 
 
 Page 119 
 
expansion in WT mice compared to their chow controls. However, the foz/foz genotype 
was found to cause increased adiposity in the NOD.B10 mice during the time course of 
the study. Further augmentation in SAT expansion was observed in the NOD.B10 mice 
when the foz/foz genotype was combined with HF diet. At 6 weeks of age, HF-fed 
NOD.B10 foz/foz mice already displayed increased adiposity compared to its chow 
controls (1.3 ± 0.1 vs 0.7 ± 0.1, as a % of body weight, p<0.05) (Figure 21B). By 12 
weeks of age, these mice had developed significantly higher SAT weights when 
compared to foz-chow mice (3.2 ± 0.1 vs 2.6 ± 0.1, as a % of body weight, respectively, 
p<0.01) (Figure 21B).  
In the Balb/c WT mice, a similar pattern of SAT weights as the NOD.B10 WT mice 
was observed (Figure 21C). However, the adiposity caused by the foz/foz genotype 
alone was lower in the Balb/c mice when compared to the NOD.B10 mice.  A similar 
pattern of progressive increase in adiposity was observed in the HF-fed Balb/c foz/foz 
mice when compared to the foz-chow mice at 6 weeks of age (1.5 ± 0.1 vs 0.6 ± 0.1, as 
a % of body weight, respectively, p<0.0001) and 12 weeks of age (2.7 ± 0.1 vs 1.7 ± 
0.1, as a % of body weight, respectively, p<0.0001) (Figure 21D). 
Comparison of the increase in adiposity of HF-fed foz/foz mice in both strains suggested 
that at 12 weeks of age, the NOD.B10 mice had significantly higher adipose tissue 
expansion than their Balb/c counterparts (3.2 ± 0.1 vs 2.8 ± 0.1,as a % of body weight, 
p<0.01) (Figure 21F). 
 
In summary, subcutaneous adipose tissue was progressively expanding normally in the 
HF-fed foz/foz mice of both strains without any signs of adipose restriction. 
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Figure 21: Subcutaneous WAT accumulation in mice fed experimental diets from 4 to 12 weeks 
of age. Absolute tissue weights (left panel) and tissue reported as % body weight (right panel) of 
(A-B) NOD.B10, (C-D) Balb/c and (E-F) comparison between the HF-fed foz/foz mice of both 
strains. Similar progressive adipose expansion in the HF-fed foz/foz mice of both strains was 
observed until 12 weeks of age. Data are means ± SEM of 10 mice per group. Two-way 
ANOVA with Bonferroni post-hoc test. §§§p<0.001, §§§§p<0.0001, WT-chow vs WT-HF; 
+p<0.05, ++++p<0.0001, WT-chow vs foz-chow; ♯♯♯p<0.001, ♯♯♯♯p<0.0001, WT-HF vs foz-HF; 
¶p<0.05, ¶¶p<0.01, ¶¶¶p<0.001, ¶¶¶¶p<0.0001, foz-chow vs foz-HF; *p<0.05,NOD.B10 vs Balb/c.  
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     3.4.2 Mesenteric WAT expansion 
Mesenteric WAT around the small intestine were extracted, weighed and presented as 
absolute weights (left panel) and relative to % of body weight (right panel) in Figure 22. 
NOD.B10 mice from all mice groups displayed similar absolute mesenteric WAT 
weights at 6 weeks of age (Figure 22A). Interestingly, when these values were 
expressed as % of body weight, HF-fed NOD.B10 foz/foz mice exhibited higher 
accumulation of mesenteric fat compared to the controls. HF-feeding in the WT mice 
was observed to cause a slight tendency to accumulate more mesenteric fat than the 
WT-chow controls (Figure 22A-B). The foz/foz genotype on the NOD.B10 strain caused 
progressive augmented mesenteric WAT expansion compared to the WT mice 
throughout the time course (Figure 22A-B). Furthermore, the foz/foz mice fed on HF-
diet developed even further significant increase in adiposity when compared to their 
chow-fed foz/foz mice controls from 6 weeks of age (1.3 ± 0.1 vs 0.6 ± 0.1, as % of 
body weight, p<0.01) to 12 weeks of age (3.2 ± 0.1 vs 2.4 ± 0.1, as % of body weight, 
p<0.001) (Figure 22B). 
Balb/c WT mice displayed a similar pattern of mesenteric fat expansion as the 
NOD.B10 mice (Figure 22C). Chow-fed Balb/c foz/foz mice exhibited a progressive 
increase in mesenteric adipose tissue which was significantly higher than its WT-chow 
controls (Figure 22C-D), but similar to the WT-HF mice. Similar to the NOD.B10 mice, 
by 12 weeks of age, HF-fed Balb/c foz/foz mice developed higher adiposity than chow-
fed foz/foz mice (3.7 ± 0.2 vs 2.6 ± 0.1, as % of body weight, p<0.0001) (Figure 22D). 
Comparison of the mesenteric WAT weights of HF-fed foz/foz mice of both strains 
showed that at 12 weeks of age, both mice strains had similar absolute mesenteric WAT 
weights, but normalization to body weight gain suggest that the Balb/c mice had higher 
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mesenteric fat expansion than its NOD.B10 counterparts (3.7 ± 0.2 vs 3.2 ± 0.1, as % of 
body weight, respectively, p<0.05) (Figure 22E-F). 
Taken together, these results suggest that mesenteric WAT was expanding normally in 
the HF-fed foz/foz mice of both NOD.B10 and Balb/c strains, similar to subcutaneous 
WAT expansion. However, accumulation of mesenteric fat appeared to be less in HF-
fed NOD.B10 foz/foz mice compared to HF-fed Balb/c foz/foz mice. 
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Figure 22: Right mesenteric white adipose tissue weights. Absolute weights (left panel) and 
tissue weight normalized to body weight (right panel) of (A-B) NOD.B10, (C-D) Balb/c mice 
and (E-F) comparison between HF-fed foz/foz mice of both strains. Progressive adipose 
expansion in the HF-fed foz/foz mice of both strains was observed until 12 weeks of age. Values 
are the means ± SEM of 16-23 mice from in each group. Two-way ANOVA with Bonferroni 
post-hoc test. §§p<0.01, §§§§p<0.0001, WT-chow vs WT-HF; ++++p<0.0001, WT-chow vs foz-
chow; ♯♯♯p<0.001, ♯♯♯♯p<0.0001, WT-HF vs foz-HF; ¶¶p<0.01, ¶¶¶¶p<0.0001, foz-chow vs foz-
HF; *p<0.05, NOD.B10 vs Balb/c. 
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     3.4.3 Peri-ovarian WAT expansion 
Peri-ovarian adipose tissue from the right side of the mice was extracted, weighed and 
presented as absolute tissue weights (left panel) and normalized to % of body weight 
(right panel) at different ages in both NOD.B10 and Balb/c mice strains (Figure 23).  
All NOD.B10 mice groups exhibited similar absolute peri-ovarian WAT weights at 6 
weeks of age (Figure 23A). Upon normalization to % of body weight, it was observed 
that HF-feeding caused a tendency to increased peri-ovarian adiposity in these mice 
compared to chow controls from 6 weeks of age (Figure 23B). However, this increase in 
adipose weight was not significant and comparatively lower in the WT mice compared 
to the foz/foz mice. The foz/foz genotype in the NOD.B10 foz/foz mice led to a 
progressive increase in peri-ovarian adipose expansion throughout the time course 
(Figure 23A-B) and by 12 weeks of age, adipose tissue weights of these mice were  
significantly higher than the WT-chow controls (2.5 ± 0.1 vs 0.6 ± 0.1, as % of body 
weight, p<0.0001) (Figure 23B).  
The combination of HF diet and the foz/foz genotype in the NOD.B10 foz/foz mice 
triggered a significantly higher adipose tissue expansion, and at 12 weeks of age, these 
mice had double the adiposity than the WT-HF mice (3.9 ± 0.3 vs 1.5 ± 0.1, as % of 
body weight, p<0.0001) and foz-chow mice (3.9 ± 0.3 vs 2.8 ± 0.2, as % of body 
weight, p<0.0001) (Figure 23B). 
Balb/c WT and foz/foz mice displayed a similar pattern of progressive peri-ovarian 
adipose tissue expansion similar to its NOD.B10 counterparts (Figure 23C-D). HF-
feeding and the foz/foz genotype in the Balb/c foz/foz mice caused higher peri-ovarian 
adiposity at 12 weeks of age, when compared to WT-HF mice (3.9 ± 0.3 vs 1.5 ± 0.1, as 
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% of body weight,  p<0.001) and foz-chow mice (3.9 ± 0.3 vs 1.5 ± 0.1, as % of body 
weight, p<0.0001) (Figure 23D). 
Comparison of the increase in adiposity of HF-fed foz/foz mice of both strains suggests 
no difference in peri-ovarian adipose expansion between both strains (Figure 23E-F). 
Taken together, peri-ovarian adipose tissue was found to be progressively expanding 
similarly in HF-fed foz/foz mice of both strains throughout the study period. 
 
Summary of results relating to development of adipose restriction 
Fat pad measurements of subcutaneous WAT and visceral WAT depots (mesenteric and 
peri-ovarian) suggested that in response to HF-feeding, foz/foz mice of both NOD.B10 
and Balb/c strains had very similar adipose tissue expansion. Contrary to what was 
predicted, if there is adipose restriction in the HF-fed NOD.B10 foz/foz mice, it is more 
likely to be in the mesenteric WAT rather than in the subcutaneous WAT.  
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Figure 23: Peri-ovarian WAT expansion from 6 until 12 weeks of age. Absolute tissue weight 
(left panel) and tissue weight expressed as % body weight (right panel) in (A-B) NOD.B10, (C-
D) Balb/c mice and (E-F) comparison between HF-fed foz/foz mice of both strains. Progressive 
adipose tissue expansion was observed in the HF-fed foz/foz mice of both strains until 12 weeks 
of age. Values are the means ± SEM of 6-23 mice from each group. Two-way ANOVA with 
Bonferroni post-hoc test. §§p<0.01, WT-chow vs WT-HF; +++p<0.001, ++++p<0.0001, WT-chow 
vs foz-chow; ♯♯p<0.01, ♯♯♯p<0.001, ♯♯♯♯p<0.0001, WT-HF vs foz-HF; ¶p<0.05, ¶¶¶p<0.001, 
¶¶¶¶p<0.0001, foz-chow vs foz-HF. 
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     3.4.4 Brown adipose tissue (BAT) measurements 
Since BAT activity is inversely proportional to obesity, BAT from the dorsal adipose 
tissue was extracted, weighed and presented as absolute tissue weight (left panel) and 
normalized to % body weight (right panel) from NOD.B10 and Balb/c mice to 
determine any obesity-induced changes in BAT depots (Figure 24).  
All NOD.B10 mice groups displayed similar BAT weights at 6 weeks of age (Figure 
24A-B).HF-feeding did not induce BAT expansion in WT mice. The foz/foz genotype 
caused a progressive increase in BAT weight in NOD.B10 foz/foz mice at 12 weeks of 
age, compared to WT-chow mice (0.5 ± 0.03 vs 0.2 ± 0.01, as % of body weight, 
p<0.0001) (Figure 24B). The combination of HF-feeding and the foz/foz genotype in the 
NOD.B10 foz/foz mice led to significantly higher BAT expansion, compared to WT-HF 
mice at 12 weeks of age (0.5 ± 0.02 vs 0.3 ± 0.02, as % of body weight, p<0.0001) 
(Figure 24B). However, when normalized to % of body weight, NOD.B10 foz/foz mice 
on both chow and HF diets displayed similar BAT expansion (Figure 24B). 
Balb/c WT mice exhibited similar BAT expansion as the NOD.B10 counterparts 
(Figure 24C-D). However, unlike the NOD.B10 mice, BAT expansion in chow-fed 
Balb/c foz/foz mice was less than the HF-fed foz/foz mice and almost similar to the WT-
HF mice. HF-fed Balb/c foz/foz mice displayed significantly higher BAT expansion 
than the chow-fed foz/foz mice at 12 weeks of age (0.5 ± 0.02 vs 0.4 ± 0.02, as % of 
body weight, p<0.01) (Figure 24D). 
Comparison of BAT weight in HF-fed foz/foz mice of both strains showed no inter-
strain difference in BAT expansion (Figure 24E-F). In summary, unlike results observed 
in literature where BAT is inversely correlated with BMI, the HF-fed foz/foz mice of 
both strains displayed similar BAT expansion, despite the presence of obesity. 
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Figure 24: Brown adipose tissue weights. Absolute weights (left panel) and tissue weight 
relative to body weight (right panel) of (A-B) NOD.B10, (C-D) Balb/c mice and (E-F) 
comparison between the HF-fed foz/foz mice of both strains. Mice with the foz/foz genotype 
were found to have more brown adipose tissue than the WT mice. Data are means ± SEM of 6-
23 mice per group. Two-way ANOVA with Bonferroni post-hoc test. ++p<0.01, +++p<0.001, 
++++p<0.0001, WT-chow vs foz-chow; ♯♯♯p<0.001, ♯♯♯♯p<0.0001, WT-HF vs foz-HF; ¶p<0.05, 
¶¶p<0.01, foz-chow vs foz-HF. 
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3.5 Determination of changes in circulating plasma adipokine profile  
Adipose tissue dysfunction is associated with altered adipokine profiles, and previous 
studies on the NOD.B10 foz/foz mice have shown that after 24 weeks on HF diet, these 
mice develop hypoadiponectinemia and increased serum MCP-1 levels.[360] Therefore, 
plasma adiponectin and MCP-1 levels were analyzed to determine any changes in 
secretion of these adipokines and how this relates temporally with changes in glucose 
regulation, hepatic changes and other parameters of adipose function/dysfunction. 
 
     3.5.1 Analysis of plasma adiponectin 
Plasma obtained from cardiac blood during harvesting was used to measure circulating 
adiponectin levels in both NOD.B10 and Balb/c mice.  
NOD.B10 mice exhibited no difference in plasma adiponectin levels in any mice group 
at 6 weeks of age (Figure 25A). HF-feeding did not affect adiponectin levels in the WT 
mice compared to chow-fed control mice (10.8 ± 0.4 vs 11.6 ± 0.4 μg/mL, respectively). 
The foz/foz genotype also did not cause any alteration in adiponectin levels in NOD.B10 
foz/foz mice when compared to WT-chow mice (11.1 ± 0.9 vs 10.8 ± 0.4 μg/mL, 
respectively).However, the combination of HF-feeding and the foz/foz genotype in the 
NOD.B10 foz/foz mice caused a progressive drop in plasma adiponectin levels after 8 
weeks of age and by 12 weeks of age, these mice had significantly reduced adiponectin 
levels compared to foz-chow mice (8.3 ± 0.5 vs 11.1 ± 0.9 μg/mL, respectively, 
p<0.01).  
Balb/c mice did not display any difference in plasma adiponectin levels in any mice 
groups at both 6 and 12 weeks of age (Figure 25B). HF-fed Balb/c foz/foz mice 
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exhibited a slight tendency to reduce adiponectin levels. However, this reduction was 
not significant.  
At 12 weeks of age, no inter-strain differences in adiponectin levels were observed in 
HF-fed foz/foz mice (Figure 25C).  
 In summary, HF-fed NOD.B10 foz/foz mice developed hypoadiponectinemia at 12 
weeks of age compared to its genotype and diet controls. On the other hand, although 
HF-fed Balb/c foz/foz mice did not exhibit a significant decrease in adiponectin levels to 
its WT and diet controls, at 12 weeks of age, it displayed similar reduced adiponectin 
levels as its NOD.B10 counterparts. This suggests that both NOD.B10 and Balb/c mice 
fed on HF diet do not differ with respect to circulating adiponectin levels. This is 
against the hypothesis that differential susceptibility of NOD.B10 mice to excess energy 
supply is an early or primary defect in the unhealthy obesity that can be induced in the 
NOD.B10 strain. 
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Figure 25: Plasma adiponectin levels from WT and foz/foz mice fed on chow or HF diet from 4 
to 12 weeks of age. (A) NOD.B10, (B) Balb/c strains and (C) comparison between the two 
strains at 12 weeks of age.  Plasma adiponectin levels decreased in foz/foz mice on HF-diet of 
NOD.B10 and Balb/c strains at 12 weeks of age. Data are means ± SEM of 10 mice per group. 
Two-way ANOVA with Bonferroni post-hoc test. ♯♯♯p<0.001, WT-HF vs foz-HF; ¶¶p<0.01, 
¶¶¶p<0.001, foz-chow vs foz-HF. 
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     3.5.2 Analysis of Plasma Monocyte Chemoattractant Protein-1 (MCP-1)  
MCP-1 is secreted by various cells and is responsible for recruitment and infiltration of 
monocytes into active areas of inflammation. Elevated MCP-1 levels are often used as a 
marker for inflammation. Therefore, circulating MCP-1 levels were measured from 
cardiac blood plasma obtained from NOD.B10 and Balb/c mice on the day of harvesting 
at 6 and 12 weeks of age for detection of inflammation.  
At 6 weeks of age, no significant difference in plasma MCP-1 levels was observed 
between NOD.B10 and Balb/c strains among any mice groups (Figure 26A).  
At 12 weeks of age, a significant increase in MCP-1 levels was observed with HF-
feeding in NOD.B10 WT and foz/foz mice, which exhibited markedly higher levels than 
their Balb/c counterparts (77.7 ± 20.9 vs 25.6 ± 5.1 pg/mL, WT-HF NOD.B10 vs 
Balb/c, p<0.05) and (154.2 ± 31.4 vs 97.1 ± 15.5 pg/mL, foz-HF NOD.B10 vs Balb/c, 
p<0.05) (Figure 26B). HF-fed Balb/c foz/foz mice also displayed an increased plasma 
MCP-1 level, which was however, lower than its NOD.B10 counterpart.  
In summary, plasma MCP-1 levels were increased in the HF-fed foz/foz mice of both 
strains at 12 weeks of age, but the NOD.B10 mice displayed higher circulating plasma 
MCP-1 levels than its Balb/c counterparts. 
 
Summary of results related to altered adipokine profile 
Only HF-fed NOD.B10 foz/foz mice displayed significantly reduced plasma adiponectin 
levels by 12 weeks of age. However, a similar non-significant reduction was observed 
in the HF-fed Balb/c foz/foz mice. Plasma MCP-1 level was increased in both these 
mice groups, suggesting the presence of inflammation. However, HF-fed NOD.B10 
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foz/foz mice exhibited higher plasma MCP-1 levels, which may imply that these mice 
develop higher degree of inflammation compared to the Balb/c mice. Without other 
measurements, however, the site of this increase in inflammation is uncertain. It could 
be increased inflammation of adipose tissue, but NASH could also be a source of 
increased plasma MCP-1. 
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Figure 26: Plasma monocyte chemoattractant protein-1 (MCP-1) levels of NOD.B10 and Balb/c 
mice strains at (A) 6 and (B) 12 weeks of age. HF-fed foz/foz mice of both strains display 
elevated plasma MCP-1 levels at 12 weeks of age. However, the plasma MCP-1 levels were 
higher in HF-fed foz/foz mice on the NOD.B10 background. Data are means ± SEM of 10 mice 
per group. Two-way ANOVA with Bonferroni post-hoc test. ♯♯♯♯p<0.0001, WT-HF vs foz-HF; 
¶¶¶¶p<0.0001, foz-chow vs foz-HF; *p<0.05, NOD.B10 vs Balb/c. 
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3.6 Peri-ovarian adipose tissue gene expression analysis   
The preceding results do not equivocally indicate the presence or absence of adipose 
restriction and/or dysfunction as early abnormalities in the NOD.B10 mice compared to 
the Balb/c mice, in response to excessive nutrient supply. The whole animal weights 
and body composition data were suggestive of adipose restriction, but this was not 
confirmed when individual adipose tissue weights were measured. The propensity to 
develop hepatomegaly with increased TG content early on, in the HF-fed NOD.B10 
foz/foz mice, however, would be consistent with early “relative” adipose tissue 
restriction in this mouse group. Adipose dysfunction in HF-fed NOD.B10 foz/foz mice 
compared to Balb/c foz/foz mice was not evident from the adiponectin measurements. 
However, the high MCP-1 levels in HF-fed NOD.B10 foz/foz mice could be indicative 
of a greater propensity of this mice strain to develop adipose inflammation.  
To further discern the status of the adipose tissue in the various mice groups, therefore, 
the mRNA expression of various adipose tissue-specific genes responsible for normal 
adipose physiology, adipokines and markers for inflammation were analyzed in the 
peri-ovarian adipose tissue. 
 
     3.6.1 Housekeeping genes 
The mRNA expression levels of various markers of adipose tissue differentiation and 
function, adipokines and inflammation were evaluated at two different ages (6 and 12 
weeks) for both strains in the peri-ovarian adipose tissue. Corrections for sample 
variations in the amount of starting peri-ovarian tissue sample, RNA integrity and 
cDNA sample amplified were carried out by the use of stable endogenous controls 
(housekeeping genes).  
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Expression of various housekeeping genes were tested, including: ribosomal protein 
L13a (RPL13a), β-2-microglobulin (B2M), hypoxanthine phosphoribosyltransferase-1 
(HPRT-1), 18S rRNA, glyceraldehyde 3- phosphate dehydrogenase (GAPDH) and 
cyclophillin. Of these, RPL13a, B2M and HPRT-1 displayed significant differential 
expression between the two strains and were excluded from the study (Figure 27A-F). 
However, 18S rRNA, GAPDH and cyclophillin exhibited stable expression in both 
strains across all mice groups at 6 and 12 weeks of age (Figure 28A-F). Therefore, these 
three genes were chosen as housekeeping genes and the geometric mean of these 
housekeeping genes were used to normalize the mRNA expression of various genes 
during the analysis (Figure 29).  
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Figure 27: mRNA expression of housekeeping genes. (A-B) Ribosomal protein L13a (RPL13a) 
(A-B), (C-D) beta-2-microglobulin (B2M) and (E-F) hypoxanthine phosphoribosyltransferase-1 
(HPRT-1) in WT and foz/foz mice of NOD.B10 and Balb/c strains fed on chow and HF diet, at 6 
and 12 weeks of age. The expressions of these housekeeping genes were not stable across mice 
groups and were excluded from the experiment. Data are means ± SEM of 10 mice per group. 
Two-way ANOVA with Bonferroni post-hoc test. ++p<0.01, +++p<0.001, ++++p<0.0001, WT-
chow vs foz-chow; ♯p<0.05, ♯♯♯♯p<0.0001, WT-HF vs foz-HF; *p<0.05, ***p<0.001, NOD.B10 
vs. Balb/c.       
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Figure 28: mRNA expression of stable housekeeping genes. (A-B)18s rRNA, (C-D) 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and (E-F) cyclophillin in WT and foz/foz 
mice of NOD.B10 and Balb/c strains fed on chow and HF diet, at 6 and 12 weeks of age.  The 
expressions of these genes were found to be stable across mice groups.  Data are means ± SEM 
of 10 mice per group. Two-way ANOVA with Bonferroni post-hoc test. No significant 
difference found.  
 
 
18s rRNA
R
el
at
iv
e 
ex
pr
es
si
on
WT-Chow WT-HF Foz- Chow Foz- HF
0.00
0.05
0.10
0.15
0.20 NOD.B10 Balb/c
18s rRNA
R
el
at
iv
e 
ex
pr
es
si
on
WT-Chow WT-HF Foz- Chow Foz- HF
0.00
0.05
0.10
0.15
0.20 NOD.B10 Balb/c
GAPDH
R
el
at
iv
e 
ex
pr
es
si
on
WT-Chow WT-HF Foz- Chow Foz- HF
0.00
0.05
0.10
0.15
GAPDH
R
el
at
iv
e 
ex
pr
es
si
on
WT-Chow WT-HF Foz- Chow Foz- HF
0.00
0.05
0.10
0.15
Cyclophillin
R
el
at
iv
e 
ex
pr
es
si
on
WT-Chow WT-HF Foz- Chow Foz- HF
0.0
0.2
0.4
0.6
0.8
Cyclophillin
R
el
at
iv
e 
ex
pr
es
si
on
WT-Chow WT-HF Foz- Chow Foz- HF
0.0
0.2
0.4
0.6
0.8
A
F
D
E
C
B
6 weeks 12 weeks
                                                                                                             Results 
 
 Page 139 
 
 
 
 
 
 
 
 
 
Figure 29: Geometric mean of 3 housekeeping genes- 18s rRNA, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and cyclophillin expression in WT and foz/foz mice of NOD.B10 and 
Balb/c strains fed on chow and HF diet, at (A) 6 weeks and (B) 12 weeks of age. This data was 
used to normalize the mRNA expression of various genes. Data are means ± SEM of 10 mice 
per group. Two-way ANOVA with Bonferroni post-hoc test. No significant difference found.  
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3.6.2 mRNA expression of genes related to adipogenesis 
Changes in adipose tissue differentiation in the NOD.B10 and Balb/c mice groups were 
determined by analysis of the mRNA expression of PPAR-γ, C/EBP-α and SREBP-1c, 
which are genes responsible for driving the final stage of adipogenesis and activating 
the transcription of various adipose-specific genes.  
 
     3.6.2.1 Peroxisome proliferator activated receptor-γ (PPAR-γ) 
At 6 weeks of age, the mRNA expression of PPAR-γ was similar between mice groups 
within each strain (Figure 30A). Chow-fed Balb/c foz/foz mice displayed lower PPAR-γ 
expression compared to its NOD.B10 counterparts (0.6 ± 0.05 vs 1.0 ± 0.1, relative 
units, p<0.05).  
At 12 weeks of age, there was no significant difference in the mRNA expression of 
PPAR-γ between NOD.B10 and Balb/c strains (Figure 30B). HF-feeding increased 
PPAR-γ expression in NOD.B10 WT mice (0.8 ± 0.1 vs 1.4 ± 0.1, relative units, WT-
chow vs WT-HF, p<0.05) and Balb/c WT mice (0.6 ± 0.1 vs 1.0 ± 0.1, relative units, 
WT-chow vs WT-HF, p<0.05). HF-fed NOD.B10 foz/foz mice exhibited a non-
significant trend for increased PPAR-γ expression at 12 weeks of age (Figure 30B). 
 
     3.6.2.2 CCAAT/enhancer-binding protein alpha (C/EBP-α) 
The mRNA expression of C/EBP-α was similar in all the mice groups of both NOD.B10 
and Balb/c strains at 6 and 12 weeks of age (Figure 30C-D). 
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     3.6.2.3 Sterol regulatory element-binding protein-1c (SREBP-1c) 
SREBP-1c also displayed similar expression in all the mice groups of both NOD.B10 
and Balb/c strains at 6 and 12 weeks of age, apart from an increase with HF-feeding in 
NOD.B10 WT mice at 6 weeks of age only (Figure 30E-F).  
 
Summary of results  
The mRNA expression of PPAR-γ, C/EBP-α and SREBP-1c in response to HF-feeding, 
the foz/foz genotype and the combination of both, showed no consistent pattern in either 
mice strain at 6 or 12 weeks of age. As the expression of these genes did not decrease in 
the HF-fed foz/foz mice of either strain, there was no evidence of adipose 
dedifferentiation in these experiments.  
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Figure 30: mRNA expression of transcriptional factors and enzymes related to adipogenesis: 
(A-B) Peroxisome proliferator activated receptor-γ (PPAR-γ), (C-D) CCAAT/enhancer-binding 
protein-α (C/EBP-α) and (E-F) sterol regulatory element-binding protein-1c (SREBP-1c) in 
peri-ovarian WAT of WT and foz/foz mice of NOD.B10 and Balb/c strains fed on chow and HF 
diet, at 6 and 12 weeks of age. PPAR-γ expression increased in HF-fed mice of both strains at 
12 weeks of age, while SREBP-1c increased in HF-fed NOD.B10 WT mice at 6 weeks of age 
only. Data are means ± SEM of 10 mice per group. Two-way ANOVA with Bonferroni post-
hoc test. §p<0.05, WT-chow v/s WT-HF; *p<0.05, NOD.B10 vs. Balb/c.  
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3.6.3 mRNA expression of genes related to fatty acid uptake and intracellular 
transport 
Adipose tissue differentiation in the NOD.B10 and Balb/c foz/foz mice fed on HF diet 
was further determined by mRNA analysis of genes related to adipose tissue 
physiology, such as the uptake and intracellular transport of circulating fatty acids into 
the adipocytes for storage. 
 
     3.6.3.1 Lipoprotein lipase (LPL) 
At 6 weeks of age, the mRNA expression of LPL was similar in all mice groups of both 
NOD.B10 and Balb/c strains (Figure 31A).  
At 12 weeks of age, HF-fed NOD.B10 foz/foz mice displayed a significantly higher LPL 
expression than WT-HF mice (0.5 ± 0.05 vs 0.3 ± 0.03, relative units, respectively, 
p<0.01) and foz-chow mice (0.5 ± 0.07 vs 0.2 ± 0.04, relative units, respectively, 
p<0.001) (Figure 31B). However, no inter-strain difference in LPL expression was 
observed in any mice groups. 
 
     3.6.3.2 Angiopoietin-like-4 (ANGPTL4) 
At 6 weeks of age, there was no change in ANGPTL4 expression between mice groups 
in both strains, other than higher ANGPTL4 expression in HF-fed NOD.B10 WT mice 
compared to its Balb/c counterparts (0.6 ± 0.08 vs 0.4 ± 0.06, relative units, p<0.01) 
(Figure 31C).  
At 12 weeks of age, there was an increase in ANGPTL4 expression on HF-feeding of 
foz/foz mice of both strains (Figure 31D). HF-fed NOD.B10 foz/foz mice had almost 
double the expression of ANGPTL4 compared to chow-fed NOD.B10 foz/foz mice (1.0 
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± 0.07 vs 0.5 ± 0.05, relative units, respectively, p<0.0001) and WT-HF mice (1.0 ± 
0.07 vs 0.5 ± 0.08, relative units, respectively, p<0.0001). HF-fed Balb/c foz/foz mice 
also displayed similar increased ANGPLT4 expression compared to the foz-chow mice 
(0.6 ± 0.10 vs 0.3 ± 0.03, relative units, respectively, p<0.01). However, ANGPTL4 
expression in HF-fed Balb/c foz/foz mice was still lower compared to their NOD.B10 
counterparts (0.6 ± 0.09 vs 1.0 ± 0.07, relative units, respectively, p<0.01).  
 
     3.6.3.3 Stearoyl-CoA desaturase-1 (SCD-1) 
At 6 and 12 weeks of age, HF-diet was found to drive the increase in mRNA expression 
of SCD-1 in both WT and foz/foz mice of NOD.B10 and Balb/c strains (Figure 31E-F). 
However, the response to HF diet was equivalent in both mice strains. 
 
     3.6.3.4 Fatty acid transporter protein- CD36  
At 6 weeks of age, CD36 mRNA expression was similar in all mice groups of both 
strains (Figure 32A).  
At 12 weeks of age, HF-fed NOD.B10 foz/foz mice displayed higher CD36 expression 
when compared to foz-chow mice (3.5 ± 0.4 vs 1.7 ± 0.1, relative units, p<0.001) and 
WT-HF mice (3.5 ± 0.4 vs 1.3 ± 0.1, relative units, p<0.001) (Figure 32B). HF-fed 
Balb/c foz/foz mice also displayed a similar increase in CD36 expression at 12 weeks of 
age when compared to foz-chow mice (2.1 ± 0.2 vs 1.7 ± 0.1, relative units, 
respectively, p<0.001) and WT-HF mice (2.1 ± 0.2 vs 1.4 ± 0.2, relative units, 
respectively, p<0.001).  
However, no inter-strain differences in CD36 expression were discovered at both ages.  
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     3.6.3.5 Adipose protein 2 (aP2)/Fatty acid binding protein 4 (FABP4) 
At 6 weeks of age, similar mRNA expression of aP2/FABP4 was observed in all mice 
groups of both strains (Figure 32C).  
However, at 12 weeks of age, chow-fed Balb/c WT mice exhibited higher aP2 
expression compared to its NOD.B10 counterparts (0.7 ± 0.06 vs 0.4 ± 0.06, relative 
units, respectively, p<0.05) (Figure 32D). HF-fed NOD.B10 WT mice had increased 
aP2 expression compared to WT-chow mice (0.7 ± 0.05 vs 0.4 ± 0.06, relative units, 
respectively, p<0.05). 
 
Summary of results 
HF diet induced the expression of SCD-1 which is an important enzyme of the fatty acid 
esterification process. This effect of HF diet was not altered by the presence of the 
foz/foz genotype or differentially between mice strains. The combination of HF diet and 
the foz/foz genotype caused increased expression of CD36 at 12 weeks of age, which is 
involved in fatty acid transport. Again, mice strain did not affect the adipose tissue 
CD36 response. Expression of the LDL inhibitor ANGPTL4, however, had increased 
expression in the NOD.B10 mice compared to the Balb/c mice at 6 weeks of age when 
WT mice were fed HF diet, and at 12 weeks of age when foz/foz mice were fed HF diet. 
Overall, though, the effects of HF diet and the foz/foz genotype to affect this panel of 
fatty acid uptake and intra-cellular partitioning genes differed little between the two 
mice strains.  
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Figure 31: mRNA expression of genes related to fatty acid uptake and intracellular transport in 
periovarian WAT: (A-B) Lipoprotein lipase (LPL), (C-D) angiopoietin like-4 (ANGPTL4) and 
(E-F) stearoyl-CoA desaturase-1 (SCD-1) in WT and foz/foz mice of NOD.B10 and Balb/c 
strains fed on chow and HF diet, at 6 and 12 weeks of age. Data are means ± SEM of 10 mice 
per group. Two-way ANOVA with Bonferroni post-hoc test. §p<0.05, §§p<0.01, §§§p<0.001, 
WT-chow vs WT-HF; +++p<0.001, foz-chow vs WT-chow; ♯♯p<0.01, ♯♯♯♯p<0.0001, WT-HF vs 
foz-HF, ¶¶¶p<0.001, ¶¶¶¶p<0.0001 foz-chow vs foz-HF; **p<0.01, NOD.B10 vs Balb/c.    
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Figure 32: mRNA expression of genes related to fatty acid uptake and intracellular transport in 
periovarian WAT: (A-B) Fatty acid transporter protein CD 36 and (C-D) adipose protein 2 
(aP2) in WT and foz/foz mice of NOD.B10 and Balb/c strains fed on chow and HF diet, at 6 and 
12 weeks of age. Data are means ± SEM of 10 mice per group. Two-way ANOVA with 
Bonferroni post-hoc test. §p<0.05, WT-chow vs WT-HF; ♯♯♯♯p<0.0001, WT-HF vs foz-HF; 
¶¶¶p<0.001, foz-chow vs foz-HF; *p<0.05, NOD.B10 vs Balb/c.    
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3.6.4 mRNA expression of genes related to lipolysis and lipid droplet formation 
The mRNA expression of genes responsible for driving lipolysis and lipid droplet 
formation in adipocytes were analyzed to determine any changes in adipose tissue 
function between the various groups of the two mouse strains at 6 and 12 weeks of age. 
 
     3.6.4.1 G0/G1 switch gene 2 (G0S2) 
At 6 weeks of age, G0S2 expression was unaltered in all mice groups of both strains 
(Figure 33A).  
At 12 weeks of age, HF-fed foz/foz mice of both strains exhibited a non-significant trend 
for reduced G0S2 mRNA expression compared to their WT controls (Figure 33B). 
However, no inter-strain differences in G0S2 mRNA expression were observed at both 
ages. 
 
     3.6.4.2 Adipose triglyceride lipase (ATGL) 
At 6 weeks of age, ATGL mRNA expression was observed to be reduced in the HF-fed 
NOD.B10 foz/foz mice compared to the WT-HF controls (0.4 ± 0.04 vs 0.9 ± 0.09, 
relative units, respectively, p<0.001), as well as in HF-fed Balb/c foz/foz mice compared 
to WT-HF mice (0.5 ± 0.04 vs 0.8 ± 0.07, relative units, respectively, p<0.001) (Figure 
33C).  
At 12 weeks of age, the down-regulation of ATGL expression was also prevalent in HF-
fed NOD.B10 foz/foz mice compared to WT-HF mice (0.5 ± 0.06 v/s 0.7 ± 0.03, relative 
units, respectively, p<0.01), as well as in HF-fed Balb/c foz/foz mice compared to WT-
HF mice (0.4 ± 0.04 v/s 0.7 ± 0.06, relative units, respectively, p<0.01) (Figure 33D). 
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No inter-strain differences in ATGL expression were observed at both 6 and 12 weeks 
of age. 
 
     3.6.4.3 Hormone sensitive lipase (HSL) 
At 6 weeks of age, the mRNA expression of the lipolytic enzyme HSL displayed a 
similar pattern to ATGL expression, where HF-feeding caused reduction in expression 
in foz/foz mice of both strains (Figure 33E).  
At 12 weeks of age, interestingly, HF-feeding led to an up-regulation of HSL expression 
in the NOD.B10 and Balb/c WT mice compared to WT-chow controls (Figure 33F). 
Conversely, HF-fed NOD.B10 foz/foz mice exhibited reduced HSL expression when 
compared to WT-HF mice (0.6 ± 0.03 vs 0.9 ± 0.09, relative units, respectively, 
p<0.001). However, no significant inter-strain difference in HSL expression was 
observed in any mice groups of both strains (Figure 33E-F).  
 
     3.6.4.4 Adipose differentiation related protein (ADRP) 
At 6 weeks of age, mRNA expression of ADRP was similar between mice groups 
within each strain. However, inter-strain differences in mRNA expression were 
observed in the chow-fed Balb/c WT mice, which had higher ADRP expression 
compared to its NOD.B10 counterpart (0.8 ± 0.04 vs 0.4 ± 0.05, relative units, 
respectively, p<0.01) (Figure 33G). 
At 12 weeks of age, a slight tendency for increased ADRP expression was evident in 
HF-fed WT mice of both strains. Furthermore, HF-fed NOD.B10 foz/foz mice displayed 
a significant elevation in ADRP mRNA expression compared to the foz-chow mice (1.7 
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± 0.10 vs 0.6 ± 0.05, relative units, respectively, p<0.0001) and WT-HF mice (1.7 ± 
0.10 vs 0.6 ± 0.06, relative units, respectively, p<0.0001) (Figure 33H). Similarly, HF-
fed Balb/c foz/foz mice had higher ADRP expression than the foz-chow mice (1.6 ± 0.10 
vs 0.7 ± 0.04, relative units, respectively, p<0.0001) and WT-HF mice (1.6 ± 0.10 vs 0.9 
± 0.10, relative units, respectively, p<0.0001).  However there were no significant inter-
strain differences in the mRNA expression of ADRP in any mice group.   
 
Summary of results 
ATGL and HSL, which are both lipolytic enzymes responsible for the breakdown of 
TG, exhibited reduced expression at the mRNA level in the HF-fed foz/foz mice of both 
strains, compared to WT controls, suggesting down-regulation of lipolysis in the 
periovarian adipocytes of these mice. This is at variance from the effect of HF-feeding 
in WT mice in which HSL mRNA expression increased in both strains. ADRP, which is 
involved in the formation of lipid droplets in adipocytes, had higher expression in the 
HF-fed foz/foz mice of both strains. The net effect of reduced lipolytic activity with 
increased lipid droplet associated protein, would favor the accumulation of more TG in 
the adipose tissue of HF-fed foz/foz mice that have the greatest excess nutrient load to 
accommodate. However, there was no obvious difference between the NOD.B10 and 
Balb/c mice strains in this adipose tissue response. 
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Figure 33: mRNA expression of genes related to lipolysis and lipid droplet inflammation in 
peri-ovarian WAT: (A-B) G0/G1 switch gene 2 (G0S2), (C-D) adipose triglyceride lipase 
(ATGL) and (E-F) hormone sensitive lipase and (G-H) adipose differentiation related protein 
(ADRP) in WT and foz/foz mice of NOD.B10 and Balb/c strains fed on chow or HF diet at 6 
and 12 weeks of age. Data are means ± SEM of 10 mice per group. Two-way ANOVA with 
Bonferroni post-hoc test. §§§p<0.001, WT-chow vs WT-HF; ♯♯p<0.01, ♯♯♯p<0.001, 
♯♯♯♯p<0.0001, WT-HF vs foz-HF; ¶¶¶¶p<0.0001, foz-chow vs foz-HF; **p<0.01, NOD.B10 vs 
Balb/c. 
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3.6.5 mRNA expression of adipokines 
Adipose tissue dysfunction leads to altered adipokine profiles. Therefore, the effects of 
excess nutrition due to HF-feeding and the foz/foz genotype were determined by 
analyzing the mRNA expression of various adipokines at 6 and 12 weeks of age in the 
peri-ovarian adipose tissue of both strains. 
 
     3.6.5.1 Adiponectin 
At 6 weeks of age, the mRNA expression of adiponectin was similar in most mice 
groups in both strains, with the exception of HF-fed NOD.B10 foz/foz mice which 
displayed reduced adiponectin expression compared to the WT-HF mice (0.5 ± 0.1 vs 
0.8 ± 0.1, relative units, p<0.05) (Figure 34A).  
At 12 weeks of age, HF-fed NOD.B10 foz/foz mice developed a reduction in 
adiponectin mRNA levels compared to the foz-chow mice (0.2 ± 0.04 vs 0.7 ± 0.05, 
relative units, p<0.001) and WT-HF mice (0.2 ± 0.04 vs 0.8 ± 0.07, relative units, 
p<0.001) (Figure 34B). Similarly, HF-fed Balb/c foz/foz mice had reduced adiponectin 
expression when compared to the WT-HF mice (0.4 ± 0.03 vs 0.8 ± 0.15, relative units, 
p<0.001). No inter-strain differences in adiponectin expression were observed in any 
mice groups.  
 
     3.6.5.2 Leptin 
At 6 weeks of age, the mRNA expression of leptin trended higher, although not 
significantly, with HF-feeding in WT and foz/foz mice of both strains (Figure 34C). 
Leptin levels were generally higher in the NOD.B10 mice compared to Balb/c mice, but 
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this was only significant for HF-fed WT mice (0.8 ± 0.2 vs 0.4 ± 0.1, relative units, 
WT-HF NOD.B10 vs Balb/c, p<0.001).  
At 12 weeks of age, HF-feeding caused an increase in leptin expression in the WT mice 
of both strains (Figure 34C). The foz/foz genotype also caused increased leptin 
expression in chow-fed NOD.B10 foz/foz mice, which displayed an 8.5 fold increase in 
leptin expression compared to WT-chow mice (1.7 ± 0.1 vs 0.2 ± 0.1, relative units, 
p<0.001). The combination of HF-feeding and the foz/foz genotype led to 3.6 times up-
regulation of leptin expression in the NOD.B10 foz/foz mice when compared to WT-HF 
mice (2.2 ± 0.1 vs 0.6 ± 0.1, relative units, p<0.001). Balb/c foz/foz mice on chow and 
HF diet also displayed a similar pattern.  
However, inter-strain differences in mRNA expression were observed where leptin 
expression was almost 30% higher in chow-fed NOD.B10 foz/foz mice compared to 
their Balb/c counterparts (2.2 ± 0.1 vs 1.5 ± 0.1, relative units, p<0.01) as well as HF-
fed NOD.B10 foz/foz mice compared to their Balb/c counterparts (1.7 ± 0.1 vs 1.0 ± 0.1, 
relative units, p<0.001).   
 
     3.6.5.3 Tumor necrosis factor-α (TNF-α) 
At 6 weeks of age, the mRNA expression of TNF-α was not altered in any mice groups 
in both strains (Figure 34E).  
However, at 12 weeks of age, HF-fed NOD.B10 foz/foz mice developed significantly 
elevated TNF-α mRNA expression compared to WT-HF mice (0.2 ± 0.07 vs 0.08 ± 
0.03, relative units, p<0.01)(Figure 34F). Nonetheless, there was no difference in TNF-
α expression between NOD.B10 and Balb/c strains at both 6 and 12 weeks of age. 
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     3.6.5.4 Interleukin-6 (IL-6) 
At 6 weeks of age, the mRNA expression of IL-6 was similar in all mice groups within 
each strain, except chow-fed NOD.B10 foz/foz mice which exhibited higher IL-6 
expression compared to its Balb/c counterpart (0.9 ± 0.1 vs 0.4 ± 0.1, relative units, 
p<0.05) (Figure 34G).  
At 12 weeks of age, HF-fed NOD.B10 foz/foz mice had almost double the expression of 
IL-6 when compared to foz-chow mice (1.8 ± 0.2 vs 0.8 ± 0.1, relative units, 
respectively,  p<0.001) and WT-HF mice (1.8 ± 0.2 vs 0.7 ± 0.1, relative units, 
respectively, p<0.0001) (Figure 34H).  HF-fed Balb/c foz/foz mice also displayed a 
similar pattern of IL-6 mRNA expression. However, there were no inter-strain 
differences in IL-6 expression. 
 
Summary of results 
As expected with obesity, and in agreement with plasma levels, the mRNA expression 
of adiponectin was reduced in the HF-fed foz/foz mice of both strains. Leptin expression 
was increased in the foz/foz mice of both strains, with higher expression in the 
NOD.B10 mice. The expression of pro-inflammatory cytokines TNF-α and IL-6 was 
observed to be increased in the HF-fed foz/foz mice of both strains suggesting the 
presence of inflammation in these mice by 12 weeks of age, but not at 6 weeks of age. 
Overall, these results are indicative of the presence of adipose tissue dysfunction and 
inflammation in response to HF-feeding and the foz/foz genotype by 12 weeks of age, in 
both strains of mice. The findings that leptin mRNA levels were higher in NOD.B10 
mice are of interest, but alone do not suggest a greater degree of dysfunction in response 
to overfeeding in this strain compared to Balb/c mice. 
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Figure 34: mRNA expression of adipokines: (A-B) adiponectin, (C-D) leptin, (E-F) tumour 
necrosis factor-α (TNF-α) and (G-H) interleukin-6 (IL-6) in NOD.B10 and Balb/c mice in peri-
ovarian WAT. Data are means ± SEM of 10 mice per group. Two-way ANOVA with 
Bonferroni post-hoc test. ++++p<0.0001, WT-chow vs foz-chow; ♯p<0.01, ♯♯p<0.05, ♯♯♯p<0.001, 
♯♯♯♯p<0.0001, WT-HF vs foz-HF; ¶¶p<0.01, ¶¶¶p<0.001, ¶¶¶¶p<0.0001, foz-chow vs foz-HF; 
*p<0.05, **p<0.01, ***p<0.001, NOD.B10 vs Balb/c. 
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 3.6.6 mRNA expression of genes related to inflammation 
To assess the effects of HF-feeding and the foz/foz genotype on adipose inflammation in 
the two mice strains, the mRNA expression of markers for inflammation was analyzed. 
 
     3.6.6.1 Cluster of differentiation 68 (CD68) 
At 6 weeks of age, the mRNA expression of CD68 was not altered in any of the mice 
groups in both strains (Figure 35A).  
At 12 weeks of age, CD68 expression in HF-fed NOD.B10 foz/foz mice was highly 
increased when compared to foz-chow mice (7.1 ± 0.6 vs 1.7 ± 0.4, relative units, 
p<0.0001) and WT-HF mice (1.7 ± 0.4 vs 0.8 ± 0.2, relative units, p<0.0001) (Figure 
35B). HF-fed Balb/c foz/foz mice also displayed a similar up-regulation in CD68 
expression compared to its controls. However, CD68 expression in HF-fed NOD.B10 
foz/foz mice was more prominent compared to its Balb/c counterpart (7.1 ± 0.6 vs 3.1 ± 
0.6, relative units, p<0.0001).  
 
     3.6.6.2 Cluster of differentiation 11c (CD11c) 
At 6 weeks of age, the mRNA expression of CD11c was similar between all mice 
groups in both strains (Figure 35C).  
At 12 weeks of age, the mRNA expression of CD11c was found to be highly increased 
in HF-fed NOD.B10 foz/foz mice when compared to foz-chow mice (3.6 ± 0.3 vs 1.1 ± 
0.1, relative units, p<0.0001) and WT-HF mice (3.6 ± 0.3 vs 0.3 ± 0.1, relative units, 
p<0.0001) (Figure 35D). The same pattern was also observed in the HF-fed Balb/c 
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foz/foz mice. There was no significant inter-strain difference in CD11c mRNA 
expression in any of the mice groups.  
 
     3.6.6.3 Monocyte chemoattractant protein-1 (MCP-1) 
At 6 weeks of age, no significant difference in the mRNA expression of MCP-1was 
observed between the mice groups of both strains (Figure 35E). However, inter-strain 
differences in MCP-1 expression were observed at this age. HF-fed NOD.B10 WT mice 
displayed higher MCP-1 expression compared to its Balb/c counterparts (0.05 ± 0.01 vs 
0.02 ± 0.003, relative units, p<0.05). Chow-fed NOD.B10 foz/foz mice also showed 
higher MCP-1 expression compared to their Balb/c counterparts (0.04 ± 0.01 vs 0.02 ± 
0.003, relative units, p<0.05) (Figure 35E).  
At 12 weeks of age, Balb/c WT mice increased MCP-1 expression only with HF-
feeding (Figure 35F). However, a major up-regulation in MCP-1 expression was 
noticeable in the chow-fed NOD.B10 foz/foz mice compared to WT-chow mice (0.3 ± 
0.1 vs 0.04 ± 0.01, relative units, p<0.0001). The combination of HF-diet and the foz/foz 
genotype in NOD.B10 foz/foz mice further increased MCP-1 expression at 12 weeks of 
age, when compared to WT-HF mice (0.6 ± 0.04 vs 0.06 ± 0.02, relative units, 
p<0.0001). However, HF-fed Balb/c foz/foz mice did not exhibit similar up-regulation 
of MCP-1 expression at this age.  
Inter-strain differences in MCP-1 expression was observed with the up-regulation of 
MCP-1 mRNA found to be significantly higher in the chow-fed NOD.B10 foz/foz mice 
compared to their Balb/c counterparts (0.35 ± 0.06 vs 0.07 ± 0.001, relative units, 
p<0.0001), as well as in the HF-fed NOD.B10 foz/foz mice compared to their Balb/c 
counterparts (0.63 ± 0.04 vs 0.12 ± 0.03, relative units, p<0.0001). 
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Summary of results 
The combination of HF-feeding and the foz/foz genotype clearly causes inflammation in 
both mice strains; however, the pattern is not the same between strains. The CD68 
response, a marker of macrophage infiltration, was greater in the HF-fed foz/foz mice of 
NOD.B10 strain compared to the Balb/c mice at 12 weeks of age. More remarkably 
different between strains was the MCP-1 response, which was dramatically increased in 
both chow-fed and HF-fed NOD.B10 foz/foz mice compared to Balb/c mice which had 
no increase in MCP-1 mRNA levels. These results suggest the findings of the higher 
circulating MCP-1 levels found in the HF-fed NOD.B10 foz/foz mice compared to their 
Balb/c counterparts at 12 weeks of age being at least partly from adipose tissue. Also of 
note in these results is the complete absence of these inflammatory markers at 6 weeks 
of age, suggesting these changes occur later than this age. 
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Figure 35: mRNA expression of genes related to inflammation in periovarian WAT: (A-B) 
CD68, (C-D) CD11c and (E-F) monocyte chemoattractant protein-1 (MCP-1) in NOD.B10 and 
Balb/c mice strains at 6 and 12 weeks of age. Data are means ± SEM of 10 mice per group. 
Two-way ANOVA with Bonferroni post-hoc test. §p<0.05, WT-chow vs WT-HF; 
++++p<0.0001, WT-chow vs foz-chow; ♯♯♯♯p<0.0001, WT-HF vs foz-HF; ¶¶¶¶p<0.0001, foz-
chow vs foz-HF; *p<0.05, ****p<0.0001, NOD.B10 vs Balb/c. 
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4. Discussion and Conclusion  
4.1 Discussion and Conclusion 
The rapid increase in global obesity rates have led to a massive health and economic 
burden with increased mortality arising from obesity-related co-morbidities such as 
T2D and NASH.[6, 48, 83] To better understand the determinants for the development of 
T2D and NASH in chronically over-nourished individuals may lead to new modalities 
of therapy for disease prevention. This thesis has focussed on the potential role of a 
dysfunctional response of adipose tissue to over-nutrition, T2D and NASH pathogenesis 
using Alms 1 mutant mice on different backgrounds. Past studies by Larter et al on the 
female NOD.B10 foz/foz mice demonstrated that after 24 weeks on HF diet, these mice 
develop obesity, adipose restriction, liver injury, inflammation and resultant hepatic 
lipid overload resulting in NASH.[360] Preliminary studies on the Balb/c foz/foz mice on 
the same HF diet displayed only the development of obesity, with no associated 
metabolic conditions, suggesting that these mice are diabetes-resistant and do not 
develop NASH. The dramatic strain differences in these mice models therefore allow us 
to characterize the underlying metabolic interactions between adipocytes, islet β-cells 
and hepatocytes in response to HF feeding. Thus, the overall aim was to determine the 
role of adipose tissue in the determination of a healthy obesity response or obesity 
associated with metabolic diseases in Balb/c mice compared to NOD.B10 mice. 
The first specific aim was to determine the early response and time-course of adipose 
tissue expansion, gene expression and inflammation, together with a secreted adipokine 
profile, of NOD.B10 and Balb/c mice, to the overfeeding challenges of HF diet, the 
foz/foz genotype and the combination of both. 
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As predicted, the combination of HF feeding and the foz/foz genotype promoted marked 
obesity in both strains of mice, with the suggestion from whole body weight 
measurements and DEXA, that initial weight gain up to 8 weeks of age (or 4 weeks on 
HF diet) was greater in the HF-fed NOD.B10 foz/foz mice than their Balb/c 
counterparts. Furthermore, the adipose tissue expansion in HF-fed NOD.B10 foz/foz 
mice, but not Balb/c mice, appeared to slow from 10 to 12 weeks of age suggesting the 
possibility of adipose restriction commencing at this time in the NOD.B10 strain. The 
finding that the livers of the HF-fed NOD.B10 foz/foz mice were accumulating more TG 
than the HF-fed Balb/c foz/foz mice would also be consistent with this, as this suggests 
overflow of fatty acid storage from adipose tissue to the liver.  However, when the 
weights of individual fat depots were measured, adipose tissue restriction could not be 
found. A possible explanation for this discrepancy is that only select adipose depots 
rather than the total depots were being sampled. 
These differences in initiation of weight gain could be attributed to variations in food 
intake and energy expenditure, arising from strain differences, which will be a focus for 
future investigations.  
By 12 weeks of age, the effects of HF feeding and the foz/foz genotype on adipose tissue 
differentiation factors were minimal with no obvious strain differences.  With respect to 
genes relating to adipocyte function, the combination of HF feeding and the foz/foz 
genotype certainly caused changes by 12 weeks of age. For example, SCD-1, CD36, 
ANGPTL4, and ADRP were all increased in HF-fed foz/foz mice of both strains, 
although the effect was significantly greater for ANGPTL4 in the NOD.B10 compared 
to the Balb/c strain. Similarly, the lipolysis genes ATGL and HSL were similarly 
reduced in HF-fed foz/foz compared to HF-fed WT mice in both strains of mice. Thus, 
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these functional changes appear to be adaptation to the marked excess nutrient load that 
is unrelated to whether the mice develop T2D or NASH. 
 The mRNA expression of the adipose tissue inflammatory cytokines TNF-α and IL-6 
were increased and the expression of the adipokine adiponectin was decreased in the 
peri-ovarian adipose tissue of HF-fed foz/foz mice at 12 weeks of age similarly in both 
strains of mice, indicative of MetS-like adipose tissue changes induced by the excess 
nutrient supply in both strains. Adiponectin levels inversely correlate to obesity and can 
predict severity of steatosis and transition to NASH, with positive association to insulin 
sensitivity.[316] The expression of leptin was also increased in HF-fed foz/foz mice of 
both strains, with a greater effect in the NOD.B10 mice. Although the significance of 
this is unclear, leptin is known to increase the expression of pro-inflammatory 
adipokines like TNF-α, IL-6 and MCP-1.[316].  
Obesity is associated with macrophage infiltration and increased expression of pro-
inflammatory adipocytokines. [362] Of particular interest was the finding of much greater 
increases of CD68, a marker for M1 macrophages, and MCP-1 by 12 weeks of age in 
HF-fed foz/foz mice of NOD.B10 strain compared to Balb/c mice, suggestive of greater 
inflammation in the adipose tissue of the over-nourished NOD.B10 mice. MCP-1 
expression increases in obese mice and its expression promotes monocyte infiltration, 
which differentiate into adipose tissue macrophages (ATM) further aggravating 
inflammation by secreting cytokines. [363] These findings were not present at 6 weeks of 
age. Unfortunately, data is not available to indicate at what age these changes 
commenced in the HF-fed NOD.B10 foz/foz mice. 
In keeping with the adipose mRNA levels, plasma adiponectin levels were mildly 
reduced and plasma MCP-1 levels were increased in HF-fed foz/foz mice of both mouse 
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strains. Furthermore, MCP-1 levels were higher in HF-fed NOD.B10 foz/foz mice 
compared to their Balb/c counterparts. 
The second specific aim was to determine the temporal relationship between the adipose 
tissue responses to the overfeeding challenges in the two mice strains and the 
development of T2D and NASH. 
Despite similar development of obesity in both NOD.B10 and Balb/c foz/foz mice on 
HF diet, only the HF-fed NOD.B10 foz/foz mice exhibited early evidence of impaired 
glucose tolerance at 5 weeks of age and developed hyperglycaemia at 8 weeks of age, 
which progressed to diabetes by 12 weeks of age. Interestingly, this was associated with 
profound hyperinsulinaemia evident at 8 weeks of age, indicating that despite increased 
plasma insulin levels, normal post-prandial glucose levels could not be maintained in 
these mice. On the other hand, HF-fed Balb/c foz/foz mice maintained normoglycaemia 
with moderate elevation of plasma insulin levels. The severe hyperinsulinaemia in the 
NOD.B10 mice could be suggestive of very severe insulin resistance developing in 
these mice, defective insulin clearance, possibly the presence of circulating insulin-
specific antibodies binding to and inactivating the insulin molecules, or abnormal 
processing of insulin producing less active insulin demanding huge compensatory 
responses from the β-cells of the NOD.B10 strain. These abnormalities in glucose 
regulation and insulin secretion are very early compared to the changes that develop in 
adipose tissue. 
Similar to observations made in long-term studies, NOD.B10 foz/foz mice developed 
hepatomegaly, hepatic injury and transition from simple steatosis to NASH when fed on 
HF diet, whereas the Balb/c mice did not.[360] Hepatomegaly development was already 
evident at 8 weeks of age, which was earlier than expected. Although increased hepatic 
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TG content, expressed as mg/g, developed similarly in both mice strains, HF-fed 
NOD.B10 foz/foz mice had a greater total hepatic TG content, suggesting that the 
hepatomegaly observed in these mice could be due to abnormal ectopic TG deposition. 
ALT was used as a marker of hepatocellular damage. ALT levels increased in the HF-
fed NOD.B10 foz/foz mice only and this occurred from 10 weeks of age after the 
development of hyperglycaemia and hyperinsulinaemia. 
Despite development of obesity, T2D and NASH in NOD.B10 foz/foz mice fed on HF 
diet by 12 weeks of age, the evidence from our temporal studies suggested no major 
effect on adipose tissue restriction within the time frame of the study. Adipose 
restriction may occur to a greater degree later on, since previous studies have shown 
that the onset of adipose restriction in NOD.B10 foz/foz mice occurs after 10 weeks on 
HF diet, whereas this study ended at 12 weeks of age (8 weeks on HF diet).[360]  
In summary, these studies demonstrate that by 12 weeks of age, HF-fed NOD.B10 
foz/foz mice already developed obesity and T2D, in parallel with development of 
hepatomegaly, hepatocellular injury, increased hepatic TG content and NASH, without 
strong evidence for concomitant adipose restriction or adipose dedifferentiation; 
whereas the Balb/c foz/foz mice remained diabetes and NASH resistant. A pro-
inflammatory environment occurs in both mice strains, leading to chronic low grade 
inflammation associated with obesity and obesity-induced insulin resistance. 
Hyperglycaemia and hyperinsulinaemia clearly differentiated the NOD.B10 metabolic 
disease prone mice from the Balb/c metabolic disease resistant strain and both these 
anomalies occurred very early on. Therefore, it can be inferred that adipose tissue plays 
a secondary role in the pathogenesis of the metabolic disorders in this mouse model, 
while islet β-cell dysfunction, including the quality of the insulin produced, may be the 
primary factor responsible for the development of both adipose tissue dysfunction and 
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NAFLD and the triggering of the progression to NASH. These results do not preclude 
positive pathogenic feedback loops between the islet β-cell, adipocytes and hepatocytes 
in the progressive worsening in the metabolic state of HF-fed NOD.B10 foz/foz mice. 
 
 
4.2 Limitations of study  
     4.2.1 Monitoring at different ages  
NOD.B10 mice were monitored at 6, 8, 10 and 12 weeks of age, whereas Balb/c mice 
were only monitored at 6 and 12 weeks of age. Since Balb/c mice were the control mice, 
no major changes were expected before 12 weeks of age. However, as Balb/c foz/foz 
mice on HF diet displayed a different pattern in the development of obesity, it would be 
worthwhile to conduct studies on the Balb/c mice at 8 and 10 weeks of age, similar to 
the NOD.B10 mice.  
The mRNA expression of adipose-specific genes, adipokines and inflammatory markers 
were only analysed at 6 and 12 weeks of age. Since no adipose dedifferentiation or loss 
of function was observed in both mice strains at 12 weeks of age, analysis of mRNA 
expression before this age is not required. However, the results show onset of 
hyperglycaemia and hepatomegaly at 8 weeks in the NOD.B10 foz/foz mice and NASH 
appears earlier than 12 weeks of age. The mRNA expression of inflammatory markers 
was also highly increased in both mice strains at 12 weeks of age. Therefore it may be 
advisable to analyse the expression of these markers at an earlier age to detect age of 
onset of inflammation in these mice. 
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     4.2.2 Expression of genes at mRNA level only  
The expression of adipogenic genes and adipokines were studied by measuring their 
mRNA levels. However, various studies that demonstrated that the mRNA levels of a 
gene do not always correlate to its protein levels, due to factors such as translational and 
post-translational modifications, RNA secondary structures and protein half-lives. [364] 
Therefore measurement of both mRNA and protein levels is recommended to determine 
gene expression. Since in this study, circulating plasma protein levels of all the genes 
were not analysed, Western Blot or sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) coupled with mass spectrometry would substantiate the 
results obtained from the mRNA levels of these genes.  
 
4.3 Proposed subsequent investigations 
     4.3.1 Food intake studies 
Balb/c foz/foz mice fed on HF diet displayed later onset of obesity at 8 weeks of age, 
compared to its NOD.B10 counterparts. Therefore, measurement of food intake of these 
mice could possibly determine whether differences in food consumption caused a 
different pattern in weight gain in these mice. Preliminary experiments on the food 
intake of the Balb/c mice have already been initiated, with food consumption 
measurements taken over 3 days in each week from 4 to 12 weeks of age, along with 
body weight measurements. Balb/c mice fed on HF diet displayed higher calorie intake 
compared to the chow-fed mice. However, food intake measurements of NOD.B10 
mice, conducted currently with Balb/c mice, are also necessary to determine any 
variations in calorie intake, and will be conducted during future investigations. 
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     4.3.2 Gene expression in subcutaneous adipose tissue 
In this study, only peri-ovarian adipose tissue was used to determine the mRNA 
expression of various adipogenic genes and adipokines, and inflammatory markers such 
as CD68 and CD11c. However, studies have shown that the expression of certain genes 
and adipokines are different in the adipose tissue depending on their location. Visceral 
adipose tissue is associated with hypoadiponectinemia and increased IL-6 secretion. [365] 
Therefore, analysis of the mRNA expression of these genes in more subcutaneous 
adipose and visceral (e.g. mesenteric) tissue sites could be conducted to corroborate 
whether adipose dedifferentiation or inflammation occurs in both these adipose tissue 
depots at 12 weeks of age. 
 
4.3.3 Qualitative studies  
In this study, adipose restriction and dysfunction was identified through quantitative 
experiments such as mRNA expression of adipogenic genes and plasma levels of 
adipokines. Similarly, the presence of inflammation was predicted from increased 
mRNA expression of inflammatory markers. In the liver, steatosis and progression of 
NAFLD to NASH was deduced from increased hepatic TG content and elevated plasma 
ALT levels.  
Therefore, qualitative experiments such as Oil Red-O staining to illustrate hepatic 
steatosis, and immunohistochemistry (IHC) analysis of adipose tissue and liver to 
outline the presence of inflammatory macrophages and crown-like structures, could 
provide visual corroboration to results obtained quantitatively in this study. 
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4.3.4 Use of knock out mice 
The results of this study suggest that the adipose tissue inflammatory changes, in 
particular the increase in MCP-1, in the HF-fed NOD.B10 foz/foz mice occurs after the 
development of hyperglycaemia and hyperinsulinaemia. In order to more convincingly 
show the hyperglycaemia and hyperinsulinaemia develop independently of adipose 
tissue inflammation, the MCP-1 knock out mice could be backcrossed on to NOD.B10 
WT Alms 1 mutant mice. As MCP-1 is expressed in multiple tissues, an MCP-1 adipose 
specific MCP-1 knock out mouse would be of particular interest. 
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Solutions: 
 The constituents and preparation of solutions mentioned in Chapter 2 are shown below. 
DNA Lysis buffer  
For preparation DNA lysis buffer, the following solutions were constituted: 
• 1 M Tris pH 8.0: Added 60.57 g of Trizma® base (Cat# T1503, Sigma Aldrich, 
CA, USA) in 500 mL of Milli-Q water and pH adjusted to 8.0 using 10 mol/L 
NaOH (Cat# S0899, Sigma Aldrich, CA, USA) and pH meter (Orion STAR 
A211, Thermo Scientific, MA, USA) 
• 0.1 M EDTA: Added 7.44 g of EDTA (Cat# E9884, Ethylenediaminotetraacetic 
acid, Sigma Aldrich, CA, USA) in 200 mL of Milli- Q water 
• 5 M NaCl: Added 58.44 g of NaCl (Cat# S5886, Sigma Aldrich, CA, USA) in 
200 mL of Milli-Q water 
• 10% SDS: Added 20 g Sodium Dodecyl sulfate (Cat# L4390, Sigma Aldrich, 
CA, USA) in 200 mL of Milli-Q water 
For preparation of 1 L DNA lysis buffer, the following were added: 
• 100 mL of 1 M Tris pH 8.0  
• 50 mL of 0.1 M EDTA  
• 40 mL of 5 M NaCl 
• 20 mL of 10% SDS 
The solution was topped up to 1 L with Milli-Q water, then sterile-filtered using 0.22 
µm filter (Millipore Corporation, Massachusetts, USA) and stored at room temperature. 
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70% ethanol 
For preparation of 70% ethanol, the following solutions were constituted: 
• 70 mL absolute ethanol (cat# 214, Univar, Ajax FineChem, NSW, Australia) 
• 30 mL Milli-Q water 
 
75% ethanol 
For preparation of 75% ethanol, the following solutions were constituted: 
• 75 mL absolute ethanol (cat# 214, Univar, Ajax Fine Chem, NSW, Australia) 
• 25 mL Milli-Q water 
 
TE Buffer 
For preparation of 1 L of TE buffer, the following solutions were constituted: 
• 10 mM Tris-HCl pH 8.0 (Triethanolamine hydrochloride, Cat# T1502, Sigma 
Aldrich, CA, USA) 
• 0.5 M EDTA: (Cat# E9884, Sigma Aldrich, CA, USA)  
For preparation of 1 L of TE buffer, the following were added: 
• 1.21 g of 10 mM Tris-HCl pH 8.0 
• 2 mL of 0.5 M EDTA 
The solution was pH adjusted to 8.0 using NaOH and topped up to 1 L with Milli-Q 
water, sterile-filtered using 0.22 µm filter (Millipore Corporation, Massachusetts, USA) 
and stored at room temperature. 
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TAE buffer (Tris-Acetic acid-ethylenediaminetetracetic acid buffer) 
For preparation of 1 L of 50X TAE buffer, the following were added: 
• 242 g of Tris (Trizma® base, Cat# T1503, Sigma Aldrich, CA, USA) 
• 18.61 g of EDTA (Ethylenediaminotetra acetic acid, Cat# E9884, Sigma 
Aldrich, CA, USA) 
• 57.1 mL of glacial acetic acid (Cat# 537020, Sigma Aldrich, CA, USA) 
The solution was topped up to 1 L with Milli-Q water, then sterile-filtered using 0.22 
µm filter (Millipore Corporation, Massachusetts, USA) and stored at room temperature. 
A running solution of 1X TAE buffer was then prepared by diluting 10 mL of 50X TAE 
buffer in 990 mL of Milli-Q water. 
 
KOH (Potassium Hydroxide) 
For preparation of 0.5 M KOH, the following were added: 
• 5.6 g KOH (Cat# P5958, Sigma, CA, USA) 
• 200 mL of 95% ethanol (prepared by diluting 190 mL absolute ethanol (Cat# 
214, Univar, Ajax Fine Chem, NSW, Australia) in 10 mL of Milli-Q water) 
 
MgSO4 (Magnesium Suphate) 
For the preparation of 0.15 M MgSO4, the following were added: 
• 11.07 g of MgSO4.7H20 (Cat# 230391, Sigma Aldrich, CA, USA) 
• 300 mL of Milli-Q water 
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DEPC-water 
For preparation of 1 L of DEPC-water, the following were added: 
• 1 mL of diethyl pyrocarbonate (Cat # D5758, Sigma Aldrich, CA, USA) 
• 1 L of Milli-Q water 
The solution was stirred overnight with a magnetic stirrer at 37oC and autoclaved before 
use. 
 
Loading buffer for electrophoresis  
For the preparation of loading buffer, the following were added: 
• 25 mg of bromophenol blue (Cat# B8016, Sigma, CA, USA) 
• 4 g of sucrose (Cat# S0389, Sigma, CA, USA) 
• 10 mL of Milli-Q water 
 
 
Figure 37: Mice ear notch chart for identification of each mouse. 
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